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Abstract
Scorpion and snake venoms consist of diverse mixtures of peptides and proteins with 
varying biological activities and offer an attractive source for the development of novel 
therapeutics. Smp24 (24 aa) and Smp43 (43 aa) are antimicrobial peptides (AMPs) that 
were identified from the venom gland of the Egyptian scorpion Scorpio 
maurus palmatus. These alpha-helical peptides showed potent activity against both 
Gram positive and Gram negative bacteria with MICs ranging from 4 to 128 pg/ml. 
Four anti-bacterial peptides were purified using HPLC chromatography from the 
venom of three different species of Egyptian snakes. The molecular masses of the 
purified proteins were identified by MALDI-TOF/MS and N-terminal sequences suggest 
that they are members of the three-finger toxin superfamily. Both SEM and TEM were 
employed to visualise morphological changes and membrane damage of E. coli and S. 
aureus in response to different concentrations of Smp peptides at different time 
intervals. Using DNA microarray, we examined the transcriptomic responses of E. coli 
to sub-inhibitory doses of Smp24 and Smp43 peptides following 5 hours of incubation. 
Differentially expressed genes in the presence of peptides or a control antibiotic 
(Polymyxin B) compared with the absence of peptides were predominantly related to 
siderophore biosynthesis and transport, as well as more generalised cation transport 
and oxidative stress responses. The antibacterial effects of Smp peptides were 
inhibited in the presence of calcium and magnesium ions, but not other cations. Smp 
peptides offer a promising starting point for the development of new antimicrobial 
agents and transcriptomic analysis can help identify metabolic processes affected by 
scorpion venom AMPs which may be beneficial in understanding their mechanism of 
action.
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1 Introduction
1.1 Antimicrobial resistance
Antimicrobial resistance is an increasingly serious worldwide threat associated with 
millions of illnesses and deaths annually over the world. Antimicrobial resistance is 
predicted to cause ten million deaths in 2050 (O'Neil 2014). The emergence of 
resistant strains is endangering the efficacy of a wide range of antibiotics. Resistance is 
an old phenomenon, when sulphonamide and penicillin were marketed in the first half 
of the 20th century; researchers reported that resistance patterns started to appear 
only a few years after their introduction (Rammelkamp, Maxon 1942, Damrosch 1946).
Antimicrobial resistance is a major cause of morbidity and high healthcare spending 
worldwide. Massive epidemics as a consequence of microbial resistance to antibiotics 
emerge after their widespread clinical use, misuse and overuse, resulting in selective 
pressure by allowing survival of the resistant bacteria (Yanling, Zhiyuan et al. 2013, 
Fonkwo 2008). Sub-inhibitory and sub-therapeutic antibiotic doses can promote 
changes in gene expression and mutagenesis, leading to antibiotic resistance 
(Viswanathan 2014, Ventola 2015). Resistance to a range of antibiotics is one the 
common key factors that drive Methicillin-resistant Staphylococcus aureus epidemics 
(MRSA). MRSA was reported in the United Kingdom hospitals in 1960. Thereafter, 
MRSA have spread globally and were multiply resistant to non-(3-lactarh antibiotics 
recognized as epidemic MRSA (EMRSA) associated with serious infections in hospitals 
(Barber 1961, Devons 1961, Enright, Robinson et al. 2002, Stapleton, Taylor 2002, Udo, 
Boswihi et al. 2016).
Until 2003, carbapenem-resistant strains were extremely rare in both the UK and 
Europe. However, some carbapenem-resistant clinical isolates have been recently
2
identified within the UK. The UK has launched ambitious programs to limit and control 
the development and spread of antimicrobial resistance. The major components of 
these programs include increasing the understanding of this threat among the public 
such as hand and environmental hygiene, patient isolation and patient/staff screening 
besides reducing the prescribing of antibiotics among human and animals. Accordingly, 
a significant reduction in the incidence of Methicillin-resistant Staphylococcus aureus 
(MRSA) has been achieved within hospitals in the UK and proportions of isolates of 
some resistant species has stabliblized. Nevertheless, a significant increase has 
occurred in some infections such as bacteremia which require novel antibiotics to 
control it (Shallcross, Howard et al. 2015, Hopkins 2016).
The threat of antimicrobial resistance requires an understanding of the antibiotic 
targets as well as the biochemical and genetic aspects of antibiotic resistance 
mechanisms in order to develop antimicrobial agents that are more effective against 
bacterial resistance (Figure 1.1). Bacteria have developed Various mechanisms to resist 
novel chemotherapeutics (Rodriguez-Rojas, Rodriguez-Beltran et al. 2013). Although 
the intrinsic genes that could produce resistance to certain antibiotics in bacterial 
genomes or transfer among species, bacteria can also acquire resistance via mutations 
in existing genes (Blair, Jessica MA, et al.2015). Bacterial resistance can be achieved 
biochemically in different general ways such as efflux pumps (Poole 2005), 
modification of bacterial target sites (Lambert 2005) and enzymatic degradation 
(Figure 1.1) (Vranakis, Goniotakis eta l. 2014).
Resistant pathogens require novel antibiotic classes or new generations of marketed 
antibiotics and the crisis of antibiotic resistance has increased with the decline in new
antibiotic drugs entering the clinical development pipeline (Conly, Johnston 2005).
3
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1.2 Antimicrobial drug discovery
Different ancient cultures have used natural products to  trea t bacterial infections. 
Many observations have revealed the antagonism effect o f Penicillium  on microbial 
growth (Burdon-Sanderson 1871, Lister 1875). However, the main breakthrough in 
antim icrobial drug research was observation by Fleming in 1921 o f the susceptibility o f 
Micrococcus lysodeikticus to lysozyme. This observation led to  Fleming's discovery o f 
the specific mold species (Penicillium notatum ) tha t inhibited the growth o f 
Staphylococcus bacteria (Fleming 1922). Following this discovery penicillin was 
eventually purified and charcterised by Florey and Chain in the 1940s (Abraham, Chain 
1942). Penicillin was the firs t antim icrobial agent isolated from  a natural source. Many 
other antibiotics were released later fo llow ing penicillin's development, although the 
sulfonamide drug Prontosil was marketed as the firs t synthetic antib io tic  in the 1930s 
(Domagk 1935).
Natural products are the main source fo r the isolation o f novel antim icrobial drugs. At
the beginning o f the antib io tic era, actinomycetes and fungi were the m ajor sources
fo r antibiotics such as penicillin derived from  Penicillium  sp and fusidic acid, from  the
fungi Fusidium griseum. Approximately 65% o f current antim icrobials are produced
from  Streptomyces species including vancomycin, fosfomycin, tetracycline,
chloramphenicol, and gentamycin (Pelaez 2006, Abdulkadir, W aliyu 2012).
Streptomycin was isolated from  Streptomyces griseus by the American scientist Stanley
Waksman. Streptomycin was the firs t successful antib io tic  against tuberculosis (Schatz,
Bugle et al. 1944), and Waksman was awarded the Nobel Prize in 1952. Many o the r
antibiotics were isolated from  bacteria tha t have evolved a biosynthetic process to
protect themselves. This is a particular trend fo r soil bacteria (e.g. Bacillus sp.) in order
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to  increase dominance in the ir own ecological niche. For examples, antib iotics such as 
bacitracin and gramicidin were identified from  Bacillus licheniform is and Bacillus brevis 
respectively (Abdulkadir, Waliyu 2012).
The golden age of antib io tic discovery was from  1943 to  1960, and in this period more 
than tw enty  classes of antibiotics were released in to  global markets. The m ajority o f 
current antib io tic classes today were developed from  this earlier era (Coates, Halls et 
al. 2011, Lewis 2013). Based on the penicillin structure, antim icrobial researchers have 
succeeded in producing semi-synthetic beta-lactam antibiotics such as cephradine, 
cephalexin and cefadroxil (Elander 2003, Thakuria, Lahon 2013). Analysis o f global 
antib io tic consumption from  the 71 countries during the period o f 2000 to  2010 
revealed tha t beta-lactam antibiotics led the field (Error! Reference source not found.) 
(Van Boeckel, Gandra et al. 2014).
Broad-spectrum penicillins 
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Figure 1.2 Global antibiotic consumption in from 2000-2010 (Van Boeckel et al., 2014).
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1.3 Antibiotic innovation gap
Between the mid- sixties until the turn of the millennium, no new classes of antibiotics 
have been commercially approved, although there are some antibiotics that have been 
found in the different phases of clinical trials (Figure 1.3). Only two new classes have 
been marketed in the last fifteen years daptomycin and linezolid (Coates, Halls et of. 
2011, Gostelow, Gonzalez et al. 2014). Daptomycin (Cubicin) is a lipopeptide-based 
antibiotic produced by Streptomyces roseosporus, discovered in the 1980s and 
approved for use (Shoemaker, Simou et al. 2006, Humphries, Pollett et al. 2013, 
Kelesidis 2014). Daptomycin has a broad spectrum activity against Gram positive 
bacteria including MRSA strains and no activity against Gram negative bacteria (Streit, 
Jones et al. 2004). The most recently discovered antibiotic class is that of 
oxazolidinones, such as Linezolid. Linezolid is used to treat pneumonia, skin infection 
and bacteremia caused by vancomycin-resistant strains (Livermore 2003, Wilcox 2005).
1910 1920 1930 1940 1950 1960 1970 1980 20101990 2000
Discovery Void
Salvarsan
Penicillin
Sulfonamide
Streptomycin
Nalidixic acidBacitracin
TrimethoprimNitrofurans
LincomycinChloramphenicol
FusidicacidPolymyxin
Chlortetracydine Fosfomycin
j  | MupirociiTMetronidazoleCephalosporin
Pleuromutilin Rifamycin Carbapenem
Novobiocin OxazolidinoneErythromycin
Isoniazid Cycloserine Monobactam
DaptomycinVancomycin
Streptogramin
Figure 1.3 Illustration of the "discovery innovation gap/' (Silver 2011).
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The antibiotic drug discovery innovation gap has been caused by a combination of 
several factors (Berdy 2012) and the development of drug safety regulations has had a 
great impact on the antibiotic pipeline. These regulations have raised the cost and 
timeline of antibiotic development, resulting in a shortage of novel antibiotics in 
production. Currently, many new antibiotics are in late-stage clinical development but 
few of them belong to novel classes (Butler, Blaskovich eta l. 2016, Fernandes, Martens 
2016). More recently, the FDA has, however, announced a new, shorter and more 
feasible procedure called Special Populations Limited Medical Use (SPLMU), to 
approve some critically needed drugs to treat life-threatening diseases like resistant 
infections, allowing patients earlier access to promising new antibiotics (Spellberg
2012). Under this new program, a quinoline-based antibiotic (Sirturo ™) has been 
approved to treat multi-drug resistant tuberculosis (Dowling,-O'Dwyer et al. 2013).
From a pharmaceutical industry perspective, antibiotic drug research and development 
is unattractive economically. Most pharmaceutical companies have diminished 
investment into the discovery and development of new antibiotics due to the rapid 
increase of drug resistance caused by resistant bacteria. Pharmaceutical companies 
can gain twenty times more profit if they develop new drugs to treat chronic disease 
such as diabetes and epilepsy than generating a novel antibiotic (Figure 1.4) 
(Fernandes, Martens 2016). According to the Regional Drug and Therapeutics Centre at 
Newcastle in 2016, the cost of a 5-day treatment of antibiotics was from £0.5 to £114, 
as compared with £150 to £2500 spent on the cost of insulins for 1 year. Many novel 
antibiotic classes are urgently needed in the next fifty years to treat bacterial infection 
caused by resistant species (Coates, Halls et al. 2011).
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Figure 1.4 Drug expenditures in USA of recently launched antibiotics versus other brands 
according to the IMS Health National Sales Perspectives (NSP) database in 2016 with 
focus on Tefiaro sales over two years (Fernandes and Martens, 2016).
The decline in the antibiotic drug discovery and production pipeline may be attributed
antibiotics such as screening soil-derived actinomycetes (Lewis 2013). Recent advances 
in high throughput screening techniques may decrease costs and the time to generate 
novel antibiotics, for example, isolation chip which was used to identify a new class of 
lipid II binding antibiotics (teixobactin) (Ling, Schneider et al. 2015). Such techniques 
may encourage antimicrobial researchers and pharmaceutical companies to reinvest 
again in antibiotic drug discovery (Chan, Macarron et al. 2002, Dougherty, Barrett et al. 
2002). There is an urgent need to discover novel antimicrobial agents with different 
mechanisms of action for overcoming the life-threatening resistance of pathogenic 
microorganisms to classic antibiotics (Hancock 2001). Transcriptomic and bioinformatic 
approaches such as cDNA microarray and other sequence-based technologies may 
offer an opportunity to identify new molecular pathways, beneficial in understanding 
the mechanism of killing action of bacteria, in order to develop new antibiotic (Brazas, 
Hancock 2005, Scanlon, Postal et al. 2014).
to the limitation of some methodologies which were used previously to identify new
1.4 Antimicrobial peptides
Most living organisms are continuously exposed to a large number of pathogens and 
therefore have evolved two main defence mechanisms against infection; the innate 
immune system which constitutes the first line of non-specific host defence 
mechanism and the adaptive immune system which includes a specific recognition to a 
particular pathogen acting as a second line through generation of specific antibodies. 
The innate immune system provides a broad range of different immediate defensive 
mechanisms against the invasion by other organisms such as phagocytes, macrophages 
and natural killer cells as well as the activation and/or release of some antimicrobial 
molecules ranging from small inorganic molecules to large proteins (Ganz 2003, 
Oppenheim, Biragyn et al. 2003, Diamond, Beckloff et al. 2009).
Antimicrobial peptides (AMPs; also called host defence peptides) play a critical role in 
the innate immune defence system of all living organisms ranging from bacteria and 
other single celled organisms to plants and multicellular animals (Zasloff 2002, Zasloff 
2007, Guilhelmelli, Vilela et al. 2014). However, in organisms that have no adaptive 
immunity, AMPs represent the principal constituent of their defence mechanisms 
(Meister, Lemaitre et al. 1997). AMPs are found and secreted in varied tissues and cells 
such as epithelial surfaces, granules of phagocytic cells, haemolymph and glandular 
structures (Rosa, Barracco 2010).
Most AMPs have hydrolytic activities to kill pathogenic organisms such as bacteria, 
parasites, and viruses as well as cancer cells. They have been used as food 
preservatives and in biological control of plant pathogens and they are considered to 
be promising templates for the design of novel antibiotics. A small number of these
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peptides have been commercially developed into therapeutics such as daptomycin, 
polymyxin B and Locilex™ (an analogue of magainin 2) (Brahmachary, Krishnan et al.
2004, Jenssen, Hamill et al. 2006, Giuliani, Pirri et al. 2007, Laverty, Gorman et al. 
2011, Hintz, Matthews etal. 2015).
1.5 Antim icrobial peptide diversity, classification and structure
According to the Antimicrobial Peptide Database (APD) more than 2500 peptides have 
been discovered as of December 2015. About 75% of AMPs have been isolated from  
animal sources (Wang, Wang 2004, Wang, Li et al. 2016). In 1939 the first AMP, 
gramicidin, was discovered from the bacterium Bacillus brevis with antimicrobial 
activity on both Gram negative and Gram positive bacteria (Yamada, Shinoda et al. 
2006, Phoenix, Dennison et al. 2013).
Antimicrobial peptide research has expanded with the discovery of AMPs from multi 
cellular organisms; among the first were cecropins (Hultmark, ENGSTROM et al. 1982). 
Cecropins were initially identified in silk moth (Hyalophora cecropia) haemolymph, 
with broad spectrum activity against both Gram positive and Gram negative bacteria 
and little or no haemolytic effects (Moore, Beazley et al. 1996). Cecropins and their 
derivatives were also isolated from other insects and nematodes (Pillai, Ueno et al.
2005, Castillo, Reynolds et al. 2011).
Defensins were the first mammalian AMPs, isolated from rabbit macrophages in 1980
(Kaiser, Diamond 2000). Defensins and defensin-like peptides were also isolated from a
wide variety of organisms such as fungi (Mygind, Fischer et al. 2005), platypus venom
(Torres, Dantas eta l. 2010), and dung beetles (Hwang, Lee et al. 2009). Defensins have
also been reported in plants. However, plant defensins differ from other defensins as
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they are mainly active on fungi and yeast rather than bacteria (Stotz, Thomson et al. 
2009, de Oliveira Carvalho, Moreira Gomes 2011).
AMPs can be classified on the basis of their biological activities, biochemical properties 
or on the biological source from which have been isolated from. However, they are 
categorized based mainly on their secondary structure, into two groups namely a- 
helical structures and those with (3-sheet structures. However, some AMPs have mixed 
structures and others have non- a- or (3- structures (extended) (Figure 1.5) (Vizioli, 
Salzet 2002, Bah a r, Ren 2013).
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Figure 1.5 Structural classes of AMPs. A: a-helical magainin-2, B: 3-sheeted defensin, C: mixed 
structure of thionins, D: extended indolicidin, E: cyclic structure of gramicidin S and F: Lipopeptide 
(Daptomycin) (modified from (Ganz 2003, Lee, Hodges 2003, Jenssen, Hamill et al. 2006).
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I-a-helical AMPs
The best-studied AMPs are the a-helix peptides such as cecropins, magainins, and 
m ellitin  (Epand, Vogel 1999, Bahar, Ren 2013). Several spectroscopic studies have 
revealed tha t a-helix peptides are usually unstructured in aqueous solution and form  
helices in the presence of membrane-like models (Bechinger, Zasloff et al. 1998). The 
a-helical structure o f magainin 2 and its analogues have been abundant reported using 
circular dichroism (CD) spectroscopy and nuclear magnetic resonance (NMR) analysis 
(Ludtke, He et al. 1994, Mecke, Lee et al. 2005) in the presence o f membrane- 
m imicking environments such as solvents like trifluo roethano l (TFE) (Gesell, Zasloff et 
al. 1997) (Figure 1.5A). The secondary structure analysis o f m e littin  and cecropin B1 by 
CD and NMR revealed tw o helical segments (Bazzo, Tappin et al. 1988, Srisailam, 
Arunkumar et al. 2000).
II- p-sheet AMPs
Defensins are one o f the most common p-sheet AMPs, they are cationic peptides 
having six (vertebrates) to  eight (plants) conserved cysteine residues (Tu, Li et al. 
2015). Defensins are classified into tw o  subfamilies a- and p -defensins based on 
cysteine linking pattern (Ganz 2003). Secondary structure analysis o f human p- 
defensins by NMR revealed 3-stranded antiparallel p-sheets w ith  a single helical turn  
(Bauer, Schweimer et al. 2001, Qi, Xu et al. 2016) (Figure 1.5B).
III- Mixed structure AMPs
Some peptides have a-helix and P sheet mixed structures. For instance, th ionins are
cationic plant AMPs which includes tw o a-helices and double-stranded p-sheet w ith
three or four disulfide bonds (Figure 1.5C). For example, NMR analysis o f hordo th ion in -
a revealed tw o a-helical regions running in opposite directions and tw o  short
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antiparallel (3-sheets (Nawrot, Barylski et al. 2014, Tam, Wang et al. 2015).
IV- Extended AMPs
Indolicidin is an AMP that belongs to the cathelicidins family isolated from bovine 
neutrophils. CD spectra of indolicidin in 0-50% TFE, on neutral and negatively charged 
liposomes showed no distinct conformational change suggesting unordered peptide 
(Rozek, Friedrich eta l. 2000, Friedrich, Rozek et al. 2001, Hsu, Chen et al. 2005, Chan, 
Prenner et al. 2006a) (Figure 1.5D).
V- Cyclic AMPs
Gramicidin S is a cyclic broad spectrum AMP isolated firstly from the bacterium Bacillus 
brevis. It is synthesised by gramicidin S synthetase enzymes by forming thioester bonds 
to join two identical pentapeptides head to tail (Figure 1.5E) (Bredesen, Berg et al. 
1968, Abraham, Prenner et al. 2014). Other cyclic AMPs have a fatty acid chain 
attached to the peptide moiety (lipopeptides); the lipid tail facilitates peptide insertion 
into bacterial membranes which enhance their antimicrobial activities (Pirri, Giuliani et 
al. 2009, Meena, Kanwar 2015). For example, daptomycin is a cyclic anionic (-3  net 
charge) lipopeptide isolated from actinobacteria Streptomyces roseosporus made up of 
13 amino acids connected to a fatty acid side chain (Jung, Rozek et al. 2004, 
Steenbergen, Alder et al. 2005) (Figure 1.5F).
1.6 Im portant Properties o f AMPs
I- Net charge
Most AMPs are cationic peptides with a positive net charge from +1 to +10 that are
rich in arginine and/or lysine amino acids (Vizioli, Salzet 2002, Jenssen, Hamill et al.
2006, Zasloff 2007). They are amphipathic molecules as hydrophobic and positively
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charged amino acids are arranged in opposite regions of the structure (Melo, Ferre et 
al. 2009, Seo, Won et al. 2012). Binding of AMPs to pathogen membranes is crucial in 
order to disrupt lipid bilayer integrity and to permeabilise the membrane leading to 
cell death. The cationic amphipathic nature is essential for AMPs killing activity as it 
helps AMPs to interact electrostatically and hydrophobically with the bacterial 
membrane, which has an anionic surface and is rich in hydrophobic components 
(Wimley 2010, Midura-Nowaczek, Markowska 2014). A small number of aspartate-rich 
AMPs are anionic (charges -1 to -7), for example Dermcidin (-2 net charge) which is 
secreted by human sweat glands (Schittek, Hipfel et al. 2001, Fales-Williams, Brogden 
et al. 2002, Harris, Dennison et al. 2009, Paulmann, Arnold et al. 2012). Anionic AMPs 
interact with the membrane of the pathogen by forming cationic bridges with metal 
ions such as zinc (Fales-Williams, Brogden et al. 2002, Harris, Dennison et al. 2009, 
Becucci, Valensin et al. 2014).
II-Hydrophobicity
Previous studies on structure activity relationships of AMPs revealed that the 
hydrophobic face of AMPs enhances their affinity with target membrane lipid bilayers, 
which results in antimicrobial effects and leads additionally to cytotoxicity (Kim, Jang et 
al. 2014, Lee, Lee 2015). The hydrophobic face of peptides enhances their penetration 
into the hydrophobic core of membrane (Chen, Guarnieri et al. 2007, Bahar, Ren
2013). Thus, the replacement of hydrophobic residues with more hydrophilic ones or 
removal of hydrophobic C- or N-terminals of some cytotoxic peptides improve their 
selectivity toward prokaryotic membranes and reduces their toxicity toward 
eukaryotes (Skerlavaj, Gennaro eta l. 1996, Lee, Park eta l. 1997, Ciornei, Sigurdardottir 
et al. 2005).However, there is an optimal threshold of hydrophobicity for any AMP,
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beyond which its antimicrobial activity decreases or is abolished (Chen, Guarnieri et al. 
2007, Bahar, Ren 2013).
Ill-Helicity
The helicity of a-helical AMPs plays an important role in peptide specificity toward 
prokaryotic membranes (Matsuzaki 2009). Several studies have investigated the 
relationship of peptide helicity and hydrophobicity (Chen, Mant et al. 2005, Huang, He 
et al. 2014, Zhang, Song et al. 2016). Minimising the hydrophobicity of peptides to 
improve their therapeutic indices resulted in a remarkable decrease in a-helical 
content, due to the change in continuity of the hydrophobic/hydrophilic face of the 
helical structure.
1.7 Selectivity o f antim icrobial peptides
Phospholipids are the main target of cationic AMPs. The antibacterial activity of 
several AMPs was found to depend upon the binding affinity of the phospholipid 
constituents of bacterial membranes (Ntwasa 2012, Park, Kang et al. 2013). The 
phospholipid composition of bacterial membranes plays a key role in the mechanism 
of membrane disruption of AMPs, determining the susceptibility of bacteria and 
driving the specificity of AMPs.
Bacterial membranes contain varying amounts and composition of negatively charged
phospholipids such as phosphatidylglycerol (PG) and cardiolipin (CL) as well as
zwitterionic phospholipids such as phosphatidylethanolamine (PE). Gram positive
bacterial membranes contain no or lower amounts of PE and higher amounts of
negatively charged phospholipids when compared with Gram negative membranes
(Table 1.1) (Epand, Savage et a/. 2007, Epand, Epand 2009). Most cationic AMPs have
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less a ffin ity  fo r eukaryotic cell membranes which have mainly neutral lipids such as PE 
and phosphatidylcholine (PC). Also the presence of a large am ount o f cholesterol in a 
eukaryotic cell membrane inhibits membrane disruption by rig idifying the lipid bilayer 
structure compared w ith  the lack o f cholesterol in bacterial cell membranes which 
makes the membrane disruption by an AMP easier (Figure 1.6) (Sanderson 2005, 
Brender, McHenry et al. 2012, Seo, Won et al. 2012, Sani, Separovic 2016).
Table 1.1 Percentages of major phospholipid components of bacterial membranes
Bacterial species
% Total membrane 
phospholipid References
PE PG CL
Gram positive
S. aureus 0 58 42 (Epand et al., 2007, Epand and 
Epand, 2009)
B. subtilis 12 70 4 (Clejan, Krulwich et al. 1986)
Gram negative E. coli 80 10-15 0-10
(Shokri, Larsson 2004, Epand, 
Epand 2009)
Bacterial membrane Mammalian membrane
acidic Cationic, amphipathic peptide
phospholipid \
zwitterionic Cholesterol .....  ^  v ^n i i i
phospholipid I
\ ^  ^  /  Exterior leaflet
s t o f f l ®  m m m
Figure 1.6 Lipid bilayers mimicking bacterial and eukaryotic cell membranes
(Brender et al., 2012).
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Another significant factor driving the binding affinity of bacterial membranes is the 
asymmetric distribution of phospholipids in membrane leaflets. The outer leaflet of 
bacterial membrane consists mainly of PG, while CL is found in both membrane leaflets 
(Barsukov, Kulikov et al. 1976, Marquardt, Geier et al. 2015). Negatively charged 
phospholipids such as phosphatidylinositol (PI) and phosphatidylserine (PS) are located 
in the inner monolayer of eukaryotic membranes (Zwaal, R. F. A. 1991). PS is exposed 
externally in mammalian cells as an apoptotic signal and the presence of PS in the 
outer monolayer of cancer cell membranes play a major role in the disruption of these 
membranes by AMPs (Hoskin, Ramamoorthy 2008, Riedl, Rinner et al. 2011). Such 
asymmetry promoting electrostatic interactions of cationic peptides with negatively 
charged phospholipids in bacterial and cancer cell membranes provides another 
explanation for AMP specificity (Sato, Feix 2006).
A large number of studies have investigated AMP selectivity toward model 
membranes of various compositions, mimicking different prokaryotic and eukaryotic 
membranes. For instance, it has been found that the ability of cathelicidin AMP (LL-37) 
to induce membrane disruption is dependent on negatively charged phospholipids, as 
the peptide showed no disruptive action toward zwitterjonic membranes (Zhang, 
Ogl^cka et al. 2010). Such preferential activity toward anionic phospholipids is typical 
for abundant AMPs such as melittin (Kleinschmidt, Mahaney et al. 1997) and novicidin 
(Dorosz, Gofman et al. 2010), which showed membrane selectivity to enriched 
negative phospholipid model membranes rather than zwitterionic membranes.
Consistent with other species, several cationic AMPs from scorpion venom have been
shown to target the anionic phospholipid components in prokaryotic mimetic
membranes. For example, UyCT peptides identified from Australian scorpion venom
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Urodacus yaschenkoi induced more efficient fluorescent dye release from membrane 
bilayers mimicking E. coli and S. aureus, rather than phospholipids mimicking human 
red blood cells (Luna-Rarmrez, Quintero-Hernandez et al. 2013). From these studies, a 
strategy of how to develop these AMPs as novel antibiotics have begun to emerge, as 
the phospholipid selectivity of AMPs is used to increase their therapeutic index 
(Matsuzaki 2009, Aoki, Ueda 2013).
Some AMPs, however, are not cell-selective; they can lyse both prokaryotic and normal 
eukaryotic membranes (Shai 1999) and this represents one of the biggest barriers to 
the use of AMPs as therapeutic agents. For instance, the lytic activity of Aurein 1.2, an 
AMP isolated from the skin of the Australian tree frog is not a charge dependent as it 
has the ability to induce membrane disruption to both negative and zwitterionic 
bilayers (Shahmiri, Enciso et al. 2015). Recent studies have revealed that the 
substitution of some non-polar residues with basic and hydrophobic residues of both 
AR-23 (a melittin-related peptide) (Zhang, Song et al. 2016) and snake venom  
cathelicidin-BF (Jin, Bai et al. 2016) have resulted in a series of analogues with high 
specificity toward prokaryotic cells.
1.8 Proposed models o f m em brane disruption mechanisms o f AMPs
The interactions of AMPs with phospholipid bilayers indicate different mechanisms for 
pore formation and lysis of model membranes. The general mechanism proposed is 
that the peptides (i) interact with membranes, (ii) concentrate to reach a threshold 
concentration to (iii) permeabilise or rearrange membranes by a variety of different 
mechanisms dependent on the specific AMP (Glaser, Sachse et al. 2005, Matsuzaki 
2009, Yu, Guo et al. 2009).
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Figure 1.7 Classical models of pore forming antimicrobial peptide. (A) Barrel-stave pore: peptides 
form a bundle with a central lumen, the hydrophobic surfaces interact with the lipid core. (B) 
Carpet mechanism: a detergent-like action forming micelles which disrupt the membrane 
structure. (C) Toroidal pore: the hydrophilic portion of the peptide interacts with the phospholipid 
head groups while the hydrophobic regions associate with the lipid core. The red part of the 
peptide represents a hydrophilic surface, while blue is hydrophobic (modified from Chan, David 
I.,2006).
Several spectroscopic techniques such as CD spectroscopy and NMR, and microscopic 
techniques such as atomic force microscopy (AFM), have been used to  analyse 
membrane disruption and pore form ation mechanisms by AMPs in to  lipid bilayer 
models (Oliynyk, Kaatze et al. 2007, Fernandez, Sani et al. 2013). Three main 
mechanisms fo r artificial membrane disruption or pore form ation have been suggested 
depending on the peptide structure, membrane lipid com position and peptide 
concentration; these are the carpet, barrel-stave, and toroidal models (Figure 1.7) 
(Sengupta, Leontiadou et al. 2008, W im ley 2010).
20
The carpet model is characterised by covering the membrane with the peptide parallel 
to the membrane surface via electrostatic interactions until a threshold concentration 
is reached. This is followed by a detergent-like action forming micelles, as the polar 
residues facing the hydrophilic head groups of the phospholipids lead to the disruption 
of the membrane structure (Figure 1.7) (Shai 1999, Li, Xiang et a l .2012, Teixeira, Feio 
et al. 2012). Specific peptide-peptide interactions are not included in this model 
(Melo, Ferre et al. 2009). Multiple studies have proposed the carpet mechanism to 
explain the activity of several a-helical cationic AMPs such as cecropin P I (Gazit, Miller 
et al. 1996) and aurein 1.2 (Fernandez, Le Brun e ta l. 2012, Sani, Gagne et al. 2014). 
The findings of NMR and other spectroscopic experiments revealed that AMPs which 
are proposed to act with the carpet model were incorporated parallel to the lipid 
bilayer liposome and didn't penetrate deeper into the bilayer interior (Gazit, Miller et 
al. 1996, Yamaguchi, Huster et al. 2001). The interaction of aurein 1.2 with eukaryotic- 
like bilayers was analysed using NMR and CD spectroscopy and revealed that the 
fatty acyl chains of the outer bilayer were the most affected and not the bilayer 
interior, following peptide incorporation (Fernandez, Sani et al. 2013). Liposome 
leakage assays with fluorescent markers of varying sizes on PC/PG liposomes at 
different lipid/peptide ratios have been carried out to examine the effects of aurein 
1.2. Markers were released in an uncontrolled manner following treatment with the 
peptide, indicating a carpet mechanism for membrane breakdown (Fernandez et al., 
2012).
The barrel-stave model proposes that the peptide firstly binds to the membrane as a 
monomer, and then oligomerizes to form a bundle with a central aqueous pore; the 
hydrophobic surfaces interact with the lipid core, while the hydrophilic surfaces orient
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inwardly to line the pore (Figure 1.7). This arrangement creates an aqueous channel 
resulting in disturbance of membrane function which leads to the discharge of 
cytoplasmic contents and subsequent death of the cell (Jenssen, Hamill et al. 2006, Li, 
Xiang et al. 2012, Schmidtchen, Pasupuleti et al. 2014). The Barrel stave pore model 
has been proposed firstly for alamethicin (Baumann, Mueller 1974) describing the 
channel forming properties of the peptide. Subsequently, many studies have been 
published on alamethicin pore formation using a varied composition of phospholipid 
bilayers and a variety of techniques. Such studies revealed that alamethicin induced 
pores consisting of 6 to 11 monomers, with varied outside and inside diameters from 
18 - 26 and 40 -50 A respectively (Constantin, Brotons et al. 2007, Qian, Wang et al. 
2008, Ye, Li et al. 2012, Rahaman, Lazaridis 2014).
Other peptides, such as the magainins and melittins, insert into in the phospholipid 
bilayer forming toroidal-shaped pores (toroidal or wormhole model). In this model a 
wider ranging peptides firstly aggregate, then initiate binding of the hydrophilic 
portion of the peptide with the phospholipid head groups while the hydrophobic 
regions associate with the lipid core. The peptide insertion induces inward membrane 
bending to form a pore, lined by the head groups of the bilayer together with the 
charged and polar side chains of the peptide molecules, while the peptide hydrophobic 
side chains are oriented toward the inside of the bend (Figure 1.7) (Jenssen, Hamill et 
al. 2006, Sengupta, Leontiadou et al. 2008, Li, Xiang et al. 2012, Lee, Sun et al. 2013, 
Schmidtchen, Pasupuleti et al. 2014).
Both toroidal and barrel stave models are functionally similar but differ in the
suggested structure of the pore and membrane interactions (Gee, Burton e ta l. 2013).
The barrel-stave model was the prototype before the introduction of the toroidal
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model in the mid of 1990s to describe the pore forming mechanism of magainin (Yang, 
Harroun eta l. 2001, Matsuzaki, Murase eta l. 1996).
The toroidal pore is a lipid-dependent pore as lipids play a key role in the membrane 
bending (Sengupta, Leontiadou et al. 2008, Gilbert, Dalla Serra et al. 2014, Sychev, 
Balandin et al. 2015). The NMR data of LL-37 in PC lipid bilayers reflected 
conformational changes of lipid headgroups, as they become bent in the presence of 
LL-37 in a concentration-dependent manner suggesting a toroidal pore mechanism for 
the peptide (Henzler Wildman, Lee et al. 2003). According to biophysical studies/it is 
suggested that AMP binding to some lipid bilayer models generates membrane 
curvature depending on the lipid composition; curved membranes facilitate AMP 
insertion. These suggestions are consistent with the formation of toroidal pores 
(Hallock, Lee et al. 2003, Sato, Feix 2006, Chen, Mark 2011). The same observations 
were seen in a study of Smp24 against prokaryotic-like membranes using AFM 
(Harrison, Heath et al. 2016). Toroidal pores of varying size are observed, dependent 
on the AMP; for example, the magainin-1 pores (assembled by 4 to 10 monomers) 
have diameters ranging from 0.5 - 3 nm in mammalian and bacterial membranes 
(Watanabe, Kawano 2016), while Smp 24 induced pores in PC/PG bilayers have 
diameters averaging 80 nm (Harrison, Heath et al. 2016).
Recent models have provided minor modifications for these original prototypes
models. For instance, a variant model with irregular arrangements of peptide and lipid
molecules (disordered toroidal pore model) has been revealed through the analysis of
the interaction of magainin MG-H2 with PC phospholipid bilayers. Only one molecule
of the MG-H2 peptide is found near the centre of the pore, while other peptide
molecules line the pore (Leontiadou, Mark e ta l.  2006). Only one or two melittin
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molecules were found inserted into a pore-induced PC bilayer, also suggesting the 
disordered toroidal pore as a mechanism of melittin. This pore (diameter 1.5 nm) 
contains 8 -10  lipid head-groups (Sengupta, Leontiadou et al. 2008).
The aggregate channel model is another variant that was proposed to explain 
increasing on membrane permeability without causing cell death. Cationic peptides 
destabilise areas and gain access to both outer and inner membranes by the removal 
or displacement of lipopolysaccharide (LPS)-associated cations (Mg2+ and Ca2+) 
(Giuliani, Pirri et al. 2007, Li, Xiang et al. 2012).
1.9 O ther targets o f AMPs in bacteria
The previous models propose that AMPs induce an increase in membrane permeability 
leading to cell death (Carnicelli, Lizzi et al. 2013). AMPs may have multiple modes of 
action causing lethal cell damage including additional or alternative non-membrane 
permeabilising mechanisms, such as targeting specific intracellular molecules and 
resulting in inhibition of the biosynthesis of DNA, RNA, protein and the cell wall (Bahar, 
Ren 2013, Guilhelmelli, Vilela et al. 2014, Scocchi, Mardirossian et al. 2016).
Several studies have suggested DNA and RNA as targets for the antibacterial activity of 
some AMPs. For example, fluorescein isothiocyanate (FITC)-labelled buforin II was 
observed to penetrate the cell membrane of E. coli at subinhibitory concentrations; 
the peptide also inhibited the migration of DNA and RNA in a concentration-dependent 
manner (Park, Kim et al. 1998). Similarly, gel retardation assays have revealed the 
specific interaction of indolicidin with DNA (Hsu, Chen et al. 2005).
Some AMPs can interfere with cell wall biosynthesis. For instance, bacteriocins inhibit
septum form ation in Lactococcus lactis as a primary target o f the ir killing activity. 
Lactococcin 972 did not show any imm ediate decrease in cell v iab ility  indicating tha t 
no membrane lysis occurred upon addition of the bacteriocin (M artinez, Suarez et al. 
1996). Newer studies have found tha t bacteriocins like nisin and lactococcin 972 bind 
to  Lipid II, the main component in peptidoglycan biosynthesis which leads to  cell wall 
synthesis inh ib ition (Breukink, de Kruijff 2006, Martinez, Bottiger et al. 2008).
1.10 Bacterial resistance to  AMPs
Understanding bacterial resistance mechanisms to  AMPs is crucial in the developm ent 
and use of AMPs as anti-infective agents. Although AMPs are non-specifically targeted 
antim icrobial agents and there is a relatively low potentia l o f bacterial resistance 
emerging to  AM Ps, however bacterial resistance to  AMPs should also be highlighted in 
order to  develop and use AMPs as novel antim icrobials (Gruenheid, Le Moual 2012, 
Nawrocki, Crispell et al. 2014).
One of the common resistance strategies is AMP hydrolysis by bacterial proteases. For 
example, extracellular metalloproteases are secreted by Bacillus anthracis to  catalyse 
the hydrolysis o f peptide bonds o f some AMPs such as cathelicidin-derived peptide LL- 
37. The addition of metalloprotease inhibitors significantly increases the sensitivity o f 
B. anthracis to  LL-37, which reveals the key role o f proteo lytic activity in inducing B. 
anthracis resistance (Thwaite, Hibbs et al. 2006). Also, a num ber o f proteases secreted 
by Gram negative bacteria such as Pseudomonas aeruginosa and Proteus mirabilis 
have been reported tha t they inactivate and cleave LL-37 (Gruenheid, Le Moual 2012).
Some bacteria produce extracellular polymeric substances such as exopolysaccharides 
which are involved in biofilm  and exopolysaccharide capsule fo rm ation . These
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structures protect bacteria by binding or repulsing AMPs, to reduce their access to the 
cell (Gruenheid, Le Moual 2012, Schurr 2013). S. epidermidis produces the 
polysaccharide adhesion, as an intercellular resistance mechanism against some AMPs 
such as LL-37, and dermcidin (Costa, Henriques et al. 2009, Nawrocki, Crispell et al.
2014). Also, Neisseria meningitidis and Klebsiella pneumoniae shield their cell surfaces 
by using capsule polysaccharides to reduce the amount of AMPs reaching the bacterial 
membrane such as polymyxin B, defensins and LL-37 (Gruenheid, Le Moual 2012).
Other resistance mechanisms may be implicated such as the use of efflux pumps. For 
instance, E. coli and Klebsiella pneumoniae strains lacking the AcrAB efflux pump were 
more sensitive to polymyxin B, LL-37 and human (3-defensin-l peptides than the 
parental strain (Padilla, Llobet et al. 2010, Warner, Levy 2010). ATP-binding cassette 
(ABC) transporters are one of the most efficient resistance mechanisms involved in 
AMP export by using the energy of ATP hydrolysis (Gebhard 2012). DNA microarray 
analysis of 5. aureus following exposure to Ovispirin-1 and dermaseptin K4-S4(l-16) 
revealed a significant upregulation of vraDE (encoding an ABC transporter). The 
deletion of genes that encode ABC transporters such as yejABEF (Brucella melitensis) 
and vraDE (5. aureus) resulted in significant increase in the MIC of bacitracin and 
polymyxin B respectively compared with values on the parent strains (Pietiainen, 
Frangois et al. 2009, Wang, Bie et al. 2016).
Additionally, some bacterial species alter their membrane permeability to lower their 
sensitivity to AMPs. This mechanism includes modifications to their membrane 
structure such as reducing or neutralising surface negative charges and increasing the 
concentration of the fatty acids in order to decrease the affinity of AMPs. For example, 
examination of the outer membrane of a nisin-resistant strain of Listeria
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monocytogenes revealed a higher proportion of lipids on its surface. Some bacteria 
such as Proteus mirabilis synthesise a LPS with reduced negative net charge; this 
induces resistance to the cationic polymyxin B (Gutsmann, Hagge et ol. 2005, 
Gruenheid, Le Moual 2012). Moreover, the specific aminoacylation of the polar head 
group of phospholipids in the bacterial membrane have been also used to resist AMPs, 
for examples addition of alanine or lysine to PG to neutralise its net negative charge of 
in Pseudomonas aeruginosa or Staphylococcus aureus respectively. This 
aminoacylation is mediated by aminoacyl-phosphatidylglycerol synthases results jn 
conferring several resistance phenotypes in the presence of some AMPs such as 
protamine (Roy, Dare et al. 2009, Arendt, Hebecker et al. 2012, Joo, Fu et al. 2016).
Nevertheless, most bacterial resistance to AMPs has limitations. Bacteria have not yet 
developed effective resistance to a broad range of AMPs in the way that they have 
succeeded against some classical antibiotic classes (Kraus, Peschel 2006, Greber, 
Dawgul 2017). However, the clinical use of AMPs is still limited (Section 1.11).
1.11 Antim icrobial peptides as potentia l antibiotics in clinical pipeline
Gramicidin, bacitracin, polymyxin B, colistin and daptomycin are examples o f licensed 
and commercially available peptide-based antibiotics. They have achieved widespread 
usage as successful antibiotics to treat a broad range of infections, pointing to the 
clinical potential of other similar antimicrobials in the future.
Several new AMPs are being currently investigated and developed in different clinical 
phases, suggesting promise as future antibiotic therapies. For instance, Novexatin is a 
novel cationic peptide based on human a- and 3-defensins structures. Novexatin has 
antifungal activity, particularly against Candida and Cryptococcus species. Phase II
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clinical trials established the safety and efficacy of novexatinis as topical dermal 
therapy for fungal nail infection (onychomycosis) (Fox 2013). Also, phase II clinical trial 
data has been revealed the safety and effectivity of LL-37 as a topical treatment for 
hronic leg ulcers in patient population (Gronberg, Mahlapuu et al. 2014). Further larger 
clinical studies are required to support the use of these promising AMPs as marketed 
treatments.
Although AMPs represent promising antimicrobial therapeutic agents, their clinical and 
commercial development have some challenges due to high manufacturing costs 
associated with the chemical synthesis of peptides, in comparison with conventional 
small molecule antibiotic production (Bommarius, Jenssen et al. 2010). 
Gastrointestinal enzymatic degradation (Fosgerau, Hoffmann 2015), salt and serum 
inactivation (Mohanram, Bhattacharjya 2016), as well as short half-lives and rapid 
elimination (Kovalainen, Monkare et al. 2015), are other challenges that need to be 
overcome.
Some AMPs have failed to obtain regulatory approval as they were not able to 
demonstrate improvement over current therapies. For instance, omiganan (an 
indolicidin analogue) didn't show any significant anti-infective activity compared with 
positive controls like povidone iodinein phase III trials (Sader, Fedler et al. 2004, 
Gordon, Romanowski et al. 2005). XMP.629 peptide derived from human 
bactericidal/permeability-increasing protein (BPI) failed Phase II clinical trials as a 
topical use for acne because the peptide offered no significant clinical benefit over a 
vehicle-gel control treatment (Lim, Ammons et al. 2001, Gordon, Romanowski et al. 
2005).
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1.12 Snake and scorpion venoms
Both snakes and scorpions use the ir venoms to  immobilise the prey, defend against 
predators and help in the digestion process by solubilizing food (Kuhn-Nentwig 2003). 
Snake venom is a salivary secretion, stored in the venom gland and injected through 
specialised fangs which connect to  the gland via venom ducts (Mackessy 2016). In 
contrast, the scorpion venom apparatus consists o f a pair venom glands found in the 
telson at the end of the abdomen (metasoma) which deliver venom through sharp 
stinger (Torres-Larios, Gurrola et al. 2000). Snake venom is composed mainly o f 
mixtures o f large proteins/enzymes. However, scorpion venom is prim arily 
characterised by having smaller peptides and mucopolysaccharides. Venom 
composition can vary in ter - or intraspecifically according to  age, diet, and sex as well 
as the environmental habitat o f the snake or scorpion (Blaylock 2000, Newton, Clench 
et al. 2007, Ruiming, Yibao et al. 2010).
Most snake venoms are nonlethal, while a proportion causes significant m orta lity. 
Scorpion venoms contain some of the most lethal toxins derived from  animals. 
Scorpion venom includes a wide variety o f peptides which are categorised based on 
the ir structure in to tw o  main groups; the m ajority are disulfide-bridged peptides 
(DBPs) which usually target membrane-bound ion channels. A few  non disulfide- 
bridged peptides (NDBPs) comprise a smaller group w ith in  scorpion venom tha t exhibit 
m ultifunctional activities. DBPs are fu rthe r sub-grouped according to  the ir ion channel 
targets (Na+, K+, Ca2+and Cl") which play key roles in many essential cellu lar processes, 
such as nerve conduction or muscle contraction. Scorpion venoms also contain toxic 
enzymes such as hyaluronidase and phospholipases A2 (PLA2) (Venancio, Portaro et al.
2013, Diaz-Garcia, Ruiz-Fuentes et al. 2015, Nabi, Ahmad et al. 2015, Shanbhag 2015).
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1.13 Therapeutic uses o f snake and scorpion venoms
Early Egyptian and Chinese civilisations have used bee, scorpion and snake venoms for 
various medicinal purposes, including analgesic and anti-inflammatory agents (Utkin
2015). Snake and scorpion venoms contain a variety of biologically active molecules 
with diverse potential therapeutic applications such as anticancer agents, insecticides, 
antimicrobials, anticoagulants, and painkillers (Hmed, Serria et al. 2013, Vyas, 
Brahmbhatt et al. 2013).
Some snake venoms have hypotensive properties through the combined actions of 
bradykinin-potentiating peptides, Ca2+-channel blockers and natriuretic peptides. 
These antihypertensive molecules induce the dilation of blood vessels resulting in 
lowering blood pressure (Koh, Kini 2012, Vyas, Brahmbhatt et al. 2013). Capoten, one 
of the most widely prescribed drugs used in the treatment of hypertension since 1981, 
it has been developed based on the structure o f teprotide, isolated from the snake 
Bothrops jararaca. Teprotide is angiotensin converting enzyme (ACE) inhibitor which 
inhibits the breakdown of angiotensin and therefore prevents vasoconstriction 
(Komajda, Wimart 2000).
Numerous anticoagulant drugs have been designed based on snake venom 
components such as three-finger toxins, phospholipases A2, metalloproteinases and 
disintegrins. For instance, Tirofiban and Eptifibatide are antiplatelet drugs based on 
peptides and proteins isolated from Echis carinatus and Sistrurus miliarlus barbouri 
respectively. They inhibit platelet aggregation by interfering with the binding of the 
major platelet surface receptor to integrins. Ancrod and batroxobin are procoagulant 
serine proteases isolated from the venoms of Agkistrodon rhodostoma and Bothrops
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otrox respectively, which convert fibrinogen to fibrin. Defibrase a currently licensed 
defibrinogenating drug based on the structure of batroxobin, while Viprinex is 
approved for patients with acute ischemic stroke and is based on the structure of 
ancord (Calvete, Marcinkiewicz et al. 2005, Koh, Kini 2012, Marcinkiewicz 2013).
Some snake venom peptides of the family of three finger toxins exhibited distinct in 
vivo analgesic activities that could lead to the development of new potent pain reliever 
agents. For instance, hannalgesin, isolated from the venom of king cobra (Ophiophagus 
hannah), has been found to show significant analgesia without any neurotoxic effects 
(Pu, Wong et al. 1995, Alewood, Allerton et al. 2013).
Generally, licensed snake venom-based medicines are more numerous than those 
medicines based from scorpion venoms; this might refer to difficulties in the 
characterisation of low abundance peptides generally found in scorpion venom (Hmed, 
Serria et al. 2013). A wide range of scorpion venoms peptides have potential 
therapeutic effects but these have yet to be developed into licensed drugs. Anti­
hypertensive peptides have been isolated from scorpion venoms, for example 
bradykinin-potentiating peptides, first purified from Tityus serrulatus venom (Ferreira, 
Alves et al. 1993). A variety of scorpion venom peptides could lead to the 
development of novel analgesic agents. For example, several peptides with analgesic 
activities were isolated from the venom of Chinese scorpion Buthus martensii. Such 
peptides might be potential templates for new painkillers as most of them are insect 
neurotoxins with no cytotoxic effects against human cells (Guan, Wang et al. 2001, 
Shao, Kang eta l. 2007, Shao, Cui etal. 2014).
Chlorotoxins (CTX) isolated from Leiurus quinquestriatus are playing key roles in the
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diagnosis and development of treatment for several cancers. CTX specifically binds 
to matrix metalloproteinase 2 (MMP-2) which is overexpressed in many tumor cells 
and is involved in cancer progression (Dong, Li et al. 2011). CTX - anticancer conjugates 
enhance the delivery of some anticancer agents such as platinum-based anticancer 
drugs (Wang, Wang et al. 2015). Fluorescently-labelled chlorotoxin can be used in 
imaging diagnostics and l-radiolabelled toxin is in clinical trials to target gliomas 
(Veiseh, Gabikian et al. 2007).
1.14 Antim icrobial activities o f scorpion and snake venoms
Snake and scorpion food is frequently contaminated with a variety of potential prey-
borne pathogens (Bastos 2012). The main areas of infection for snakes are the mouth
and fang, while the telson of scorpions is the most accessible to a wide range of
pathogenic microbes (Gao, Tian et al. 2007). Salmonella and Bacillus sp are the most
frequently isolated bacteria from snakes (Garcia-Lima, Laure 1987, Shek, Tsui et al.
2009) There are a few reports of the prevalence of pathogenic infections in snakes
such as mouth rot infections caused Pasteurella and Proteus sp and ulcerative
dermatitis which may lead to snake death (Talan, Citron et al. 1991, Garcia-Lima, Laure
1987). The presence of potent antimicrobial constituents in snake and scorpion
venoms might contribute to antimicrobial protection as a host defence mechanism
when attacking prey. For example, a significant upregulation of the AMP BmKbl in the
venom gland of Buthus martensii has been detected when infected by E. coll and
Micrococcus luteus. Interestingly, the milked crude venom of the challenged
individuals showed greater antibacterial activity against Gram positive bacteria than
uninfected individuals. It has also been observed that B. martensii use their venoms as
antimicrobial sprays to protect their bodies against pathogens (Gao, Tian et al. 2007,
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Torres-Larios, Gurrola eta l. 2000).
The crude venoms of numerous scorpion species have been shown to inhibit the 
growth of diverse pathogens such as Gram negative, Gram positive bacteria, fungi and 
viruses (Erde§, Dogan et al. 2014). Varied bactericidal and viricidal activities have been 
reported from crude venoms of different species such as the Chinese Buthus martensii 
(Gao, Tian et al. 2007) and Egyptian species such as Leiurus quinquestriatus (Salama, 
Geasa 2014), Scorpio maurus palmatus and Androctonus australis (El-Bitar, Sarhan et 
al. 2015).
Three viperid venoms {Agkistrodon rhodostoma, Bothrops jararaca and B. atrox) have 
been shown to have potent antimicrobial activity against resistant bacteria strains such 
as Staphylococcus epidermidis and Enterococcus faecalis (Ferreira, Santos et al. 2011). 
Venoms of Bothrops alternatus (Argentina) (Bustillo, Leiva et al. 2008), Echis carinatus 
(Iran) (Fathi, Jamshidi et al. 2011), Egyptian snakes venoms (Pseudechis australis, Naja 
naja and Naja nigricollis) (Shebl, Mohamed et al. 2012) and Bothrops jararaca  (Brazil) 
(Cendron, Bertol et al. 2014, Lucas Henrique Cendron, 2014) all have significant 
antimicrobial activities against wide range of bacteria and fungi. These studies 
encourage further investigation to detect and identify other novel active antimicrobial 
peptides in snake and scorpion venoms using highly developed proteomic and genomic 
techniques.
1.15 Enzymes o f scorpion and snake venom s w ith  antim icrobial activities
The antimicrobial potential of snake venom enzymes is widely investigated. PLA2 and L- 
amino acid oxidases (LAAOl and LAA02) are among the best studied enzymes 
associated with antibacterial properties (Sarny, Pachiappan e ta l. 2006). Both PLA2 and
LAAO are usually responsible for the major toxic effects during snake envenomation. 
The phospholipid of the bacterial membranes is the main target of PLA2, as they 
hydrolyse the phospholipid by releasing the fatty acids from the second carbon group 
of the glycerol backbone of the membrane phospholipid (Toyama, Rodrigues et al. 
2012). Some PLA2es derived from snake venoms have displayed a variety of potent 
antibacterial activities. For example, PLA2 from Daboia russelii pulchella venom exerts 
antibacterial activity against both Gram positive and Gram negative bacteria 
(Sudharshan, Dhananjaya 2015); similar antibacterial activities have been reported for 
PLA2esfrom the venom of Naja naja (Sudarshan, Dhananjaya 2016).
LAAO is widely found in snake venoms in high concentrations. Several snake venom 
LAAOs have shown potential antibacterial activity. For example, Balt-LAAO-I, an acidic 
LAAO isolated from Bothrops alternatus venom inhibits S. aureus and E. coli growth in 
a dose-dependent manner (Stabeli, Marcussi et al. 2004). Several reports have 
suggested that the antibacterial action of LAAO might be caused by the generation of 
H2O2 during the deamination of L- amino acids which have induced the oxidative stress 
leading to membrane damage and consequently, bacterial cell death (Torres, Dantas et 
al. 2010, Lee, Tan et al. 2011).
1.16 Antim icrobial peptides from  scorpion and snake venom s
Scorpion venoms have an abundant supply of AMPs; although less than 1% 50
AMPs) of all described AMPS from living organisms were isolated from scorpion 
venoms (Harrison, Abdel-Rahman et al. 2014, Tarazi 2016). Scorpion venom AMPs are 
classified based on the presence of disulfide bonds in their structure into two main 
groups: the majority are NDBPs and DBPs (Table 1.2) (Luna-Rarmrez, Jimenez-Vargas et
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al. 2016). NDBPs are further sub-grouped according to their sequence length into long 
(>35 amino acids), intermediate (20-35 amino acids) and short (< 20 amino acids) chain 
peptides (Zeng, Corzo et al. 2005, Almaaytah, Tarazi et al. 2014, Harrison, Abdel- 
Rahman eta l. 2014).
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Scorpine is considered as the first antimicrobial DBPs was isolated from scorpion 
(Pandinus imperator) venom. The amino-terminal sequence of scorpine shares some 
similarities with insect cecropins (Possani, Corona et al. 2002).Other scorpine-like 
peptides have subsequently identified such as HgeScpIpl (Hadrurus gertschi) (Diego- 
Garcia, Schwartz et al. 2007) and Heteroscorpine-1 (Heterometrus laoticus) 
(Uawonggul, Thammasirirak et al. 2007).
To date approximately 34 antimicrobial NDBPs have been identified and functionally 
characterised from scorpions (Table 1.2). One of the most basic peptides among this 
subfamily is hadrurin (+5 net charge) (Zeng, Corzo et al. 2005). It was purified from the 
venom of the Mexican scorpion Hadrurus aztectu (Torres-Larios, Gurrola et al. 2000). 
CD spectra of pandinin 1 isolated from P. imperator showed the peptide adopts an a  
helical structure in different membrane mimicking solvents, it was predicted that Pinl 
should have two a helical regions separated by a random coil region (Corzo, Escoubas 
eta l. 2001).
Pandinin 2 (Pin 2) was the first intermediate chain AMPs charcterised were, has been 
purified from the venom of the scorpion P. imperator. Pin2 shares 60 to 70% homology 
with some AMPS from frog skin such as brevinin 1, pipinins and magainins (Corzo, 
Escoubas et al. 2001). HsAp considered as novel class intermediate chain peptides 
showed no significant homology to any other class of scorpion AMPs (Nie, Zeng et al. 
2012).
The first short chain AMPs were isolated from the African scorpion Opisthacanthus 
madagascarienis; IsCT and lsCT2 differ only in 3 positions (Dai, Yasuda e ta l,  2001). 
Pantinin-1, -2 and -3 are homologous peptides (61-81%) have been identified from the
37
venom gland of P. imperator showed considerable sequence identities (50-64%) with 
IsCT and lsCT2 (Zeng, Zhou et al. 2013). Interestingly the emergence of Hpl404  
resistance was evaluated in 5. aureus; no significant resistance for was seen until 15 
passages (Li, Xu et al. 2014).
Few small and moderate sized non-enzymatic peptides with potent antimicrobial 
effects against a wide range of bacteria and fungi have been reported from snake 
venoms (Table 1.3). Most characterised AMPs from snake venoms belong to 
cathelicidins (Wang et al., 2008, Zhao et al., 2008, Zhang et al., 2010).
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Three-finger toxins (3FTxs) are a fam ily o f cytotoxic proteins abundantly 
present in elapid and colubrid venoms. They are relatively small proteins (6-7 
KDa) in contrast to  the o ther families o f snake venom proteins. 3FTxs have 
three (3-stranded loops in the ir structure (Figure 1.8), these loops fixed to  
central core by four or five conserved disulphide bridges (Girish, Kumar et al. 
2012, Dubovskii, Utkin 2014). 3FTxs include tw o subfamilies short-chain (four 
disulfides, 60-62 residues) and long-chain (five disulfides, 66-75 residues) 
(Tsetlin 1999). They can be structurally classified into tw o  divisions as P-type 
(have Pro30 residue at the tip  o f the second loop) and S-type (presence of a 
serine residue at position 29) (Chien, Chiang et al. 1994, Menez 2002, 
Dubovskii, Utkin 2014).
Figure 1.8 Three-dimensional structures of three-finger toxins (3FTx) showing loops 
and disulphide bridges. A) Short-chain (Erabutoxin) and B) Long-chain (x-bungarotoxin). 
The loops ('fingers') are marked with Roman numbers I—III. The extension of second loop 
in long-chain 3FTx due to fifth disulphide bridge and is shown in red color (Kini, Doley 
2010 ).
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3FTxs are multi-target proteins with a wide variety of biological activities 
including neurotoxic (Jiang, Li et al. 2011), anticoagulant (Barnwal, Jobichen et 
al. 2016)) and antiplatelet (Chanda, Sarkar et al. 2013) effects. This family is 
also one of the most cytotoxic, believed to contribute to the antibacterial and 
cytolytic properties of snake venom (Dubovskii, Utkin 2014, Florea, Andrei e ta l. 
2016).
Most 3FTxs such as short-chain cardiotoxins can induce structural and 
functional effects of the heart, rich in basic residues (mainly lysine) that flank 
the tips of the loops which are otherwise dominated by hydrophobic residues 
(Anbazhagan, Reddy et at. 2007, Dubovskii, Utkin 2014). Depending on their 
amphipathic characteristics, 3FTxs can bind and insert into anionic or neutral 
lipid bilayers (Kini, Evans 1989, Efremov, Volynsky et al. 2002, Bechinger, 
Lohner 2006). The mode of action of 3FTxs against prokaryotic and eukaryotic 
model membranes has been studied using several spectroscopic techniques 
revealing that they have a higher affinity for negatively charged model 
membranes than zwitterionic surfaces. Studies also suggest that loop I play a 
key role in cardiotoxin binding to membranes (Carbone, Macdonald 1996, 
Efremov, Volynsky et a/. 2002).
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1.17 Scope of the  present study
This present study aims to explore several Egyptian scorpion and snake venoms as a 
source for novel antimicrobial peptides. It also aims to improve our understanding the 
mechanism of action of some synthetic AMP identified previously from Egyptian 
scorpion Scorpio mourus palmatus. These findings will be useful in elucidating AMP 
mechanism of action and using these peptides templates to develop therapeutically 
useful drugs.
The objectives were to:
•  Evaluate the antimicrobial and cytotoxic activities of the purified peptides from  
snake venoms and three synthetic alpha-helical (Smp) peptides identified 
previously through the genomic analysis of the Egyptian scorpion Scorpio 
mourus palmotus.
•  Identify and characterise novel AMPs from Egyptian snake venoms.
•  Examine the morphological changes of bacterial cells in response to different 
concentrations of Smp peptides treatment at different time intervals.
•  Identify the differentially expressed genes following to  exposure of Smp24 and 
Smp43 in E. coli as a model for pathogenic Gram negative bacteria.
•  Investigate the antibacterial activity o f Smp24 in presence of different 
concentrations of various cations.
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2 Materials and Methods
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2.1 Materials
All strains used in this study were provided by SHU culture collection except the Keio 
collection and the parental E. coli BW25113 were provided by the National 
BioResource Project (NBRP), National Institute of Genetics (NIG), Japan. All chemicals 
used in this study were purchased from Sigma-Aldrich, UK.
2.2 Collection of scorpion and snake venoms.
Venoms were collected from scorpions and snakes originating from Egypt's deserts. 
Scorpion venom was collected by electrical stimulation of the telson (Ozkan, Filazi 
2004, Oukkache, Chgoury et al. 2013). Venom droplets were collected in an Eppendorf 
tube lyophilised and stored at -20 °C. Venoms were extracted in 1% acetic acid and 
centrifuged (15,000 x g) to remove insoluble matter. Snake venoms were collected by 
manual milking, lyophilized and stored at -20 °C. Snake venom was extracted in water 
and centrifuged as scorpion venoms for 15,000 x g.
2.3 Peptide synthesis
Smpl3, Smp24 and Smp43 (10-20 mg each) were synthesised by solid phase FMOC 
synthesis (Prolmmune Limited, Oxford, UK). Peptide purity was > 90% (C18 reverse 
phase HPLC and mass spectroscopy). The sequences of the three peptides are given in 
Table 2.1.
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Table 2.1 Amino acid sequences of Scorpio maurus palmatus venom gland AMPs used for 
this study
Peptide Amino acids sequence
Smpl3 ILQDIWNGIKNLF
Smp24 IWSFLIKAATKLLPSLFGGGKKDS
Smp43 GVWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS
2.4  Antim icrobial activity assay and determ ination  o f m inim um  inhib itory  
concentrations
The minimum inhibitory concentrations (MICs) of the active peptides against a variety 
of organisms were determined using the BSAC broth micro-dilution method described 
by Andrews (2001) and performed on a Tecan CENios Plus (Tecan, Mannedorf, 
Switzerland). Thermo Scientific™ Nunc™ 96-Well Polypropylene MicroWell™ plates 
were used.
Serial dilutions of synthetic AMPs and purified snake venom peptides were assayed. 
Cultures without peptides were used as positive controls. Fresh uninoculated Mueller- 
Hinton broth was used as a negative control. The MIC was determined as the 
concentration of the peptides in the last well in which no growth was observed. All 
samples were tested in duplicate on two separate occasions for a total of four 
replicates. Test strains used in this project included three Gram negative bacteria, 
seven Gram positive bacteria, and one fungus and were obtained from the BMRC 
(Table 2.2).
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Table 2.2 Microorganisms used for micro-broth dilution minimum inhibitory concentration 
tests and their sources
Microorganism Source
Gram-negative Escherichia coli JM109
bacteria Klebsiella pneumoniae NCTC 13439 
Pseudomonas aeruginosa NCI MB 8295 
Staphylococcus aureus SH1000 
Staphylococcus epidermidis
Gram positive Bacillus cereus NCTC 2599 SHU culture collection
bacteria Bacillus cereus UM20.1. 
Bacillus subtilis NCIMB 8054 
Bacillus subtilis NCIMB 8056 
Bacillus subtilis NCIMB 3610
Fungus Candida albicans
2.5 Haemolytic activity assay
The haemolytic activity o f a peptide was tested using sheep erythrocytes as described 
by Corzo et al., (2001). Briefly, a 10% (v/v) suspension of washed erythrocytes in 
Phosphate-buffered saline (PBS) was incubated w ith  the purified prote in in a 96-well 
plate fo r 1 h w ith in te rm itten t shaking. The absorbance in the supernatant was 
measured at 570 nm. PBS and 10% (v/v) Triton X-100 were used as 0% and 100% 
controls respectively. The percent hemolysis was calculated using the fo llow ing 
form ula: Percent Haemolysis = 100 x [(Absorbance o f sample -  Absorbance o f negative 
control) /  (Absorbance of positive control -  Absorbance of negative contro l)].
2.6 Cytotoxicity assay
Cellular pro liferation was determ ined by measuring the am ount o f ATP generated by 
viable cells using the CellTiter-Glo luminescent cell v iability assay (Promega, Madison, 
USA) as per manufacturer's instructions. Peptides were assayed at d iffe ren t
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concentrations against a human kidney cell line (HEK293) and a human keratinocyte 
(HaCat) cell line to determine the potential toxic effects in vitro. All cell lines were 
tested routinely for mycoplasma. Cells were grown in Dulbecco's modified Eagle's 
medium (DMEM) with 5 % of fetal bovine serum (FBS), 1% penicillin/streptomycin, and 
1% glutamine. All cells were incubated at 37°C in a 5% CO2 atmosphere. The medium 
was changed twice a week. Briefly, HEK293 and HaCat cells were seeded at a density of 
2.5x l04 per well in a 96-well plate in 100 pi DMEM media and incubated with peptide 
for 24 hours. Untreated cells were used as a negative control. 10% triton (v/v) was 
used as a positive control. All treatments were performed in triplicate, in three 
independent experiments. Before cell viability was determined, plates were 
equilibrated at room temperature for 30 minutes, thereafter 100 pi CellTiter-Glo 
Reagent® was added to each well. The plate was shaken for 2 minutes to induce cell 
lysis and incubated for 10 minutes at room temperature to stabilise the luminescent 
signal. The luminescence was recorded using CLARIOstar® microplate reader and MARS 
data analysis software (BMG LABTECH, Ortenberg, Germany).
2.7 Fluorescence microscopy
Following treatment with Smp24 and Smp43 as in the previous section, HEK293 and 
HaCat cell lines were examined using Hoechst 33342 and Propidium Iodide (PI) staining 
(Sigma-Aldrich, Dorset, UK). Cells were stained with 10 pg/ml Hoechst 33342 and 10 
pg/ml PI for 30 min at 37°C and examined using a fluorescence microscope (Olympus, 
1X81, UK) and images were captured using Cell-F software.
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2.8 Purification of crude snake venoms
Individual venoms were in itia lly fractionated by size-exclusion chromatography. 
Lyophilised crude venoms (35-60 mg) were dissolved in w ater and applied to  a HiLoad 
26/600 Superdex 200 pg column (60 x2.6 cm diameter) connected to  an AKTA Prime 
system (GE Healthcare) and equilibrated w ith  10 mM sodium ch loride/50m M  sodium 
acetate buffer pH 4.3. Fractions (3 ml) were m onitored at 280/220 nm and collected at 
a flow  rate o f 0.5 m l/m in. Fractions were collected, dialysed (M W  Cut o ff 500 Da) 
against distilled w ater at 4°C using PUR-A-Lyzer™ dialysis kit (Sigma-Aldrich, USA) and 
then freeze dried. The protein concentrations were measured (NanoDrop™ 1000, 
Thermo Scientific, USA) and screened fo r antibacterial activity against d iffe ren t species 
o f bacteria.
Active fractions were resuspended in 1 ml o f w ater and fu rthe r purified by cation 
exchange chromatography w ith a SP Sepharose column (100x16 mm diameter). Prior 
to  this purification process, the column was equilibrated in buffe r (A) 10 mM sodium 
chloride/50 mM sodium acetate buffer pH 4.3. The column washed w ith  buffer A to  
remove any unbound proteins. Samples were eluted w ith  a linear gradient (20 CV) o f 
buffer (B) 1 M sodium chloride/50 mM sodium acetate buffer pH 4.3 at a flow  rate o f 
0.5 m l/m in. The chromatography was carried out at 4°C using an AKTA Prime system as 
before.
2.9 Analysis of m olecular mass by mass spectrom etry
The molecular mass of purified peptides was determ ined by mass-assisted laser
desorption ionization tim e of fligh t (MALDI-TOF) mass spectrom etry o f the fraction
obtained after separation through cation exchange chromatography. 5 pL o f fraction
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was mixed with 5 pL of matrix solution (a-cyano-4-hydroxy-cinnamic acid in 0.1% 
Trifluoroacetic acid (TFA) /acetonitrile 1:2). 0.5 -  1 pL of this mixture was transferred 
to a MALDI sample plate and allowed to dry. The molecular mass was determined 
using MALDI-TOF mass spectrometry (Voyager Spec # 1 MC) in positive ionization 
mode.
2.10 Identification of N -term inal residues
N-terminal sequencing using the Edman degradation technique was used to identify 
the first five amino acids (Alta Bioscience Ltd, University of Birmingham, Birmingham, 
UK of purified snake proteins.
2.11 Peptide homology analysis
Online bioinformatics tools were used to characterise the purified active peptides by 
comparing the N-terminal sequence to the database of published sequences of 
peptides and proteins. EXPASY BLAST software, Protein-protein BLAST (blastp) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi), was used to subject the obtained N-terminal 
sequence to a similarity search.
2.12 Preparation of cells fo r scanning electron microscopy
Overnight cultures of E. coli JM109 and 5. aureus SH1000 were diluted into fresh MH 
Broth to a cell density lx lO 6 GFU/ml then incubated at 37°C until an ODeoonm of 0.3 was 
reached (mid-exponential growth phase). Bacterial cells were treated with different 
concentrations of Smp peptides for different time intervals (10 minutes, 1 hour, and 24 
hours) at 37°C . Untreated controls were prepared in free MH medium.
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The cells were harvested by centrifugation (10,000 x g, 10 mins) re-suspended in wash 
buffer (0.1 M sodium phosphate buffer, pH 7.4), and then collected by centrifugation 
(10,000 x g, 10 mins).Cells were fixed w ith  2% glutaraldehyde in 0.1 M sodium 
phosphate at 4°C fo r 24 hours. Cells were washed tw ice w ith 0.1 M phosphate buffer 
fo r 15 minutes intervals at room tem perature. To post fix the cells, 1% aqueous 
osmium tetroxide was added and the samples were le ft at room tem perature fo r one 
hour and then washed tw ice w ith 0.1 M phosphate buffer. The samples were 
dehydrated w ith  graded ethanol solutions (75% ethanol fo r 15 minutes, 95% fo r 15 
minutes, 100% ethanol fo r 15 minutes, 100% ethanol fo r 15 minutes). Samples were 
then exposed to  100% ethanol: hexamethyldisilazane (1:1) fo r 30 m inutes fo llow ed by 
30 minutes in hexamethyldisilazane. All dehydration steps were carried out at room 
tem perature. Specimens were allowed to  air dry overnight in a fum e hood and 
mounted onto a pin-stub using a Leit-C sticky tab (Agar Scientific Ltd, Essex, UK) and 
gold coated using an Edwards S150B sputter coater (BOC Edwards, UK) and examined 
in a Philips XL-20 SEM (Philips, Eindhoven, The Netherlands) at 15kV.
2.13 Preparation of cells fo r transmission electron microscopy
TEM was used to  investigate the morphology o f bacterial cells induced only by
subinhib itory concentrations o f Smp peptides fo r d iffe ren t tim e intervals (10 minutes,
1 hour, and 24 hours) at 37°C. Samples were prepared in the same manner as fo r the
SEM experiments, except that a fter dehydration in ethanol, samples were cleared in
epoxypropane (EPP) and in filtra ted in 50/50 araldite resin: EPP m ixture overnight on a
rotor. This m ixture was changed twice, over 8 hours, w ith  fresh araldite resin m ixture
before being embedded and cured in a 60 °C oven fo r 48-72 hours.U ltrath in sections,
approximately 85nm thick, were cut on a Leica UC 6 u ltram icrotom e (Leica, W etzlar,
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Germany) onto 200 mesh copper grids, stained for 30 mins with saturated aqueous 
Uranyl Acetate followed by Reynold's Lead Citrate for 5 mins. Sections were examined 
using a FEI Tecnai Transmission Electron Microscope (FEI Tecnai™, Oregon, USA) at an 
accelerating voltage of 80Kv. Electron micrographs were recorded using a Gatan Orius 
1000 digital camera and Digital Micrograph software (Gatan, Pleasanton, USA).
2 .14  D eterm ination of killing curves
Four independent cultures of the E. coli strain JM109 were exposed to different 
concentrations (zero to MIC) of each peptide. A culture of E. coli JM109 was grown 
overnight in Mueller-Hinton broth, then diluted into fresh Mueller-Hinton broth (2x l07 
CFU/ml) 2.7 ml of this suspension was then added to 0.3 ml of peptide, and incubated 
at 37°C with shaking and grown to the exponential growth phase of an optical density 
at 600 nm (OD600) of 0.6. At specific time points, OD was measured at 600 nm 
wavelength by a Jenway 6715 (UV/Vis) spectrophotometer (Jenway, Staffordshire, UK). 
Untreated bacteria were used as negative controls. The assay was repeated three 
times and the average was reported.
2.15 Isolation o f to ta l cellular RNA
Total RNA was extracted by using a SV Total RNA Isolation System (Promega
Corporation, Madison, Wl, USA). The cells were harvested by centrifugation for 2
minutes at 14,000 x g. Pellets were resuspended and incubated for five minutes in
lOOpI of freshly prepared TE containing 0.4mg/ml lysozyme. Cells were lysed with 75 pi
SV RNA Lysis buffer, then incubated at 70°C in SV RNA dilution buffer for 3 minutes,
followed by centrifugation at 14,000 x g at room temperature for 10 minutes. 200 pi of
95% ethanol was added to the cleared lysate. The lysate was passed through a SV Total
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RNA Isolation System spin column. From this point on the manufacturer's 
recommendations were followed. The extracted RNA was assessed for its 
concentration, purity and integrity using the NanoDrop Spectrophotometer and the 
Agilent 2100 Bioanalyzer instrument (Agilent, Wokingham, UK) in order to reduce 
biases in microarray analysis caused by poor RNA quality. For RNA judged suitable for 
microarray analysis, the following criteria were met (Table 2.3) (Bhagwat, Ying et al. 
2013).
Table 2.3 Recommended parameters for RNA used for microarray analysis
Parameters Range
RNA concentration 10 - 200 ng/pL
260/280 nm >1.9
260/230 nm >1.9
RNA Integrity Number (RIN) 8-9
23S rRNA /  16S rRNA > 1.5
2.16 Gene expression m icroarray analysis
Gene Expression Analysis protocol (version 6.5, May 2010) was performed using a one- 
Colour Microarray technique (Agilent, Wokingham, UK). Unless indicated, all 
microarray reagents, data analysis software were ordered from Agilent.
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2.16.1 Sample labelling and hybridisation
For each tested sample, serial dilutions of Agilent One-Colour Spike-ln Mix which 
contains 10 pre-designed positive control transcripts were mixed with a total RNA 
input amount of 100 ng/dilution. Sample RNA, together with the internal control 
transcripts, were labelled with Cyanine 3-CTP (Cy3) dye during an amplification 
reaction using the Agilent Low Input Quick Amp Kit. The generated fluorescent 
complementary RNA (cRNA) products were then purified (RNeasy Mini Kit, Qiagen). 
The yield of the linearly amplified cRNA and the Cy3 specific activity were quantified by 
absorbance at 260 nm. To reduce its structural complexity, 600 ng cRNA of each 
sample was fragmented to reduce the size of the cRNA to approximately 50-200 bases 
with a median of around 85 bases. The fragmentation step took place at 60°C for 30 
min using a Fragmentation Mix for 8- pack microarray format. Such fragmentation 
would improve cRNA specificity and binding efficiency to the oligo arrays which have 
60mers as the target probes. 25 pL of the fragmentation reaction were combined with 
25 pL hybridisation buffer and immediately loaded onto the gasket slide. The 8 x 15K 
whole E. coli K12 oligo array slide was placed on top of the gasket slide loaded with 
hybridisation mixture and the microarray slide chamber was prepared. Assembled 
slide chambers were placed in a hybridisation rotator (10 rpm, 65°C) hybridization 
oven. After 17 hours, hybridised slides were disassembled, washed and then scanned 
at 3 pm resolution using Agilent C Microarray Scanner (Agilent, Wokingham, UK) pre­
set with the default settings for a 8 x 15K Microarray Format. All samples were tested 
in duplicate on each of two separate arrays.
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2.16.2 Data analysis
A fter detecting the fluorescence signals o f the hybridised slides, the Agilent Feature 
Extraction (FE) Software (version 10.7) was used to  process the generated image. A 
pre-defined protocol (GEl_107_Sep09) tha t matches the slide type was in itia ted to 
im port a set o f parameter values and settings, which allow the software to  align the 
default grid to  the image. Following identification o f the image spots, the software 
autom atically performs a background correction and dye normalisation by subtracting 
the background intensities from  the foreground intensities and scale average signal 
intensity fo r each sample to  the average signal intensity fo r all samples in order to  flag 
and reject the outliers and low quality probes. This was followed by an autom atic 
computing o f feature log ratios (Agilent's Processed Signal value) and the ir p-values. 
The FE prelim inary processing ends w ith  producing a quality control (QC) report fo r 
each array image, which includes statistical results w ith  thresholds useful fo r 
evaluating the reproducib ility and re liab ility o f the microarray, and an exportable raw 
data file in a "tx t" form at, which contains all the parameters, statistical calculations 
and the annotation inform ation associated w ith  the Agilent m icroarray used in the 
experiment.
Raw "tx t" data files were then analysed using Agilent GeneSpring GX software (version 
13.1) (http ://w w w .genom ics.ag ilent.com /artic le .isp?pageld=2141). Briefly, in tensity 
values were subjected to  a log2 transform ation and normalisation to  the 75th 
percentile-shift normalisation. The im ported data files were then grouped and 
assigned to  the experim ent parameters and conditions. For instance, data files o f cells 
treated w ith peptide were assigned to  the condition "trea ted", while the contro l cells 
were assigned to  the condition "untreated". To identify d iffe rentia lly  expressed genes,
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statistical analysis was performed by using unpaired T-test and applying a Benjamini- 
Hochberg multiple testing correction method to correct the computed p-values. 
Finally, the list of the identified genes was filtered to include only genes with a > 2 fold 
change using the built-in fold change function before exporting the list into an Excel 
file.
2 .17 Gene cluster and pathw ay enrichm ent analysis
Database for Annotation, Visualisation and Integrated Discovery (DAVID) software 
tools was used for gene and molecular pathways analysis 
(https://david.ncifcrf.gov/home.isp). In our work, the significant biological process 
terms and pathways enrichment analyses of the differentially expressed genes were 
performed using DAVID 6.7 with the thresholds of p-value <0.05 and enrichment gene 
count >2. Functional annotation clustering (FAC) allows clustering of Gene Ontology 
(GO) categories sharing a significant number of genes.
2 .18 Reverse transcriptase-polym erase chain reaction (RT-PCR)
RT-PCR was performed to confirm the microarray expression data obtained by 
bioinformatics analysis. Total RNA was isolated from cell samples as described 
previously. RNA was reverse transcribed into cDNA with a QuantiTect Reverse 
Transcription Kit (Qiagenlnc., Chatsworth, CA, USA). Manufacturer's instructions were 
followed and briefly as follows. Sample RNA was mixed with water in the presence of 
RNase and incubated at 42°C for 3 minutes, this was followed by the addition of 
polymerase and nucleotide mix plus Quantiscript RT buffer. The cocktail was incubated 
for a further 30 min at 42°C, then Incubated at 95°C for 3 minutes to inactivate the
55
reverse transcriptase. Once DNA has been synthesised, a Nanodrop measurement was 
taken to  determ ine the concentration of DNA.
The RT-PCR reactions were then performed on a StepOnePlusTM Real-Time PCR 
System (Applied Biosystems, California, USA) using DNA samples in order to  investigate 
gene expression levels o f investigated genes. cysG, idnT, and hcoT were used as 
housekeeping genes. These housekeeping genes have been strongly recommended by 
(Zhou, Zhou et al. 2011) as novel reference genes fo r quantifying gene expressions of 
E. coli by RT-PCR and they were stably expressed under all the conditions investigated 
in this study. Probes fo r real-time PCR were purchased from  Applied Biosystems, 
conjugated at the 5' end to  the fluorochrom e FAM, and at the 3' end to  the non- 
fluorescent quencher w ith m inor groove binder NFQ-MGB. Two pi aliquots containing 
25 ng o f the investigated samples were used in the preparation o f the to ta l ten- 
m icrolitre  reactions using the TaqMan Universal PCR Master Mix (Applied Biosystems). 
Samples were run fo r 40 cycles and results were analysed using the 2_AACt m ethod and 
presented as relative gene expression normalised to  the average cycle threshold fo r 
the three housekeeping genes. Each sample was run in trip lica te  fo r each biological 
replicate. To test the primers fo r specificity and quality, efficiency curves were 
performed.
2.19 Screening of Keio collection
In order to  identify the essential genes whose products are involved in the response of 
E. coli when treated by Smp peptides, the susceptibility o f 79 E. coli single knockout 
m utant strains was assayed. The Keio collection and the parental E. coli BW25113 were 
provided by the National BioResource Project (NBRP), National Institu te  o f Genetics
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(NIG), Japan. The pre-selection of the mutants for the assay was based on the 
differentially expressed genes produced from microarray analysis compared with that 
of the E. coli BW25113 parent strain. Also, eight strains with genes not identified as 
significant were selected from the Keio collection, having a single deletion of either 
ihfB, uxuR, hacT, cysG, ugpQ, idnT, yghB or pbpC genes and these were assayed as 
experimental controls. This assay was performed on a TecanCENios Plus (Tecan, 
Switzerland). Thermo Scientific™ Nunc™ 96-Well Polypropylene MicroWell™ plates 
were used and carried out as described in section 2.4.
2 .20 Effect o f cations on th e  antibacterial activity o f Smp24
The effect of cation concentration on the antimicrobial activity of Smp24 was tested by 
determining the MICs of the peptides against E. coli in the presence of titrated cations. 
MICs were determined by the same method as described in Section 2.4 for 
determining the effect of the salt concentration on the activity of Smp24. The 
monovalent cation, Na+ and four divalent cations, Fe2+, Mn2+, Ca2+' and Mg2+ were 
added as chloride salts with Smp24. The concentrations of cations in the assay ranged 
from 0 to 20 mM.
2.21 Analysis o f cell surface composition o f E. coli treated  w ith  Sm p24 using X- 
ray photoelectron spectroscopy (XPS)
A culture of £  coli JM109 was grown overnight in Mueller-Hinton broth, then diluted
into fresh Mueller-Hinton broth (2x l07 CFU/ml), and incubated at 37°C with shaking
and grown to the exponential growth phase represented by an optical density at 600
nm (ODeoo) of 0.4. 0.9 ml of this suspension was then added to 0.1 ml of peptide and
then incubated for 10 minutes. The cells were harvested by centrifugation (10.000 xg,
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10 minutes). Each cell sample (cells + any retained liquid) was placed as 1 pi on the 
sample holder at room temperature and atmospheric pressure. The sample holder was 
then placed in the preparatory chamber of the XPS and the atmosphere reduced to a 
pressure of 5 x 10'7 Torr. Once the sample was under vacuum the sample holder was 
cooled to -100 °C. The samples were then transferred to the analysis chamber. The 
temperature at the beginning of the analysis was -70°C but had increased to -39 °C 
once the data had been collected. The analyses were carried out using a Kratos Supra 
XPS with the monochromated aluminum source (Kratos Analytical Ltd, UK). Survey 
scans were collected between 1200 to 0 eV binding energy, at 160 eV pass energy and 
at 1 eV intervals. The analysis area was 300 to 700 pm. The data was quantified using 
theoretical Scofield relative sensitivity factors with small angular distribution and 
kinetic energy corrections. The data was calibrated for binding energy by making the 
main carbon peak C Is  at 285.0, and correcting all data for each sample analysis 
accordingly.
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3 Characterisation of novel antimicrobial peptides from 
Egyptian scorpion and snake venoms
59
3.1 Introduction
Snake and scorpion venoms have attracted some interest as a source o f novel AMPs. 
However, they have been largely unexplored fo r identification o f such agents in 
contrast to  o ther organisms (de Lima, Alvarez Abreu et al. 2005, Sarny, Stiles et al. 
2015). Thus, a w ider range of undiscovered peptides w ith potentia l antim icrobial 
activities are likely to  be found in unexplored snake and scorpion venoms.
The m ajority o f antim icrobial molecules tha t have been purified from  snake venoms 
are enzymes such as LAAO and PLA2 which constitutes the major com ponent o f snake 
venom (Torres, Dantas et al. 2010, Vargas, Londono et al. 2012, Sudharshan, 
Dhananjaya 2015). These have been purified by conventional chrom atographic 
techniques such as gel filtra tion , ion-exchange, reverse phase HPLC.
The identification and development o f therapeutic molecules from  snakes and 
scorpion venom as prototype drugs have been revolutionised by the rapid 
advancement o f new methodologies in the last tw enty years. Proteomic and genomic 
analyses have been widely used to  determ ine the d istribution o f protein fam ilies in a 
variety o f snake and scorpion venoms in order to  expand our understanding regarding 
the venom complexity.
Further insights in to venom compositions have been achieved by gene cloning by PCR- 
based methods conducted w ith  cDNA libraries o f venom gland tissue. Interestingly, 
most o f the AMPs identified from  scorpion and snake venoms have been cloned from  
the venom glands cDNA libraries combined w ith  some proteom ic analyses. A huge 
number o f antim icrobial like sequences have been recorded from  the transcriptom e
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analyses of several snake and scorpion venom glands (Ma, Zhao et al. 2009, Almeida, 
Scortecci et al. 2012).
The current study has evaluated the antimicrobial and cytotoxic activities of three 
synthetic alpha-helical peptides (Smpl3, Smp24 and Smp24), previously identified 
from Egyptian scorpion Scorpio maurus palmatus as putative AMPs using a 
combination of proteomics and transcriptome sequencing approaches (Abdel-Rahman, 
Quintero-Hernandez et al. 2013). Some of these data have been published recently by 
our group (Harrison, Abdel-Rahman et al. 2016).
Although many different species of snakes are found in Egypt, no AMPs have been 
characterised from Egyptian snake venoms. To the best of our knowledge, this study is 
the first to isolate such antibacterial peptides. This chapter examines a number of 
different venoms of Egyptian elapids and vipersin order to both purify and investigate 
the potential of some purified peptides as antibacterial agents as well as to assess 
some of their cytotoxic effects in order to increase the prospects of developing novel 
AMPs.
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3.2 Method Summary
Antimicrobial activity of Smp peptides (0-512pg/ml) was determined against Gram 
positive and Gram negative bacteria and fungi by the micro dilution method as 
described in section 2.4. The haemolytic potential was assayed against sheep 
erythrocytes and cytotoxic effects by CellTiter-Glo® assays using kidney and 
keratinocyte cell lines. Snake venoms were purified by size-exclusion and cation- 
exchange liquid chromatography. Antimicrobial activity was determined as above. 
Active fractions were characterised by MALDI-TOF mass spectrometry. N-terminal 
amino acid sequences were determined by Edman degradation. Fractions that 
displayed antimicrobial activity were assayed for their haemolytic and cytotoxic effects 
as above.
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3.3 Results
3.3.1 Antimicrobial activity of synthetic scorpion venom antimicrobial peptides
The minimum inhibitory concentrations (MICs) of Smpl3, Smp24 and Smp43 were 
determined using the broth microdilution method described in section 3.2. The test 
organisms included three Gram negative and three Gram positive bacteria as well as 
one fungi strain. The MICs are reported in Table 3.1.
No antimicrobial activities were found in Smpl3. However, Smp24 and Smp43 showed 
potent broad-spectrum activity against all organisms tested. Both peptides exhibited 
highest activity against Gram positive bacteria with MICs ranging from 4 to 64 pg/ml. 
Smp43 showed a higher activity against Gram negative bacteria (MICs 32-64 pg/ml) 
than Smp24 (MICs 32-256 pg/ml). Both Smp24 and Smp43 showed antifungal activity 
toward the yeast, C. albicans with MIC values of 32 and 128 pg/ml respectively.
Table 3.1 Minimum inhibitory concentrations (MICs of pg/ml) of synthetic Scorpio maurus 
palmatus venom antimicrobial peptides against various organisms
Microorganism Smpl3 Smp24 Smp43
Gram-negative
bacteria
Escherichia coli JM109 - 32 32
Klebsiella pneumoniae NCTC 13439 ■ - 128 64
Pseudomonas aeruginosa NCIMB 8295 - 256 64
Gram positive 
bacteria
Staphylococcus aureus SH1000 - 8 16
Staphylococcus epidermidis - 8 64
Bacillus subtilis NCIMB 8054 - 4 4
Fungus Candida albicans - 32 128
NC* Negative control was Fresh Muller-Hinton broth without peptides. -  no inhibition.
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3.3.2 Haemolytic activities of scorpion venom peptides
Smp43 showed very low haemolytic activity at the highest concentration o f 512pg/m l. 
Smp24 exhibited high haemolytic effects at the same concentration. Smp43 showed 
very low toxic ity at the maximum concentration tested (2.25 ± 0.2%) lysis at 512 
pg/m l). In comparison, Smp24 caused significant erythrocyte d isruption (88.4 ± 0.8%) 
at the same concentration. Indeed, a significant d isruption was observed between 64 
pg/m l (15.6 ± 0.5%) and 128 pg/m l (52 ± 1.7%) w ith  an increase in lysis o f 36.4% 
(Figure 3.1).
Smp24
Smp43
Peptide concentration (ug /m l)
Figure 3.1 Haemolytic activities of Smp24 and Smp43. A 10% (v/v) suspension of 
washed erythrocytes in PBS was incubated with serial dilution peptides 1 h with 
intermittent shaking. The absorbance in the supernatant was measured at 570 nm. PBS 
and 10% (v/v) Triton X-100 were used as 0 and 100% controls respectively. Error bars 
indicate SD.
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3.3.3 Cytotoxic activities of scorpion venom peptides
Smp24 caused increased damage to  HaCaT cells but only at higher concentrations (128 
and 256 pg/m l), in comparison to  Smp43 which was inactive at all concentrations 
(Figure 3.2). At 16 pg/m l no peptide caused more than 15± 1.7% HEK293 cell damage; 
however, a doubling o f the concentration caused 56 ± 6.6% cell damage w ith  Smp43 
and Smp24 showed a similar decrease in cell v iab ility  67.3 ± 3.9% (Figure 3.3). Low 
cytotoxic activity was detected fo r Smp24 against HEK293 at concentrations higher 
than MICs fo r Gram positive strains (4-8 pg/m l).
Both tested cell lines were examined by fluorescence microscopy to  assess the cell 
death pathway after incubation w ith Smp24 and Smp43. A fte r 24 h; untreated cells 
showed normal structure w ithou t any signs o f apoptosis or necrosis, whereas dead 
cells appeared red due to  staining w ith  PI which cannot cross intact cell membranes. 
Neither cell lines showed any morphological hallmarks o f apoptosis such as nuclear 
fragm entation a fter incubation w ith  Smp24 (Figure 3.4 and Figure 3.6). Only the 
highest concentration o f Smp43 (256 pg/m l) induced apoptosis in a few  human 
keratinocytes as indicated by the green arrows (Figure 3.5). Our results indicated tha t 
exposure to  increasing doses o f e ither Smp24 or Smp43 over a period o f 24 hours 
decreased the viability o f HEK293 cells in a dose-dependent fashion as the num ber o f 
Pl-stained cells increased (Figure 3.6 and Figure 3.7). The highest concentration of 
Smp43 (256 pg/m l) did not affect the v iab ility  o f HaCaT cells as evidenced by Hoechst 
staining (Figure 3.5), although the numbers o f dead cell treated w ith  Smp24 increased 
at 128 pg/m l (Figure 3.4).
Both Smp peptides decreased the viability o f HEK293 cells in a concentration-
dependent manner w ith  a noted effect seen at 32 pg/m l w ith  both peptides.
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Interestingly, HaCaT skin cell lines were not affected by Smp43 at 4x MIC 128 pg/m l fo r 
24 hours o f incubation, while Smp24 showed a noted decrease in cell v iab ility  at the 
same concentration.
HaCaT cell line
Smp43
Smp24
Peptide concentration (ug/ml)
Figure 3.2 Evaluation of ATP-based cytotoxicity of human keratinocytes (HaCat) 
incubated with Smp peptides at various concentrations after 24 h of incubation.
Control (HaCat) cells without treatment used as a control. HaCat cells were incubated 
with the different concentrations (8-256 pg/ml) of Smp24 and Smp43. 10% (v/v) Triton 
X-100 was used as positive control. Error bars indicate SD.
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Figure 3.3 Evaluation of ATP-based cytotoxicity of human kidney cells (HEK293) 
incubated with Smp peptides at various concentrations after 24 h of incubation.
Control (HEK293) cells without treatment used as a control. HEK293 cells were 
incubated with the different concentrations (8-256 |ig/ml) of Smp24 and Smp43. 
10% (v/v) Triton X-100 was used as positive control. Error bars indicate SD.
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Smp24 and Smp43 are broad spectrum AMPs have been characterised from  the venom 
gland of the Egyptian scorpion Scorpio mourus palmotus. They have potent activity 
against both Gram positive and Gram negative bacteria (MICs 4 to  128 pg/m l). The in 
vitro  cytotoxicity assay indicated tha t HEK293 cells were more vulnerable to  the Smp 
peptides-induced cytotoxicity than HaCaT cells.
In the follow ing sections, crude snake venoms w ill be separated through HPLC 
chromatography to  purify AMPs from  snake venoms as follow:
Snake crude venom
Size exclusion chromatography
Fractions
Antimicrobial activity assaying :
Active fraction for further Purification
Cation exchange chromatography
Fractions
Antimicrobial activity assaying <-*-
Active fraction for characterisation
Cytotoxicity assaying
Mass determination
N-terminal sequencing
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3.3.4 Purification of Naja haje venom peptides by size exclusion chromatography 
and cation exchange chromatography
60 mg of the elapid snake Naja haje crude venom extract was separated by Superdex
200 gel filtration. Chromatography resulted in 6 fractions designated N H l to NH6
(Figure 3.8). Each fraction was dialysed against ultrapure water, freeze-dried and
dissolved in 1 ml of water. Fractions were assayed against Gram negative bacteria
(Escherichia coli) and Gram positive bacteria {Staphylococcus aureus and Bacillus
subtilis) (Table 3.2). Three fractions (NH2, NH3 and NH4) showed antimicrobial activity.
NHF2 exhibited full growth inhibition on all tested bacteria, whereas NH3 and NH4
showed full inhibitory activity against only Bacillus subtilis, with partial inhibitory
activity against Escherichia coli compared with negative controls.
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Figure 3.8 Fractionation of crude Naja haje venom by size-exclusion chromatography. Six
peaks were obtained from the chromatography of 60 mg Naja haje crude venom on a 
HiLoad 26/600 (60 x2.6 cm diameter) Superdex 200 pg column at pH 4.3. Sample was eluted 
at 0.5 ml/min flow rate via 1.5 column volume of buffer A. Protein concentration was 
monitored at 280 nm and the collected fractions (3 mL/tube) were numbered from NH1 to 
NH6. Peak NH3 and NH4 were pooled together (NH3/4). The peak labelled with a black 
arrow exhibited inhibitory antibacterial activity against Escherichia coli, Staphylococcus 
aureus, and Bacillus subtilis. Peaks labelled with red arrow have an inhibitory activity against 
Bacillus subtilis.
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Table 3.2 Antimicrobial activity of Naja haje fractions after gel filtration chromatography
Peak
Protein
concentration
(mg/ml)
Growth inhibition
Gram negative Gram positive
E. coli S. aureus B. subtilis
NH1 0.01 ■ - - -
NH2 0.5 ++ ++ ++
NH3 3.2 + ++
NH4 6.2 + - ++
NH5 0.5 - - -
NH6 0.02 - - -
Negative control was Fresh Muller-Hinton broth without peptides. -  no inhibition, + partial inhibition 
and ++ Full inhibition.
Growth inhibition was determined using the broth microdilution method. Fractions were 
incubated with 1X106 CFU/ml of overnight culture for 15 hours at 37°c. The optical density 
(OD) at a wavelength of 600 nm was read every 10 mins. Full inhibition was determined when 
OD =0.
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NH2 was eluted mid-way through the run when one column volume of buffer had 
passed through the column (Vt 320ml, separation range 10 - 60 kDa) suggesting that 
the protein had a MW  > 10 kDa. NH3 and NH4, with elution characteristics of low 
molecular weight peptides, were pooled (NH3/4) and further purified on a cationic SP 
Sepharose column. A NaCI gradient (0.1-1 M) was run and four peaks were collected 
(NH3/4-1 to NH3/4-4) (Figure 3.9). Each fraction was dialysed against ultrapure water, 
freeze-dried and then dissolved in 1 ml of water. Antibacterial activities were assayed 
against a range of Gram positive and Gram negative organisms (Table 3.3). Only peak 
NH3/4-4 (0.5 mg/ml) exhibited potent antibacterial activity, but, surprisingly, only 
against B. subtilis.
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Figure 3.9 SP Sepharose cation exchange elution profile of NH3/4 from size exclusion 
fractionation of Naja haje (Figure 3.8). The column (100x16 mm diameter) was washed 
with buffer A (50 mM Sodium acetate pH 4.3) to remove any unbound proteins, and the 
bound proteins were eluted with a linear gradient of 20 column volumes of NaCI (0.1-1 M) 
in the same buffer. Sample was eluted at 0.5 ml/min flow rate. Protein concentration was 
monitored at 280 nm and collected fractions (3 mL/tube) were numbered from NH3/4-1 to 
NH3/4-4. The peak labelled with a black arrow fully inhibited the growth of Bacillus subtilis. 
NaCI gradient is shown by green line.
1 M
0.1 M
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Table 3.3 Antimicrobial activity of Naja haje fractions after SP Sepharose cation exchange 
chromatography
Growth inhibition
Microorganism NH3/4- NH3/4- NH3/4- NH3/4-
1 2 3 4
Gram- E. co//JM109 - - - -
negative Klebsiella pneumoniae NCTC 13439 - - - -
bacteria
Pseudomonas aeruginosa NCI MB 8295 - - - -
5. aureus SH1000 - - - -
S. epidermidis - - - -
Gram Bacillus cereus NCTC 2599 - - - -
positive Bacillus cereus UM20.1. - - - -
bacteria
B. subtilis NCI MB 8054 - - - ++
B. subtilis NCI MB 8056 - - - ++
B. subtilis NCI MB 3610 - - - ++
Negative control was Fresh Muller-Hinton broth w ithout peptides. -  no inhibition. ++ Full inhibition
Growth inhibition was determined using the broth microdilution method. Fractions were 
incubated with 1X106 CFU/ml of overnight culture for 15 hours at 37°c. The optical density 
(OD) at a wavelength of 600 nm was read every 10 mins. Full inhibition was determined when 
OD =0.
Naja haje crude venom
I
Size exclusion chromatography  
Fractions
Antimicrobial activity assaying
NH3 and NH4 for further Purification 
Cation exchange chromatography
Fractions NH3/4-1 to NH3/4-4
NH1 to NH6
NH3/4
Antimicrobial activity assaying
NH3/4-4 for characterisation
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3.3.5 Purification of Naja nubiae venom peptides by size exclusion chromatography 
and cation exchange chromatography
Naja nubiae (Nubian spitting cobra) crude venom (35 mg) was fractionated by gel
exclusion chromatography on a HiLoad 26/600 Superdex 200 column and resolved into
four protein peaks (Figure 3.10). Whole venom inhibited the growth of £  coli, S.
aureus, and B. subtilis. When individual peaks were screened for antibacterial activity
against the same bacterial species, only peaks NN2 and NN3 showed antibacterial
activity and only against B. subtilis. Both NN2 and NN3 were pooled, concentrated and
dialysed against ultrapure water.
rrAu *’*
200-a
Figure 3.10 Fractionation of crude Naja nubiae venom by size-exclusion chromatography.
Four peaks were obtained from fractionating 60 mg Naja nubiae crude venom on a HiLoad 
26/600 (60 x2.6 cm diameter) Superdex 200 pg column at pH 4.3. The column was eluted at 0.5 
ml/min flow rate via 1.5 column volume of buffer A. Protein concentration was monitored at 
280 nm and the collected fractions (3 mL/tube) were numbered from NN1 to NN4. Peaks 2 and 
3 were pooled together (NN2/3). Peaks labelled with red arrow have an inhibitory activity 
against Bacillus subtilis.
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The pooled fractions (NN2/3) were fu rthe r resolved in to five peaks on a SP Sepharose 
cation exchange column 16X100 column by applying NaCI gradient (Figure 3.11). Only 
peak 3 (NN2/3-3) exhibited potent antibacterial activity against B. subtilis  (Table 3.4).
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Figure 3.11 SP Sepharose cation exchange elution profile of pooled fractions NN2/3 from 
size exclusion fractionation Naja nubiae (Figure 3.10). The column (100x16 mm diam eter)
was washed with buffer A (50 mM Sodium acetate pH 4.3) to remove any unbound proteins, 
and the bound proteins were eluted with a linear gradient of 20 column volumes of NaCI (0.1- 
1 M) in the same buffer. Sample was eluted at 0.5 ml/min flow rate. Protein concentration 
was monitored at 280 nm and the collected fractions (3 mL/tube) were numbered from 
NN2/3-1 to NN2/3-5. The peak labelled with a red arrow fully inhibited the growth of Bacillus 
subtilis. NaCI gradient is shown by green line.
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Table 3.4 Antimicrobial activity of Naja nubiae crude venom and fractions
Naia nubiae
Microorganism growth inhibition
£  coli 5. aureus B. subtilis
Crude venom ++ ++ ++
NN1 - -
Superdex NN2 . _  . ++
200 NN3 - - ++
NN4 - - - '
Fractionation
NN2/3-1 - - -
NN2/3-2 - -
SP
Sepharose
NN 2/3-3
. - - ++
NN2/3-4 - -
NN 2/3-5 - . -
Negative control was Fresh Muller-Hinton broth w ithout peptides. -  no inhibition. ++ Full inhibition
Growth inhibition was determined using the broth microdilution method. Fractions were 
incubated with 1X106 CFU/ml of overnight culture for 15 hours at 37°c. The optical density 
(OD) at a wavelength of 600 nm was read every 10 mins. Full inhibition was determined when
0 0  = 0 ‘ Naja nubiae crude venom
4
Size exclusion chromatography 
Fractions
ir
NN1 to NN4
I
Antimicrobial activity assaying
NN2/3
NN2 and NN3 for further Purification
Cation exchange chromatography I
i r
Fractions NN2/3-1 to  NH3/4-5
Antimicrobial activity assaying
NN2/3-3 for characterisation 
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3.3.6 Purification of Walterinnesia aegyptia venom peptides by size exclusion 
chromatography and cation exchange chromatography
50 mg o f the Egyptian elapid Walterinnesia aegyptia (Black Desert Cobra) was
fractionated by gel exclusion chromatography on a HiLoad 26/600 Superdex 200
column and resolved in to  fou r protein peaks (Figure 3.12). The crude venom
inhibited the growth o f E. coli, S. aureus, and B. subtilis. However, when individual
fractions were screened fo r antibacterial activity, only peak WG4 showed
antibacterial activity and only against B. subtilis. WG4 was pooled, dialysed and
concentrated and subsequently purified on a SP Sepharose cation column.
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Figure 3.12 Fractionation of crude Walterinnesia aegyptia venom by size-exclusion 
chromatography. Four peaks were obtained from fractionating 50 mg Walterinnesia aegyptia 
crude venom on a HiLoad 26/600 (60 x2.6 cm diameter) Superdex 200 pg column at pH 4.3. 
The column was eluted at 0.5 ml/min flow rate via 1.5 column volume of buffer A. Protein 
concentration was monitored at 280 nm and the collected fractions (3 mL/tube) were 
numbered from W Gl to WG4. Peaks 4 was collected for further purification. Peak labelled 
with red arrow have an inhibitory activity against Bacillus subtilis.
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Six protein peaks were obtained when WG4 (10 mg) was fractionated by SP Sepharose 
cation chromatography by applying NaCI gradient (Figure 3.13). Three protein peaks 
(WG4-2, W G4-3, and WG4-4) exhibited potent antibacterial activity exclusively against 
B. subtilis. These fractions also showed slight inh ib itory activity against d iluted (1X106 
CFU/ml) cultures o f E. coli (1X103 CFU/ml) (Table 3.5).
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Figure 3.13 SP Sepharose cation exchange elution profile of pooled peak fractions (F4) from 
SEC fractionation of Walterinnesia aegyptia venom (Figure 3.12). The column (100x16 mm 
diameter) was washed with buffer A (50 mM Sodium acetate pH 4.3) to remove any unbound 
proteins, and the bound proteins were eluted with a linear gradient of 20 column volumes of 
NaCI (0.1-1 M) in the same buffer. Sample was eluted at 0.5 ml/min flow rate. Protein 
concentration was monitored at 280 nm and the collected fractions (3 mL/tube) were 
numbered from WG4-1 to WG4-5. The peaks with dotted black circle fully inhibited the 
growth of Bacillus subtilis. NaCI gradient is shown by green line. Figure 3.13 inset: Growth 
curve of E. coli (1X103 CFU/ml) culture in the absence or presence of WG4-2 (0.4 mg/ml).
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Table 3.5 Antimicrobial activity of Walterinnesia aegyptia crude venom and fractions
Walterinnesia aeavptia
Microorganism growth inhibition
E. coli S. aureus B. subtilis
Crude venom ++ ++ ++
W Gl - - -
Superdex WG2 - - -
200 WG3 - - -
WG4 - - ++
Fractionation WG4-1 - - -
SP
WG4-2 + - ++
Sepharose
WG4-3 + - ++
WG4-4 + - ++
WG4-5 - - -
Negative control was Fresh Muller-Hinton broth without peptides. -  no inhibition, + partial inhibition 
and ++ Full inhibition.
Growth inhibition was determined using the broth microdilution method. Fractions were 
incubated with 1X106 CFU/ml of overnight culture for 15 hours at 37°c. The optical density 
(OD) at wavelength of 600 nm was read every 10 mins. Full inhibition was determined when 
OD =0.
Walterinnesia aegyptia crude venom
I
Size exclusion chromatography  
Fractions
i r
WG1 to WG4
I
Antimicrobial activity assaying
WG4 for further Purification  
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W G4  
1
Ir"
Fractions WG4-1 to W G4-5
J
Antimicrobial activity assaying
W G4-2 to W G4-4 for characterisation
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B.B.7 Purification of Echis carinatus venom peptides by size exclusion 
chromatography and cation exchange chromatography
The Size-exclusion chromatography o f Egyptian viper E. carinatus (saw-scaled viper)
venom on a HiLoad 26/600 Superdex 200 pg column resulted in obtaining fou r peaks
(Figure 3.14). These fractions were assayed against E. coli, S. aureus and B. subtilis.
Whole venom of E. carinatus inhibited the growth o f E. coli and S. aureus at 500 pg/m l.
Of the individual peaks, only EC3 showed slight growth inh ib itory activity against S.
aureus and B. subtilis. EC3 was collected, dialysed and loaded onto a SP Sepharose
cation column and fractionated by applying NaCI gradient fo r fu rthe r purification.
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Figure 3.14 Fractionation of crude Echis carinatus venom by size-exclusion chromatography.
Four peaks were obtained from fractionating 35 mg Naja nubiae crude venom on o HiLoad 
26/600 (60 x2.6 cm diameter) Superdex 200 pg column at pH 4.3. The column was eluted at 0.5 
ml/min flow rate via 1.5 column volume of buffer A. Protein concentration was monitored at 
280 nm and the collected fractions (3 mL/tube) were numbered from EC1 to EC4. Peak labelled 
with red arrow have an inhibitory antibacterial activity against B. subtilis and S. aureus.
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Ten eluted peaks resulted from  SP Sepharose chromatography of EC3 (Figure 3.15). No 
fractions showed any activity against E. coli, S. aureus or B. subtilis.
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Figure 3.15 SP Sepharose cation exchange elution profile of EC3 from SEC fractionation of Echis 
carinatus (Fig.3.14). The column (100x16 mm diameter) was washed with buffer A (50 mM Sodium 
acetate pH 4.3) to remove any unbound proteins, and the bound proteins were eluted with a linear 
gradient of 20 column volumes of NaCI (0.1-1 M) in the same buffer. Sample was eluted at 0.5 
ml/min flow rate. Protein concentration was monitored at 280 nm and the collected fractions (3 
mL/tube) were numbered from EC3-1 to EC3-10. NaCI gradient is shown by green line.
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3.3.8 Haemolytic activities of snake venom peptides
NH3/4-4, WG4-2, WG4-3, WG4-4 and NN2/3-3 displayed low or no haemolytic activity 
on sheep erythrocytes at concentrations o f 50 pg/m l (Figure 3.16).
Snake venom  derived  peptides
Figure 3.16 Haemolytic activities of Snake venom peptides of 50 pg/ml. A 10% (v/v) 
suspension of washed erythrocytes in PBS was incubated with serial dilution peptides 
1 h with intermittent shaking. The absorbance in the supernatant was measured at 
570 nm. PBS and 10% (v/v) Triton X-100 were used as 0 and 100% controls 
respectively. Error bars indicate SD.
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3.3.9 Cytotoxic activities of snake venom peptides
The cytotoxic potential of snake venom purified peptides and synthetic scorpion 
peptides was determined using an ATP assay, to determine the ATP content of cells 
following incubation of HEK293 and HaCaT cells for 24 hours.
Cytotoxicities of each of snake-derived venom peptide were comparable in the two cell 
lines. NH3/4-4 exhibited the lowest level of cytotoxicity towards the two cell lines; the 
percentages of cell viability were 85 ± 1% for HEK293 cells and 11 ± 1  % for HaCaT cells 
at a concentration of 50 pg/ml (Figure 3.17). However, HEK293 cells were more 
vulnerable to WG4-2 and NN2/3-3-induced cytotoxicity in dose-dependent manner 
(Figure 3.18). After 24 hours of exposure to either 50 pg/ml of WG4-2 or NN2/3-3, the 
percentage cells viability reduced to 55 ±2% and 61.5% ±2% (HEK293), and 73 ±4.9% 
and 90 ±4% (HaCaT) respectively.
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HaCaT cell line
Snake venom derived peptides concentration (ug/m l)
Figure 3.17 Evaluation of ATP-based cytotoxicity of human keratinocytes 
(HaCat) incubated with snake venom peptides at various concentrations after 
24 h of incubation. Control (HaCat) cells without treatment used as a control. 
HaCat cells were incubated with the different concentrations (8-256 |ig/ml) of 
Smp24 and Smp43. 10% (v/v) Triton X-100 was used as positive control. Error 
bars indicate SD. All treatments were performed in triplicate; in three 
independent experiments. Statistical analysis was performed by the Kruskal- 
Wallis test. *Significant P <0.05 ^^Significant P <0.01. ***Signjficant P <0.001.
HEK293 cell line
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Snake venom derived peptides concentration (ug/ml)
Figure 3.18 Evaluation of ATP-based cytotoxicity of human kidney cells 
(HEK293) incubated with snake venom peptides at various concentrations 
after 24 h of incubation. Control (HEK293) cells without treatment used as a 
control. HEK293 cells were incubated with the different concentrations (8-256 
Ug/ml) of Smp24 and Smp43. 10% (v/v) Triton X-100 was used as positive 
control. Error bars indicate SD. All treatments were performed in triplicate, in 
three independent experiments. The significance of differences between 
treated and untreated cells were statistically analysed by the two-way 
analysis of varience. ANOVA results were significant (P <0.05).
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3.3.10 Analysis of snake venom peptides by mass spectrometry
Active fractions from N. haje, N. nubiae, and W. aegyptia venoms were analysed by 
MALDI-TOF-MS (Table 3.6). MALDI-TOF spectra of the purified fractions are shown in 
Figure 3.19 to Figure 3.22.
Table 3.6 measured mass to charge ratio (m/z) of active snake venom peptides
SP Sepharose peak Masses m/z, Da
NH3/4-4 6870
WG4-2 6757
WG4-3 6715
NN2/3-3 6868
A single peptide with a molecular mass of 6870 Da was observed in the purified 
fraction from N. haje venom NH3/4-4, a minor peak at 2x m/z 13760 (Figure 3.19). 
Molecular masses of 6757 and 6715 Da were detected for W. aegyptia peptides WG4- 
2 and WG4-3 respectively (Figure 3.20 and Figure 3.21). WG4-3 was not pure with 
three proteins present, at 6594, 6731 and 6747 Da. WG4-4 yielded a MALDI mass 
spectrum with no detectable peaks when scanned up to 80KDa. The purified fraction 
(NN2/3-3) from the venom of N. nubiae venom had a calculated mass of 6868Da 
(Figure 3.22) with a number of minor peaks observed in the mass spectra representing 
m/2z, 2x m/z and 3x m/z.
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Figure 3.19 MALDI-TOF-TOF-MS spectra of purified N. haje venom peptide (NH3/4-
4). The molecular masses of peptides were determined using MALDI-TOF mass 
spectrometry in positive ionization mode. a-Cyano-4-hydroxycinnamic acid was 
used as MALDI matrix.
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Figure 3.20 MALDI-TOF-TOF-MS spectra of purified W. aegyptia venom peptide 
(WG4-2).The molecular masses of peptides were determined using MALDI-TOF 
mass spectrometry in positive ionization mode.a-Cyano-4-hydroxycinnamic acid 
was used as MALDI matrix.
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Figure 3.21 MALDI-TOF-TOF-MS spectra of purified W. aegyptia venom peptide 
(WG4-3). The molecular masses of peptides were determined using MALDI-TOF 
mass spectrometry in positive ionization mode.a-Cyano-4-hydroxycinnamic acid 
was used as MALDI matrix.
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Figure 3.22 MALDI-TOF-TOF-MS spectra of purified N. nubiae venom peptide 
(NN2/3-3). The molecular masses of peptides were determined using MALDI-TOF 
mass spectrometry in positive ionization mode.a-Cyano-4-hydroxycinnamic acid was 
used as MALDI matrix.
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3.3.11 Identification of N-terminal residues
The firs t five N-terminal amino acid residues o f NH3/4-4, WG4-2, WG4-3 and NN2/3-3 
were sequenced, and compared w ith those found in the ExPASY proteom ics database 
using a basic local alignm ent search too l (BLAST). The sequence o f NH3/4-4 was 
identical to  "Short neurotoxin 2" (Joubert 1975) which has been identified as a 
member o f the three-finger toxin superfamily. This sequence is present in a num ber o f 
d iffe ren t Naja species (Figure 3.23) Naja nivea (Botes, 1971), Naja haje (Joubert 1975) 
and Naja annulifera  (Joubert & Taljaard, 1978) but is unique to  Naja genus.
NH3/4-4 MI-HN
Naja haje MICHNQQSSQPPTIKTCPGETNCYKKQWRDHRGTIIERGCGCPSVKKGVGIYCCKTDKCNR 61
Naja nivea MICHNQQSSQRPTIKTCPGETNCYKKRWRDHRGTIIERGCGCPSVKKGVGIYCCKTDKCKR 61
Naja annulifera MICHNQQSSQPPTIKTCPGETNCYKKRWRDHRGTIIERGCGCPSVKKGVGIYCCKTNKCRR 61
Figure 3.23 N - terminal Sequence alignment of NH3/4-4 with full sequences of short neurotoxin2 
sequences (three-finger toxins) from some Naja genus venoms. N-terminal sequence of NH3/4-4 
was obtained by automated Edman degradation. Other protein sequences were obtained from the 
NCBI database. Conserved cysteine residues are shown in green colour. Residue (-) at position 3 is 
most likely due to cysteine as it cannot be detected using N-terminal sequencing, w ithout prior 
chemical modification.
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N-terminal sequencing o f both 6 kDa peptides WG4-2 and WG4-3 (NFh-Leu- Lys- (Cys)- 
Asn- Gin) also revealed the ir homology w ith  the three-finger toxins. The five amino 
acids residues are sim ilar to  Naja mossambica (Mozambique spitting cobra) cytotoxins 
CTX M l,  M3 and M4 (Figure 3.24). No sequence data was obtained fo r the N-term inus 
o f NN2/3-3, the most likely cause is tha t it is N-term inally blocked.
WG4-2 LK’NQ 
WG4-3 LK-NQ
Figure 3.24 N - terminal Sequence alignment of WG4-2 and WG4-3 with full sequences of 
Naja mossambica (Mozambique spitting cobra) cytotoxins CTX M1,M3 and M4. N-terminal 
sequence of WG4-2 and WG4-3 was obtained by automated Edman degradation. Other 
protein sequences were obtained from the NCBI database. Conserved cysteine residues are 
shown in green colour. Residue (-) at position 3 is most likely due to cysteine as it cannot be 
detected using N-terminal sequencing, without prior chemical modification.
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3.4 Discussion
Snake and scorpion venoms are enriched sources of some biologically active peptide 
with many therapeutic uses. The envenomation apparatus of snakes and scorpions 
which is used either for defence or to obtain food, is often contaminated with multiple 
pathogenic microbes (Garcia-Lima, Laure 1987, Shek, Tsui et al. 2009, Babalola, 
Balogun 2013). Since snakes and scorpions are associated with a low incidence of 
microbial infection (Talan, Citron et al. 1991), this suggests that venoms might contain 
potent antimicrobial agents protect against pathogens, although venoms remain 
largely unexamined as sources for AMPs (de Lima, Alvarez Abreu et al. 2005, Ferreira, 
Santos et al. 2011, Samy, Stiles et al. 2015).
A large number of putative AMPs have been identified from scorpion and snake 
venoms by proteomic or/and transcriptomic approaches from venom gland cDNA 
library. However, the antimicrobial and cytotoxic profiles of most of these peptides 
have not yet been fully investigated. The present study aimed to evaluate the potential 
biological activities of three such putative AMPs (Smpl3, Smp24 and Smp43), which 
have been identified from a cDNA library of the venom gland of 5. maurus palmatus 
(Abdel-Rahman, Quintero-Hernandez et al. 2013). Also, this study represents the first 
attempt to identify and characterise the peptides and proteins that having 
antibacterial activities from Egyptian snake venoms.
Although Smpl3 shares a high level of sequence identity with some potent AMPs such 
as UyCT3 and IsCT derived from Urodacus yaschenkoi (Inland robust scorpion) and 
Opisthacanthus madagascariensis respectively, it is likely that Smpl3 exhibited no
antim icrobial activity against tested bacterial strains because it has a net charge of 
zero. Electrostatic interactions play a crucial role in the binding o f cationic AMPs to  
negatively charged prokaryotic membranes (Yu, Guo et al. 2009, Bahar, Ren 2013). The 
enhancement o f antim icrobial potency of some AMPs is dependent on 
the increase in positive net charge and the number o f positively charged residues 
which could increase the electrostatic binding of the peptide to  anionic bacterial 
membranes (Zelezetsky, Tossi 2006, Jiang, Vasil et al. 2008, Phoenix, Dennison et al.
2012). Experimental modifications which e ither increase charge (e.g. to  Aam APl from  
Androctonus amoerux) (Almaaytah, Tarazi et al. 2014) or decrease charge (e.g. to  
ToAP2 from  Tityus pachyuru) (Guilhelmelli, Vilela et al. 2016) support this hypothesis.
Both Smp24 and Smp43 exhibit broad-spectrum antim icrobial activity against a wide 
range o f Gram positive and Gram negative bacteria and fungi. Smp43 (MIC 4 - 6 4  
pg/m l) was found to  have slight higher activity than Smp24 (MIC 4 - 256 pg/m l). Smp24 
has a net charge of +3 w ith fou r lysine residues 4 in comparison to  Smp43 which has a 
net charge +4 w ith seven lysines and greater positive. The greater positive charge on 
Smp43 m ight reflect the relative antim icrobial potency of the tw o  peptides.
Smp24 and Smp43 both possess higher activity against Gram positive (MIC 32-256 pg 
/m l) than Gram negative bacteria (MIC 8-64 pg/m l). Such preferential activ ity has also 
been reported fo r P in l and Pin2 which displayed up to  tw enty  tim es more potent 
activity against some Gram positive than Gram negative strains (Corzo, Escoubas et al. 
2001) as well as o ther AMPs from  P. im perator (Zeng, Zhou et al. 2013) and from  
Heterometrus petersii (Li, Xu et al. 2014). The bacterial selectivity o f some AMPs
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depends on the presence and distribution of abundant negatively charged 
phospholipids in the bacterial membranes where the phospholipid composition of 
Gram -negative membranes such E. coli is less anionic than Gram positive membranes 
S. aureus and B. subtilis which contain higher amounts of negatively charged 
phospholipids PG (Epand, Savage et al. 2007,McHenry, Sciacca et al. 2012, Aoki, Ueda
2013). Asymmetric lipid distribution has been reported in bacterial membranes, as 
neutral phospholipids as PE are located in the inner leaflet, while, PG is distributed in 
the outer leaflet. Whilst, CL is distributed over both leaflets in plasma membranes in 
Gram positive bacteria. Such membrane asymmetry is known to affect various bilayer 
properties, including binding affinity to AMPs (Barsukov, Kulikov et al. 1976, 
Marquardt, Geier et al. 2015).
Smp43 showed very low haemolytic activity at the highest concentration of 512pg/ml. 
While Smp24 exhibited highly haemolytic effect at the same concentration. Smp24 
shares 54% homology with Pin 2, while Smp43 sharing 86% identity with Pin 1 
(Harrison, Abdel-Rahman et al. 2016). Pin2 has high haemolytic activity is similar to 
that of Smp24, and Pinl is similar to Smp43 have less or no haemolytic activity even at 
high concentrations (Corzo, Escoubas et al. 2001). The haemolytic activity of Pinl 
depends on the Zwitterionic phospholipids (PC) and sphingomyelin (SM) ratio; it 
displayed higher haemolytic activity against guinea pig erythrocytes than sheep 
erythrocytes, which have less ratio of PC/SM. Therefore, Smp43 may show much 
higher haemolytic activity against other mammal erythrocytes such as human blood 
cells (rich in PC) than sheep cells (rich in SM) (Belokoneva, Villegas et al. 2003).
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Both peptides induced cytotoxic effects on HEK293 cells in a concentration-dependent 
manner with a decrease in cell viability seen at 32 pg/ml with both peptides. Smp43 
showed limited cytotoxic effect against keratinocyte HaCaT cell line at a highest 
concentration of 256 pg/ml, while, Smp24 showed significant decrease HaCaT cells 
viability at 128 pg/ml. Our previous work has indicated that both Smp24 and Smp43 
have cytotoxic effects on HepG2 liver cells in a concentration-dependent manner 
(Harrison, Abdel-Rahman et al. 2016). These results have been attributed to the overall 
negative charge on extracellular face of both cancer and prokaryotic cell membranes 
due to the presence of negatively charged phospholipids on the outer leaflet of 
prokaryotic membranes and the exposure of intracellular PS on the outer leaflet of 
cancer cell membrane as apoptotic signal (Riedl, Rinner et al. 2011). However, the 
electrostatic affinity of AMPs to anionic membranes is less important toward neutral 
eukaryotic membranes (Harrison, Abdel-Rahman et al. 2016) Hydrophobicity of Smp 
peptides (more than 60%) may has a stronger influence in terms of mammalian cell 
toxicity. Thus, a strong correlation \is reported between cytotoxicity and 
hydrophobicity, as hydrophobic residues of AMPs enhance their interaction with 
hydrophobic core of membrane (Chen, Guarnieri et al. 2007, Bahar, Ren 2013)
In conclusion, Smp24 and Smp43 are relatively short non-disulphide bridged peptides
with a spectrum of potent activity against a wide range of Gram positive and Gram
negative bacteria. There was a clear difference in the cytotoxicity of Smp43 when
compared to Smp24. Smp43 showed very low haemolytic and cytotoxic activities at
the maximum concentration tested against sheep red blood cells and HaCaT cells, in
contrast, Smp24 caused significant erythrocyte disruption and cytotoxic effects on
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HaCaT cells at the same concentration. However, both peptides were cytotoxic toward 
HEK293 cells.
In the current study, four proteins (NH3/4-4, WG4-2, WG4-3 and NN2/3-3) have been 
isolated from three Egyptian elapid venoms Naja haje (Egyptian cobra), Walterinnesia 
aegyptia (Black Desert Cobra) and Naja nubiae (nubian spitting cobra). The purified 
proteins displayed preferential activity against B. subtilis. It has been reported that B. 
subtilis exhibited high susceptibility toward crude elapid venoms such as N. 
melanoleuca (African cobra) and N. atra (Chinese cobra). In comparison, E. coli and 5. 
aureus are much more resistant to these venoms (Dubovskii, Utkin 2014).
Our results appear consistent with the findings of Ovadia and colleagues that has 
demonstrated the preferential activity of a cytotoxin (CT P4) isolated from Naja 
nigricoilis toward B. subtilis and Micrococcus flavus with no apparent antimicrobial 
activities against Gram negative bacteria and fungi (Mollmann, Gutsche et al. 1997). 
Unfortunately, the amino acid sequence of this toxin has not been reported.
B. subtilis is one of the most commonly isolated bacteria from the oral cavity, 
oropharynx and cloaca of diverse snakes (Shek, Tsui et al. 2009, Jho, Park et al. 2011, 
Babalola, Balogun 2013). In addition, B. subtilis has the most anionic membrane 
compared with 5. aureus and E. coli membranes. B. subtilis contain higher amounts of 
PG distributed in the outer leaflet of their membrane (Clejan, Krulwich et al. 1986, 
Epand, Savage et al. 2007, Epand, Epand 2009). This suggests that the membrane- 
damaging activity of elapid peptides that have been purified are dependant on the 
presence of anionic phospholipids in the outer leaflet of the bilayer.
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The cytotoxic effects o f the purified proteins have been evaluated against d iffe rent 
eukaryotic cells. All purified proteins showed no haemolytic activ ity at the highest 
concentration 50 pg/m l. Whereas, the ATP assay has dem onstrated tha t the purified 
protein from  N. haje venom (NH3/4-4) exhibited less cytotoxic e ffect against both 
tested cell lines (HaCaT and HEK293) at the highest concentration 50 pg/m l, but both 
WG4-2 and NN2/3-3 showed cytotoxic effect against HEK293 cell line in a 
concentration-dependent manner.
Few enzymatic peptides w ith  antim icrobial activities derived from  snake venoms such 
as cathelicidins , myotoxins and waprins (Nair, Fry et al. 2007, Wang, Hong e t al. 2008, 
Oguiura, Boni-Mitake et al. 2011, Yamane, Bizerra et al. 2013). O ther snake venom 
cytotoxic peptides such as three-finger toxins (3FTxs) (~60 amino acids) m ight 
contribute  to  the snake venom antibacterial activities profile although very few  studies 
have explored this potential (Dubovskii, Utkin 2014).
The molecular masses o f the purified proteins and N-term inal sequences suggests tha t 
they are members o f the 3FTxs family. NH3/4-4 is identical to  the N-term inal sequence 
short neurotoxin2 o f N. haje (Joubert 1975), N. nivea (Botes 1971) and N. annulifera  
(Joubert, Taljaard 1978). WG4-2 and WG4-3 have the same N-term inal sequence as 
the cardiotoxins CTX- M l  and M2 o f N. mossambica (OTTING, STEINMETZ et al. 1987, 
Chien, Chiang et al. 1994) and CTX-1 of N. nigricollis (Rees, Bilwes et al. 1990, Bilwes, 
Rees et al. 1994). Only tw o  cytotoxins have been reported fo r N. nigricollis are toxin y 
(Bilwes, Rees et al. 1994) and toxin a (Zinn-Justin, Roumestand et al. 1992). 
Interestingly, the firs t five amino acids o f the N-terminal end o f toxin y were found to
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share 100% identity with the N- terminal of both purified proteins from W. aegyptia 
venom WG4-2 and WG4-3 (Bilwes, Rees et al. 1994). Conversely, a newer study (Chen, 
Kao et al. 2011) showed that toxin y have a prominent antibacterial activity against 
both E. coli and S. aureus through a permeabilising effect of the toxin as evidenced 
from fluorescent dye leakage studies (Chen/Kao et al. 2011). The common LCK 
sequence of the peptides isolated in this chapter, unique among many cardiotoxins of 
the Naja genus (Chen, Rose et al. 1991, Dubovskii, Lesovoy et al. 2003).
The most dominant protein components of elapid venoms are 3FTxs. 3FTxs constitutes 
half the contents of the Naja venoms (Dufton, Hider 1988, Chen, Rose et al. 1991). 
Only two 3FTxs proteins (Wa-lll; 6852 Da and Wa-IV; 6782 Da) have been previously 
identified in W. aegyptia (Samejima, Aoki-Tomomatsu et al. 1997, Tsai, Wang et al. 
2008). Both Wa-lll and Wa-IV are similar in size to WG4-2 and WG4-3. However, WG4- 
2 and WG4-3 have completely different N-terminal sequences compared with Wa-lll 
and Wa-IV, suggests these proteins represent novel additions to the W. aegyptia 3FTx 
family. Although abundant 3FTxs have been isolated from other Naja species like N. 
naja, the potential short chain 3FTxs (NN2/3-3) from N. nubiae venom may represent 
the first member of the 3FTxs family from this snake.
The majority of cardiotoxins have a potent haemolytic activity such as CTX1 (Gorai, 
Sivaraman 2016) and CTX3 (Troiano, Gould et al. 2006, Kao, Lin et al. 2010). The 
haemolytic activity of the snake peptides is consistent with results of various studies 
showing that some the cytotoxins have no haemolytic effect for example, Beta-
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cardiotoxin CTX27 from Ophiophagus hannah (King cobra) venom (Rajagopalan, Pung 
eta l. 2007).
Although no previous data have investigated the cytotoxic effect of cardiotoxins on 
HaCaT and HEK293 cell lines, it has been reported that only P-type cardiotoxin can bind 
to zwitterionic membranes (Sue, Rajan et al. 1997). The analysis of the structure of 
various 3FTxs revealed that, loop I and II of 3FTxs are rich in cationic residues while 
loop III is the hydrophobic surface (Girish, Kumar eta l. 2012). Thus, P-type cardiotoxins 
(Pro30 residue at the tip of the second loop) have binding activity more strongly to 
zwitterionic membranes than S-type toxins (have serine residue) as P-type use the tips 
of all three loops in the penetration while S-type inserts via the tip of the loop I only 
(Chien, Chiang et al. 1994, Efremov, Volynsky et al. 2002).
The findings of the interactions of the purified proteins with eukaryotic cell lines 
suggest that both WG4-2 and NN2/3-3 appear to belong to P-type CTs as they able to 
induce membrane disruption of kidney cell lines. These findings are consistent with 
Chien et al., (1994) that have demonstrated that P-type cardiotoxin s such as CTX M l,  
M4 and M5 which have similar N- terminal sequence to both WG4-2 and WG4-3 have 
higher affinity to zwitterionic membranes (Louw 1974, Chien, Chiang et al. 1994). The 
full-length sequences of purified proteins are needed in order to classify it as S-type or 
P-type cardiotoxins.
Our findings indicate that NH3/4-4, WG4-3, WG4-2 and NN2/3-3 proteins have 
antimicrobial properties with limited or no cytotoxic potential. Further studies are 
needed to complete sequencing of these proteins and to investigate their mode of
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action with more details. These isolated 3FTxs may serve as starting templates for 
designing novel synthetic AMPs with enhanced antimicrobial activities and valuable 
therapeutic effect.
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4 A morphological study of the effects of Smp24 and Smp43 on 
Escherichia coli and Staphylococcus aureus using scanning 
and transmission electron microscopes.
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4.1 Introduction
Imaging the action of antimicrobial peptides on living bacterial cells can provide novel 
Insights in to the mechanism of AMP action. Different spectroscopic techniques such 
as fluorescence microscopy, AFM and electron microscopes have been used to 
demonstrate morphological changes of living cells treated with AMPs (Anderson, 
Haverkamp et al. 2004, Meincken, Holroyd et al. 2005, Torrent, Sanchez-Chardi et al. 
2010, Scheinpflug, Krylova eta l. 2015).
Fluorescence microscopy provides more detailed information about AMP-bacterial 
membrane interactions. It can analyse and determine the distribution and target of 
AMPs intracellularly or extracellularly by detecting and localising attached fluorescent 
probes (Scheinpflug, Krylova et al. 2015). The interaction of fluorescently labelled 
melittin K14 with PC vesicle and with E. coli revealed insignificant pore formation in 
live bacteria, compared with the artificial membrane system. According to (Gee, 
Burton et al. 2013) a new model is needed to explain peptide-membrane interactions 
in live bacterial cells, as they discovered the complexity o f lipid-peptide interactions in 
living cells when compared with simple artificial systems.
Scanning and transmission electron microscopes were applied in several studies to 
visualise the ultrastructural damage and morphological changes to the bacterial cell 
envelope induced by AMPs. SEM and TEM are can be used as complementary 
techniques to gain insights into AMP mechanism of action when combined with other 
findings (Matsuzaki, Sugishita et al. 1997, Matsuzaki, Sugishita et al. 1999, Avitabile, 
D'Andrea et al. 2014).
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Blebs or b lister form ation on microbial surfaces are a common effect fo r AMPs. Blister­
like form ations in the outer membrane of Gram negative bacteria m ight be a ttribu ted  
to  the electrostatic interaction of cationic AMPs w ith  LPS by displacing cations from  
the ir binding sites on LPS prom oting the uptake of peptides across the outer 
membrane (Zhang, Dhillon et al. 2000, Grubor, Meyerholz et al. 2006). The appearance 
of abundant blebs has been previously reported on the surface o f Pseudomonas 
aeruginosa strains treated w ith  cathelicidin peptide SMAP29 as examined by SEM 
(Saiman, Tabibi et al. 2001a). LPS-binding studies o f full-length and truncated SMAP-29 
molecules revealed tha t presence o f m ultip le binding sites in the peptide allow binding 
LPS w ith  high a ffin ity  (Tack, Sawai et al. 2002). This a ffin ity  to  LPS has been confirmed 
by assessing the ability o f SMAP29 to  displace the fluorescent dansyl polymyxin B 
(DPX) bound to  LPS (Anderson, Yu 2005a).
The surface roughening and corrugating o f cell membrane have also been identified 
fo llow ing exposure to  several AMPs o f a wide range o f bacterial cells examined by EM 
techniques. These observations demonstrated loss o f membrane in tegrity  and the 
release o f cellular contents follow ing trea tm ent w ith  the peptides leading to  cell lysis 
and death (Lv et al., 2014, Wang et al., 2015).
EM also has been used successfully to  m onitor the action of some labelled AMPs on 
live bacteria in order to  clarify the ir antim icrobial action. Nanogold-labelled sushi 
peptide has been tracked on E. coli. Gold particles were found on the inner and oute r 
membranes, as well as in the periplasmic space and cytoplasm, while no particles were 
observed bound to  the bacteria fo r controls w ith  nanogold alone. The d is tribution  o f 
these particles has been quantified, the m ajority o f nanogold (77%) was found 
attached to  the exterior leaflet o f the outer membrane. These results suggest tha t the
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local environment at the bacterial outer surface is necessary for sushi peptide 
attachment to penetrate the membrane and enter the cell (Leptihn, Har e ta l. 2009). 
These observations were consistent with imaging of sushi peptide-treated £  coli and P. 
aeruginosa with AFM (Li, Lee et al. 2007).
Understanding the mode of action of broad spectrum Smp peptides against live 
bacterial cells will help to increase their potency and minimise their cytotoxic effects. 
Previously, AFM and quartz crystal microbalance-dissipation (QCM-D) have been used 
to study Smp peptides mechanisms on synthetic prototypical prokaryotic membranes. 
The results indicated that these peptides caused pore formation and induced the 
formation of non-lamellar lipid structures (Harrison, Heath et al. 2016). The 
interactions of AMPs against living cell membranes might be different and more 
complicated compared with simple artificial membranes (Gee, Burton et al. 2013). The 
interactions of Smp peptides with the membranes of live bacteria have not been 
clearly investigated. Therefore, one the goals of this current study is to examine 
concentration- and time-dependent effects of Smp peptides on intact E. coli and S. 
aureus cells using SEM and TEM.
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4.2 Method Summary
Both SEM and TEM were employed to examine morphological changes and membrane 
damage in E. coli and S. aureus strains in response to different concentrations of Smp 
peptides treatment across arange of time intervals. The overnight cultures of E. coli 
JM109 and S. aureus SH1000 were diluted in fresh MH Broth to a cell density lx lO 6 
CFU/ml then incubated at 37°C to grow to OD6oo=0.3 (mid-exponential growth phase). 
Bacterial cells were treated with different concentrations of either Smp24 or Smp43 
for different time intervals (10 minutes, 1 hour, and 24 hours) at 37°C. Then samples 
were prepared for SEM and TEM as described in sections 2.12 and 2.13 and then 
visualised.
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4.3 Results
4.3.1 Determination of Smp peptides concentrations used for SEM sample 
preparation
Since a high cell density is needed to observe EM images. E. coli JM109 and 5. aureus 
SH1000 were grown to mid-exponential phase then treated with Smp peptides at 
different concentrations for three time intervals (10 minutes, 1 hour, and 24 hours) to 
examine concentration- and time-dependent effects of Smp peptides on intact E. coli 
and S. aureus cells using SEM.
The inintial peptide concentration range that was used to evaluate inhibitory 
concentrations in the conditions required for SEM imaging was based on those found 
in section 2.4. Due to differences in volume and cell densities in these experiments, 
new inhibitory concentrations were defined (Figure 4.1 and Figure 4.2).
Therefore, three concentrations of each peptide; sub-MIC (one-quarter), MIC and 
supra-MIC (4x) against E. coli and S. aureus were selected for growth curves 
comparing Smp peptide exposed cultures with untreated cells (Table 4.1).
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Figure 4.1 Growth of E. coli. Treatment with Smp24 and Smp43, at the MIC (32 pg/ml) and 
one -quarter (8 pg/ml) of the MIC concentrations.
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Figure 4.2 Growth of S.aureus. Treatment with Smp24 and Smp43 at the MIC (16 pg/ml) and 
one -quarter (4 pg/ml) of the MIC concentrations.
Table 4.1 Peptide concentrations used for SEM sample preparation
Bacteria
Concentrations (pg/ml)
Sub- MIC (l/4x) MIC Supra -MIC (4x)
E. coli 8 32 128
S. aureus 4 16 64
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4.3.2 SEM of E. coli and 5. aureus incubated with Smp peptides for 10 minutes
Untreated E. coli and S. aureus cells showed normal bright smooth intact surfaces 
(Figure 4.3A and Figure 4.4 A). E. coli cells developed surface protrusions of numerous 
small nubs and blister like structures (indicated with red arrows) after incubation with 
concentration of Smp24 below the MIC and at the MIC concentrations for 10 minutes 
(Figure 4.3B and D). In comparison, E. coli cells appeared very rough, corrugated 
(marked by orange arrow) and shrunken when treated by equivalent concentrations of 
Smp43 (Figure 4.3C and E).
Distortions of the morphology of E. coli were observed in many treated cells at 
greater than MIC concentrations of both peptides with depressions and fractures on 
their surfaces. Numerous cells look corrugated as indicated by the orange arrows 
(Figure 4.3F and G).
Following exposure for the same period of time, the sub-MIC concentrations of either 
peptide resulted in the appearance of bacterial membrane blebs in 5. aureus cells 
(Figure 4.4 B and C). MIC and supra-MIC concentrations induced little cell membrane 
damage with accumulation of cell debris at this period of time (Figure 4.4 D- G).
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4.3.3 SEM of E. coli and 5. aureus incubated with Smp peptides for 1 hour
After 1 of hour incubation, most E. coli cells treated with sub-MIG concentrations of 
Smp24 showed obvious consistent with roughening and corrugating membrane 
damage, it also revealed few ruptured cells (Figure 4.5B). In comparison, damage of 
Smp43 treated cells at the same concentration was less evident; although most cells 
maintained intact cell structures, a few showed surface corrugated patterns and 
ruptured membranes (Figure 4.5C).
Many damaged E. coli cells were seen with more blebbing and corrugated surfaces 
following treatment of either peptide at MIC concentrations (Figure 4.5D and E). 
Panels F and G in Figure 4.5 showed many distinguishable lysed E. coli cells treated 
with supra-MIC concentrations of either Smp24 or Smp43.
After treatment of 5. aureus with either Smp24 or Smp43 for 1 hour, completely lysed 
cells accompanied with the intracellular material extrusion were observed in a 
concentration dependent manner, as nearly no intact cells were seen in S. aureus cells 
exposed to Supra-MICs of both peptides (Figure 4.6F and G). The damage is indicated 
by yellow arrows showed the complete loss of membrane integrity.
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4.B.4 SEM of E coli and 5. aureus incubated with Smp peptides for 24 hours
After 24 hours of incubation with concentrations of Smp peptides below the MIC and 
at the MIC, a small number of E  coli cells were shrunken and have corrugated surfaces 
(Figure 4.7B - E). Also, some blebs were seen on the surface of a few S. aureus treated 
cells at the same concentrations (Figure 4.8E). No cells were harvested after 24 hours 
of Smp peptides treatments at supra-MIC concentrations which induce cell death and 
led to cell lysis.
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4.3.5 TEM images of E. coli and S. aureus incubated with sub- MICs of Smp24 and 
Smp43
To investigate the morphological changes of bacterial cells, TEM was employed to  
study the membrane in tegrity  o f bacterial cells before and afte r trea tm ent w ith  Smp 
peptides. E .coli and S. oureus cells were treated w ith sub-MICs of Smp24 or Smp43 fo r 
10 minutes, 1 hour, and 24 hours. The samples were fixed and cut in to  th in  sections. 
For each treatm ent duplicate samples were prepared and numerous sections were cut 
from  each.
As shown in Figure 4.9 (panels A and B) and Figure 4.10 (panels A and B), the 
untreated E.coli and 5. aureus cells were all uniform ly shaped, w ith  an undamaged 
structure and intact cell envelops. W hile a fte r 10 minutes o f incubation w ith  both 
peptides, many treated E. coli cells showed morphological changes as cells w ithou t cell 
envelops and cells w ith  separated cell surface components. In some cases the 
cytoplasmic contents had leaked out o f the cells and exhibited obvious cytoplasmic 
clear zones as indicated by blue arrows in panels C and D. Some leakage o f cellular 
material was seen after the exposure o f S. aureus cells to  Smp peptides fo r 10 m inutes 
of incubation as shown in Figure 4.10 C and D
The m ajority o f the treated cells appeared severely morphologically affected a fte r 1 
hour o f incubation. They exhibited completely damaged membranes and cellular 
content spillage. Disrupted membranes were observed fo r E. coli cells being treated 
w ith Smp24 fo r 1 hour (Figure 4.9 E and F). Formation o f ghost cells which have intact 
cell envelopes w ithou t cellular contents were visualised after 10 m inutes and 1 hour 
and indicated by green arrows. It was obvious tha t S. aureus cells underwent lysis a fte r
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1 hour of incubation with SMP peptides as they exhibited damaged and ruptured 
envelops with released cellular contents (Figure 4.10 E and F).
After 24 hours of incubation, a regular cell shape was seen. A small number of E. coli 
cells showed morphological changes such as roughened membranes, zones of 
translucent cytoplasm and separation of outer membrane and cytoplasmic membrane 
(Figure 4.9 G and H). Also, the majority of the cells were indistinguishable from 
untreated cells. However, some zones of transparent cytoplasm were evident as seen 
in Figure 4.10 (panels G and H).
In conclusion, TEM images showed significant morphology changes as result of the 
exposure of bacterial cells to Smp peptides at sub-MICS up to 1 hour of incubation.
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Figure 4.9 Transmission electron microscope images taken of E. coli JM109 cells incubated with
Smp peptides at sub-MIC for different time intervals. Cells were cultured at 37 °C to mid-log phase
before treatment. (A) Untreated cells after 10 minutes; (B) Untreated cells after 1 hour; (C) Smp24-
treated cells for 10 minutes; (D) Smp43-treated cells for 10 minutes; (E) Smp24-treated cells for 1
hour; (F) Smp43-treated cells for 1 hour; (G) Smp24-treated cells for 24 hours; (H) Smp43-treated
cells 24 hours. The green arrows point to ghost cells that are not surrounded by a cell wall. Images
shown are representative of twenty images from three replicates.
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Figure 4.10 Transmission electron microscope images taken of 5. aureus SH1000 cells 
incubated with Smp peptides at sub-MIC for different time intervals. Cells were 
cultured at 37 °C to mid-log phase before treatment: (A) Untreated cells after 10 
minutes; (B) Untreated cells after 1 hour; (C) Smp24-treated cells for 10 minutes; (D) 
Smp43-treated cells for 10 minutes; (E) Smp24-treated cells for 1 hour; (F) Smp43- 
treated cells for 1 hour; (G) Smp24-treated cells for 24 hours; (H) Smp43-treated cells 
24 hours. The blue arrows indicate the cytoplasmic clear zones. Images shown are 
representative of twenty images from three replicates.
4.4 Discussion
Interactions between Smp peptides and synthetic prokaryotic membrane models have 
been previously investigated using liposome leakage assays, AFM and QCM-D. These 
data suggested tha t the bactericidal mechanism of Smp peptides against prokaryotic 
like membranes is toroidal pore form ation (Harrison, Heath et al. 2016). W hile in the 
current study, we investigated interaction o f Smp peptides w ith live bacterial cells to  
support our understanding o f the antibacterial mechanism o f these molecules in order 
to  develop the ir therapeutic potentia l as novel antim icrobial agents.
In the current study, SEM was perform ed on tw o  species of bacteria E. coli and 5. 
aureus, as representatives o f Gram positive and Gram negative bacteria to  visualise 
morphological changes fo llow ing exposure to  Smp peptides at d iffe rent concentrations 
and intervals o f tim e to  investigate the dose-dependent and tim e-dependent 
interactions o f Smp peptides against E. coli and S. aureus.
Formation o f blebs was evident fo r the tw o  species o f bacteria at sub-MIC and MIC 
concentrations after 10 minutes o f incubation. Our SEM observations provide 
morphological evidence o f the potent permeabilising activity o f Smp peptides at MIC 
and supra-MIC concentrations after 1 hour o f treatm ent. The treated cells were 
obviously roughened and disrupted when treated w ith  the peptide. Also, they 
exhibited changes to  the ir morphology such as shortening and membrane corrugating.
In addition to  SEM, TEM was employed to  study the m orphological and in trace llu la r 
changes o f E. coli and 5. aureus fo llow ing tre a tm e n t w ith  Smp peptides at sub-MIC 
concentrations a fte r 10 m inutes, 1 hour and 24 hours o f incubations. S ub-inh ib itory 
concentrations o f numerous antim icrobia l agents were com m only used to  evaluate
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the morphological and u ltrastructu ra l changes fo llow ing  antim icrobials challenge 
using TEM (Haukland, Ulvatne et al. 2001, Chen, Zhan et al. 2009, Wenzel, Chiriac et 
al. 2014). Our TEM images o f these cells treated w ith  sub-MICs concentrations o f both 
Smp peptides confirm  the interaction o f the peptides w ith  the bacterial membranes 
causing significant rupture and leakage o f cytoplasm contents which lead to  cell death. 
Apparent morphological changes were seen in the Smp treated cells such as 
cytoplasmic clear cells w ith  intact cell membranes form ing ghost cells compared w ith  
the control sample which showed regular shapes w ith  homogenous electron density.
Similarly, other cationic AMPs e.g. m elittin , magainin, moricin and King cobra venom 
AMP(OH-CATH) have induced the appearance of blebs and blisters like protusions a fte r 
a few  minutes o f trea tm ent at the Sub-MICs concentrations (Skerlavaj, Benincasa et al. 
1999, Saiman, Tabibi et al. 2001b, Mangoni, Papo et al. 2004, Chen, Zhan et al. 2009, 
Hu, Wang et al. 2013). Blebbing appears on the bacterial cell surface as a result o f 
expansion o f the outer membrane due to  the antibacterial activity o f AMP peptides 
(Hancock, Rozek 2002). Moreover, form ation o f blebs and blisters may be indicative o f 
the electrostatic interactions of Smp or o ther cationic AMPs such as LfcinB (bovine 
AMP) w ith  the anionic bacterial cell membrane. It has been suggested tha t interactions 
include displacement o f divalent cations (Ca2+, Mg2+) o f the outer bacterial membrane 
by the large peptides and tha t this results in blebs form ation (Hancock, Rozek 2002, 
Grubor, Meyerholz et al. 2006). Blebbing form ation  has also been a ttr ibu ted  to  
detachment o f cytoskeleton from  the cell membrane causing the la tte r to  swell 
(Omardien, Brul et al. 2016).
When the attached AMP aggregated on the bacterial surface at a high enough 
concentration, permeabilisation o f the cell membrane is induced leading to  cell death
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(Chan, Prenner et ol. 2006b). The permeabilisation effect o f AMPs may also be 
confirmed by the electrostatic interactions between basic residues o f the AMP and the 
negatively charged phospholipids o f the bacteria membranes (Matsuzaki, Sugishita et 
al. 1997). The 24-residue AMP GI24; a derivative o f PMAP-36, interacts w ith  anionic 
phospholipids to  induce membrane permeabilisiation. Also, the bee venom AMP 
m elittin  destabilise bacterial cell membranes by binding the anionic phospholipids 
inducing cell lysis (Oren, Shai 1997). The SEM examination o f M e littin - and GI24 
treated E. coli revealed the roughening and corrugating o f the membrane surface at 
the MIC after 1 hour o f incubation which is sim ilar to  Smp peptide effect against E. coli 
at the MIC after the same period o f tim e (Lv, Wang et al. 2014, Wang, Chou et al. 
2015).
The attraction to  phospholipids is one of the most frequently proposed mechanisms 
fo r a-helical peptides, permeablisation o f the bacterial membrane causing cell death 
(Shai 1999). Both Smp peptides are positively charged; net charge o f Smp24 is +3 and 
Smp43 is +4. The positive net charge o f the AMPs enhances the ir a ttraction  to  
phospholipids.
These findings are consistent w ith  the previous AFM micrographs o f Smp peptides 
against synthetic prokaryotic membrane models which identified the importance of the 
electrostatic attraction o f Smp peptides to  negatively charged bilayers fo r induction of 
membrane damage (Harrison, Heath et al. 2016). The same topography o f 
permeabilisation has been reported in several AFM and SEM studies o f d iffe ren t 
species o f bacteria treated by AMPs. For instance, the AFM and EM analyses o f the 21 
residue lugworm AMP arenicin interacts w ith  E .coli revealed a sim ilar e ffect on
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bacterial membranes as we have observed w ith  Smp peptides (Andra, Jakovkin et al. 
2008).
Smp peptides have more than 60% hydrophobic residues in the ir am ino acids 
sequences. The hydrophobic interactions o f AMPs and the lipid constituents o f the 
bacterial membranes have been proposed to  lead to  membrane destabilization. This 
in terpreta tion is in full agreement o f the proposed mechanism of several AMPs such as 
the 26-residue amphipathic a-helical AMP V13Kl (Chen, Guarnieri et al. 2007). 
Interestingly, in the la tte r study they found tha t there is an optim um  hydrophobicity in 
which maximum antibacterial activity o f V13Kl. Any alteration o f this hydrophobicity 
decreases its antim icrobial effect (Chen, Guarnieri et al. 2007).
Both hydrostatic and hydrophobic interactions o f AMPs w ith  the bacterial membranes 
are necessary fo r the antibacterial action o f AMPs (Shai 1999). Similarly, the 
mechanism of action o f magainins on bacterial cells determ ined against Gram negative 
bacteria can be summarised in tw o  main steps; interaction w ith  anionic 
lipopolysaccharides and then aggregation to  form  pores (Hancock, Rozek 2002, 
Grubor, Meyerholz et al. 2006). According to  (Saiman, Tabibi et al. 2001b), bacteria are 
unlikely to  develop a resistance fo r peptides w ith  this mode of action. AMPs act non- 
specifically on the entire bacterial membrane (Park, Park et al. 2011). Development o f 
microbial resistance by changing conserved targets such as the cell membrane or by 
gene m utation to  such mechanism of action is d ifficu lt requiring significant a lteration 
to  the physiology o f the cell (Zasloff 2002, Matsuzaki 2009, Aoki, Ueda 2013).
Similar micrographs o f ghost cells form ation  have been reported in TEM studies o f
bacterial cells treated w ith some cationic AMPs such as TEM studies o f E. coli treated
w ith  a variety o f AMPs (Chappie, Mason et al. 1998, Anderson, Haverkamp e t al. 2004,
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Chen, Zhan et al. 2009, Makobongo, Gancz et al. 2012) . The formation of ghost cells 
suggest that cationic AMPs induce the formation of pores which were more evident at 
the 1-hour time point of Smp24 treated E coli. It seems to be a general mechanism for 
cationic AMPs which form transmembrane pores when the peptides inserted into the 
lipid constituents of the bacterial membranes (Sengupta, Leontiadou et al. 2008, 
Makobongo, Gancz et al. 2012, Bahar, Ren 2013, Chen, Jia et al. 2013).
In addition, some extracellular electron-dense materials and sloughing of cell walls 
from some cells have been visualised using TEM following the exposure to sub-MIC 
concentrations of Smp peptides after 10 and 60 minutes. Similarly, the TEM 
micrographs of AMPs such as RRIKA, NK-2 against different species of bacteria 
revealed the same observations (Hammer, Brauser et al. 2010, Mohamed, Hammac et 
al. 2014). These findings support the permeabilisation effect of cationic AMPs against 
bacterial cells (Hartmann, Berditsch et al. 2010).
The highly disintegrated membranes of Smp peptide treated bacteria may increase the 
influx of water into the cytoplasm which induces cytoplasmic membrane rupture 
leading to a discharge of cytoplasmic materials. The cytolysis effect of Smp peptides 
was seen for supra-MICs concentrations as many E  coli lysed cells with cytoplasmic 
contents release and debris have been observed even after 10 minutes of incubation. 
Similarly, the high concentrations of other cationic AMPs; GS and PGLa lead to 
membrane damage and cell content leakage resulting in cell death (Hartmann, 
Berditsch et al. 2010).
However, the majority of £  coli and S. aureus of the mid-exponential growth phases
exposed to sub-MIC and MIC concentrations of Smp peptides showed no prominent
morphological changes after 24 hours of incubation (Figure 4.7-8). They showed
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normal cell shape w ith an undamaged structure o f the ir membranes and homogenous 
electron-dense materials. Very few  cells revealed morphological changes in the form  
o f roughened membranes and blisters on the ir surfaces at the MIC of Smp peptides. 
These results revealed tha t sub-MIC and MIC concentrations as determ ined by broth 
m icrodilution o f Smp peptides were insufficient fo r allowing the peptide binding and 
interaction w ith all of E. coli and S. aureus cells at the m id-exponential g row th phase, 
unbound viable bacterial cells continuously grew and the peptide effect declined a fte r 
longer exposure fo r 24 hours (Pacor, Giangaspero et al. 2002). These findings 
dem onstrate the dose-dependent manner o f Smp peptides against bacterial 
membranes.
Some Smp24 treated E. coli at the MIC concentration revealed electron-dense 
materials inside the cells when examined using TEM similar to  the reported effects o f 
w aterfow l cathelicidin peptide dCATH (Gao, Xing et al. 2015) and C12K- 2 3 1 2  against E. 
coli suggesting the aggregation of biological macromolecules.
In conclusion, both SEM and TEM are influentia l imaging techniques tha t a llow us to  
gain insights in to AMP action. Our findings o f EM micrographs indicated tha t Smp 
peptides and bacterial interactions m ight take place in a stepwise fashion including 
peptide binding and insertion into bacterial membranes which lead to  membrane 
permeabilisation and cytoplasmic contents leakage even at low concentrations. Firstly, 
the amphipathic properties o f Smp peptides could help peptides to  in teract w ith  the 
negatively charged bacterial membrane hydrostatically by binding to  positively 
charged amino acid residues and embedded in the non-polar components o f the 
bacterial membrane by the hydrophobic residues. Then, the embedded peptides 
aggregate and reach a threshold concentration which induces the  membrane
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permeability to from pores or rupture the bacterial membrane. Finally, the contents of 
the cells were released inducing cell death.
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5 Transcriptomic profiling of Escherichia coli following 
exposure to Smp24 and Smp43.
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5.1 Introduction
Bacteria have evolved mechanisms to  recognise and respond to  AMPs by d ifferentia lly 
expressing genes as a response to  stress or as a unique resistance mechanism against 
each AMP (Brazas, Hancock 2005, Fehri, Sirand-Pugnet et al. 2005, Pietiainen, 
Gardemeister et al. 2005). The d ifferentia lly  expressed genes of bacteria in response to  
d iffe rent types o f stress and treatm ent has been widely investigated using DNA 
microarray in order to  identify and characterise the biological processes and pathways 
most affected (Overhage, Bains et al. 2008, Monras, Collao et al. 2014).
High-density gene detection techniques like DNA microarrays can facilita te  the 
prediction o f the mode o f action o f antibiotics. For instance, m icroarray analysis has 
been used to  investigate the mechanisms of increased activity o f a com bination o f tw o 
antibiotics; Fosfomycin and tobramycin (F:T) against P. aeruginosa compared w ith  
tobramycin alone under anaerobic conditions (McCaughey, McKevitt et al. 2012). It 
was found tha t n itrate reductase genes narG  and narH  were down regulated 
significantly in response to  growth in F:T under anaerobic conditions. Interestingly, 
nitrate reductase m utant strains showed higher sensitivity to  F:T in anaerobic 
conditions compared w ith an aerobic environm ent which confirm  the role o f nar 
genes in inducing increased activity o f F:T against P. aeruginosa as revealed by 
microarray analysis (McCaughey, Gilpin et al. 2013).
Bacterial resistance mechanisms to  antibiotics can also be investigated using 
microarray. Bang-Ce Ye and colleagues (Yu, Yin et al. 2012) have investigated and 
identified the d ifferentia lly  expressed genes and pathways induced by fusaricidin 
against Bacillus subtilis by DNA microarray technique. They revealed tha t the most
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upregulated genes are known to  be regulated by owextracytoplasmic function sigma 
factor which indicate tha t this regulon may play an im portant role in B. subtilis 
resistance to  fusaricidin. Also, fusaricidin addition has led to  an increase in the 
catabolism o f fa tty  and amino acids and the loss o f some intracellular ions tha t induce 
cation transport into the cell which may point to  the mode o f action o f fusaricidin 
against B. subtilis. These findings indicate tha t a microarray-based approach allows fo r 
a more comprehensive analysis o f bacterial responses to  antibiotics.
DNA microarray has been used to  provide insights in to the mode o f action o f AMPs 
and AMP-resistance mechanisms to  understand how bacteria respond to  AMPs. E. coli, 
S. aureus, and B. subtilis have often been used as models to  study the mechanism of 
action o f AMPs as the complete genome o f these bacteria have been sequenced (Yu, 
Yin et al. 2012, Suzuki, Horinouchi et al. 2014, Kramer, van Hijum et al. 2006, Li, Lai et 
al. 2007). For instance, the responses of S. aureus, fo llow ing exposure to  some linear 
cationic AMPs, such as tem porin L, dermaseptin K4-S4 (1-16) and ovispirin-1 were 
analysed by DNA microarray. These AMPs share some upregulated genes w ith  cells 
treated by cell w a ll-inh ib ition antibiotics such as vancomycin. The functional clustering 
analysis o f gene groups induced by these peptides displayed some specific pathways 
implicated in the resistance mechanism o f 5. aureus. In particular, an ABC transporter 
encoded by the vraDE regulon was induced strongly by ovispirin-1 and dermaseptin 
K4-S4 (1-16) (Pietiainen, Francois et al. 2009). Gene expression patterns o f E. coli were 
analysed using DNA microarray in response to  d iffe ren t antim icrobial peptides derived 
from  human and animal resources (Audrain, Ferrieres et al. 2013). This study 
concluded tha t the sublethal doses an AMP derived from  human apolipoprote in  E
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induced some distinct pathways that contribute to cell wall stress resistance (Audrain, 
Ferrieres et al. 2013).
Smp peptides offer a promising starting point for the development of new 
antimicrobial agents and transcriptomic analysis can help identify metabolic processes 
affected by AMPs which may be beneficial in understanding their mechanism of action. 
The main objective of this chapter is to identify differentially expressed genes 
following exposure of E. coli to Smp24 and Smp43 as a model for pathogenic Gram 
negative bacteria. A genome-wide phenotypic profiling of Smp peptide sensitivity in 
the KEIO collection strains of E. coli single gene knockout mutants was carried out to 
address the effect of deletion of some highly differentially expressed genes identified 
by microarray.
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5.2 Method Summary
Bacteria were cultured overnight at 37°C in M uller Hinton broth, MICs and 
subinhib itory concentrations were determ ined by serial m icrodilution methods. Total 
RNA was extracted, then assessed fo r its concentration, purity and in tegrity. RNA was 
labelled w ith  Cyanine 3-CTP (Cy3) dye and the com plim entary RNA (cRNA) was 
amplified and Cy3 specific activity was quantified. The labelled cRNA was loaded onto a 
gasket slide and assembled on the microarray slide, which contains 8  x 15K whole E. 
coli K12 oligo arrays. A fte r hybridization, slides were disassembled, and then scanned 
using an Agilent C M icroarray Scanner (Agilent, Wokingham, UK). All samples were 
tested in duplicate on each of tw o  separate arrays We analysed the changes in gene 
expression of E. coli to  sub-inhib itory doses of the Smp24 and Smp43 peptides and 
polymyxin B as a positive control using Agilent GeneSpring GX software (version 13.1). 
In order to  identify genes tha t affect the susceptibility o f E. coli to  Smp peptides, the 
Keio collection o f knockout mutants o f d iffe rentia lly  regulated genes were screened 
against Smp24 and Smp43. TaqMan RT-PCR primers were used as a reference to  
evaluate the accuracy o f expression from  microarray in three experiments fo r four 
genes identified through keio collection screening (two upregulated genes, fepA  and 
f iu  and tw o down regulated genes, fdnG  and proB).
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5.3 Results
5.3.1 Determination of subinhibitory concentrations
In order to study gene expression patterns in response to Smp peptides, E. coli 
cells were exposed to subinhibitory concentrations of tested peptides. 
Subinhibitory concentrations stimulate bacterial adaptation to different stresses, 
including antimicrobial effects. These concentrations affect cellular physiology and 
genetic expression profiles which can assist in the identification of the mode of action 
of Smp peptides.
Killing curves were performed to identify subinhibitory concentrations of Smp24, 
Smp43 and Polymyxin B against E. coli. Subinhibitory concentrations were 
determined as concentrations that induce a measurable stress response without 
totally inhibiting the growth of E. coli over four to five hour time periods when 
compared with untreated cells. Subinhibitory Smp peptide concentrations ranged 
from a concentration of zero to the MIC. It was observed that the growth of E. coli 
was reduced at Smp24, Smp43, and Polymyxin B concentrations of 12, 7 and 0.18  
pg/ml respectively (Figure 5.1).
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Figure 5.1 Growth of E. coli K12. Treatment with Smp24 at concentration of 12 pg/ml (A), Smp43 
7 pg/ml (B) and Polymyxyin B 0.24 pg/ml (C),
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5.3.2 Pre-microarray analysis quality control
Before carrying ou t the  m icroarray experim ent, the  qua lity  and p u rity  o f the  
extracted RNA samples were assessed by the  NanoDrop spec tropho tom ete r (Figure 
5.2) then confirm ed by the Agilen t 2100 Bioanalyzer (Figure 5.3). All the  tested 
samples were o f a h ighly pure and un-degraded RNA. The QC reports o f the  Agilen t 
Feature Extraction Software showed a good qua lity  hybrid isation  represented by 
the  level and d is tribu tion  o f the  detected signals (Figure 5.4), and the  Spike-ln 
L inearity Plot re flects the  accuracy and rep rodu c ib ility  o f the probes signals (Figure 
5.5).
9/12/2014 10:55 AMMeasurement completeRe-blank Print Screen Recording
Measure
OttiliePrint Report Show ReportBlank User
Overlay control Clear graph each Sample Sam ple Type
1.60
1.40 Sam ple ID
1.20
Sam ple #
S 0.80
Abs. 0.784
0.60
A-260 10 mm path 1.5-18
A-280 10 mm path
0.20
2.20260/280
0.00
260/230 1.98
- 0 .1 7 -
ng/uL 61.9W avelength nm
3.5 .2  BB749 0 .0 3 /1 1 2 /2 4
Figure 5.2 Nanodrop spectrophotometer analysis for RNA extracted from E. coli untreated at
260 nm. The concentration is shown is 61.9 ng/pl. 260/280 ratio is 2.2 and 260/230 ratio is
1.98.
136
RIN=8.7
40
20
0
16S 23S
20 25 30 35 40 45 50 55 60(s]
Figure 5.3 Representative electropherogram for total RNA sample using the Agilent 
Bioanalyzer of E. coli untreated. The electropherogram peaks include 16S rRNA (16S), and 23S 
rRNA (23S). Peak intensities are shown as fluorescence units (FU). (Inset: Instrument software 
generated 'virtual gel 'pattern). The RIN value is indicated.
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Figure 5.4 Representative histogram of microarray signal plot of E coli treated with 
a sub lethal dose of Smp43. Following subtraction of the background intensity, FE 
software plots the number of spots against the log of the processed signal to create a 
Histogram of Signals Plot. A bell-shape confirms a normal distribution of the (Cy3) 
signals intensity across the array.
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Figure 5.5 Representative Agilent Spike-ln QC Report of E.coli 
treated by sub lethal dose of Smp43. Log (Signal) versus Log 
(Relative Concentration) Plot. Spike-in Linearity Plot shows the 
linear increase in the detection level from the lowest detection 
limit up to the optimal saturation point using the detection levels 
of the serially diluted spike-in internal positive controls. Small 
error bars occurs when the signal level is close to the saturation 
point, while more visible error bars indicate that the signal is close 
to the background noise. FE extracted data are considered reliable 
when falling within the signal range, while the signal increases 
linearly with the concentration of the target.
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5.3.3 Microarray gene expression analysis
Analysis of raw data started with importing "txt" data files generated by the Feature 
Extraction software into Agilent GeneSpring software followed by an automatic 
computing of the 75th percentile-shift normalisation. In order to identify genes that 
were differentially expressed due to the presence of Smp peptides in E. coli three 
different peptides were used for the transcriptome analysis: Smp24, Smp43 and 
polymyxin B. Polymyxin B was chosen as a well characterised AMP positive control. 
Samples for transcriptome analyses were collected from bacterial cultures treated with 
sublethal concentrations of AMPs and were compared with control samples without 
peptide treatment. All genes with at least a two-fold change in expression in two 
independent array experiments with two replicates were recorded (Figure 5.6)
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Figure 5.6 Gene expression of E. coli treated by a subinhibitory 
concentration of Smp43. Volcano plot in Genespringl3.1 with P- 
values and intensity ratios (treated versus untreated) as log- 
scaled axes. Significant differences at p < 0.05 with >2-fold 
intensity ratios are shown. Red dots indicate significantly 
differentially expressed transcripts; upregulated (right) and down 
regulated (left).
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In to ta l, 313 significantly d iffe rentia lly  expressed transcripts were identified, 
d istributed over the three comparisons of each peptide against the inh ib ito r-free  
control. Comparing Smp24 treatm ent w ith  the control revealed 130 d iffe rentia lly  
expressed transcripts (109 coding fo r known RefSeq genes), Smp43 induced 84 
d ifferentia lly  expressed transcripts ( 6 8  known), and polymyxin B induced 99 
d ifferentia lly  expressed transcripts (76 known). The 25 most d iffe rentia lly  expressed 
genes fo r each peptide are listed in Table 5.1. We found tha t only 2 out o f the 313 
d ifferentia lly  expressed genes were common among all three treatm ents, and only 13 
genes were common between Smp24 and Smp43 (Figure 5.7). Smp24 and polymyxin B 
upregulated a large number o f genes (48 and 18 respectively) compared w ith  the 
num ber o f upregulated genes in response to  Smp43 where there were only three. Ten 
upregulated genes were induced commonly by Smp24 and polymyxin B and are listed 
in Table 5.2. Forty-eight unique upregulated transcripts were identified fo r Smp24 
treatm ent. W hile treatm ents w ith  Smp43 and polymyxin B induced 3 and 18 unique 
upregulated transcripts respectively (Figure 5.7).
There were also down regulated genes in the transcriptomes. Smp24, Smp43, and 
polymyxin B decreased the expression o f 56, 71 and 81 genes, respectively. There were 
only tw o genes down-regulated commonly by all peptides. 13 o f 153 genes were 
commonly down regulated by Smp24 and Smp43 treatm ent as shown in Table 5.3 
Also, Smp43 and polymyxin B share 38 out o f 152 down regulated expressed 
transcripts (25%) are listed in Table 5.4.
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Table 5.1 The most differentially expressed gene lists following exposure to Smp24, Smp43
and Polymyxin
Gene Fold Gene description
Symbol Change
cirA 56 outer membrane receptor for iron-regulated colicin 1 receptor
fepA 40 Ferrienterobactin receptor precursor
f,u 39 putative outer membrane receptor for iron transports
fepA 35 outer membrane receptor for ferric enterobactin
T3
<u ybiL 33 Probable tonB-dependent receptor ybiL precursor
(D
3W> entC 33 isochorismate hydroxymutase 2, enterochelin biosynthesis<U
Q.
=>
ybdB 26 orf, hypothetical protein
ybdB 23 Hypothetical protein ybdB
ECs0636 20 hypothetical protein
entB 19 2,3-dihydro-2;3-dihydroxybenzoate synthetase
entA 18 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase
CM
Q.F
nrdl 19 orf, hypothetical protein
in entF 17 Enterobactinsynthetase component F
narG 45 nitrate reductase 1, alpha subunit
narJ 27 nitrate reductase 1, delta subunit, assembly function
tdcF 24 orf, hypothetical protein
TO fdnG 11 formate dehydrogenase-N, nitrate-inducible, alpha subunit
<D+->
J O
3
ftnA 9 cytoplasmic ferritin
W><D fdnl 9 formate dehydrogenase-N, nitrate-inducible,cytochrome B556
c
5o/■s
yeiT 8 putative oxidoreductase
LJ
fdnH 7 formate dehydrogenase-N, iron-sulfur beta subunit
yqeC 6 orf, hypothetical protein
yjji 6 orf, hypothetical protein
soxS 5 regulation of superoxide response regulon
ECs0981 5 anaerobic dimethyl sulfoxide reductase subunit C
Continued
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Gene Fold Gene description
■o<u+-»(0
Symbol Change
3U><U
Q.
flgG 3 flagellar biosynthesis, cell-distal portion of basal-body rod
D
ubiH 2 2-octaprenyl-6-methoxyphenol hydroxylase
lacl 948 transcriptional repressor of the lac operon
pepD 372 aminoacyl-histidine dipeptidase
betB 151 NAD+dependent betaine aldehyde dehydrogenase
frsA 111 orf, hypothetical protein [b0239]
QPt 109 guanine-hypoxanthine phosphoribosyltransferase
sopA 100 plasmid partitioning protein
yagN 92 orf, hypothetical protein
flmC 88 hypothetical protein
betl 87 probably transcriptional repressor of bet genes
m 86 cytotoxic protein LetB
Q.
£
T3QJ+->(0
ykgF 72 orf, hypothetical protein
"5M<u
69 SopB protein
' £ 
5
yahK 62 putative oxidoreductase
oQ ykfB 54 orf, hypothetical protein
lacZ 54 beta-D-galactosidase
ccdB 52 plasmid maintenance protein
gpt 50 Xanthine-guanine phosphoribosyltransferase
harH 42 nitrate reductase 1, beta subunit
narG 39 nitrate reductase 1, alpha subunit
proB 37 gamma-glutamate kinase
yahN 34 putative cytochrome subunit of dehydrogenase
ECs0346 31 putative transporter
intF 30 putative phage integrase
ECs0360 30 high-affinity choline transport
proB 29 gamma-glutamate kinase
Continued
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Gene
Symbol
Fold
Change
Gene description
dr A 39 outer membrane receptor for iron-regulated colicin 1 receptor
fepA 23 outer membrane receptor for ferric enterobactin
ybdB 18 Hypothetical protein ybdB
ybdB 17 orf, hypothetical protein
ECs0636 15 hypothetical protein
entF 14 Enterobactinsynthetase component F
entF 14 ATP-dependent serine activating enzyme
entB 12 2,3-dihydro-2;3-dihydroxybenzoate synthetase,
entE 11 2,3-dihydroxybenzoate-AMP ligase
yncE 10 putative receptor
ybdB 10 orf, hypothetical protein
feoA 9 ferrous iron transport protein A
feoC 8 orf, hypothetical protein
lad 226 transcriptional repressor of the lac operon
frsA 135 orf, hypothetical protein
betB 127 NAD+-dependent betaine aldehyde dehydrogenase
gpt 117 guanine-hypoxanthine phosphoribosyltransferase
crl 109 transcriptional regulator of cryptic csgA gene
betT 107 high-affinity choline transport
flmC 98 hypothetical protein
pepD 94 aminoacyl-histidine dipeptidase
yagN 94 orf, hypothetical protein
sopA 90 plasmid partitioning protein
sopB 80 plasmid partitioning protein
ykfB 71 orf, hypothetical protein
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Table 5.2 Upregulated transcripts induced commonly by Smp24 and Polymyxin B.
Transcript ID
Gene Peptide (FC)
Gene description
symbol Smp24 Polymyxin B
A_07_P003540 cirA 55 39 ferric iron-catecholate outer 
membrane transporter
A_07_P016680 fepA 40 23 iron-enterobactin outer 
membrane transporter
A_07_P044007 ybdB 26 19 hypothetical protein
A_07_P031332 ybdB 23 18 hypothetical protein
A_07_P054207 ECs0636 20 15 hypothetical protein
A_07_P016731 entB 19 12 isochorismatase
A_07_P031313 entF 17 14 enterobactin synthase subunit F
A_07_P016744 ybdB 14 10 conserved protein
A_07_P009354 yncE 10 10 conserved protein
A_07_P002712 fhuA 5 5 ferrichrome outer membrane 
transporter
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Table 5.3 Down regulated transcripts induced commonly by Smp24 and Smp43
Transcript ID
Gene Peptide (FC)
Gene description
symbol Smp24 Smp43
A_07_P007073 narG 45 39 nitrate reductase 1, alpha subunit
A_07_P007083 narJ 27 20 molybdenum-cofactor-assembly 
chaperone subunit (delta subunit) 
of nitrate reductase 1
A_07_P009461 fdnG 11 8 formate dehydrogenase-N, alpha 
subunit, nitrate-inducible
A_07_P009475 fdnl 9 7 formate dehydrogenase-N, 
cytochrome B556 (gamma) 
subunit, nitrate-inducible
A_07_P003491 yeiT 8 6 predicted oxidoreductase
A_07_P009468 fdnH 7 5 formate dehydrogenase-N, Fe-S 
(beta) subunit, nitrate-inducible
A_07_P000799 napC 5 4 nitrate reductase, cytochrome c- 
type, periplasmic
A_07_P004926 dmsC 5 3 dimethyl sulfoxide reductase, 
anaerobic, subunit C
A_07_P036723 hybA 5 3 hydrogenase 2 protein HybA
A_07_P002090 hypC 4 4 protein required for maturation 
of hydrogenases 1 and 3
A_07_P012100 hybD 3 3 predicted maturation element for 
hydrogenase 2
A_07_P018368 cfa 2 3 cyclopropane fatty acyl 
phospholipid synthase 
(unsaturated-phospholipid 
methyltransferase)
A_07_P041771 yhaV 2 3 Hypothetical protein yhaV
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Table 5.4 Down regulated genes induced commonly by Smp43 and polymyxin B
Gene
symbol
Peptide (FC)
Gene description
Smp43 polymyxin
betA 26 43 choline dehydrogenase, a flavoprotein
betB 151 127 betaine aldehyde dehydrogenase
betT 24 39 high-affinity choline transport
ccdA 15 26 plasmid maintenance protein
ccdB 52 44 High-affinity choline transport protein
cod A 19 9 cytosine deaminase
flmC 88 98 hypothetical protein
ECS0346 29 44 putative transporter
ECs0360 30 28 high-affinity choline transport
frsA 111 135 orf, hypothetical protein
garR 15 15 putative dehydrogenase
QPt 50 51 Xanthine-guanine phosphoribosyltransferase
intF 30 42 putative phage integrase
lad 948 226 transcriptional repressor of the lac operon
lacY 26 41 galactoside permease
lacZ 54 67 beta-D-galactosidase
mhpR 20 21 transcriptional regulator for mhp operon
mmuM 25 40 putative enzyme
norG 39 9 nitrate reductase 1, alpha subunit
norH 42 12 nitrate reductase 1, beta subunit
pepD 372 94 aminoacyl-histidine dipeptidase
proB 37 38 gamma-glutamate kinase
sopA 100 90 plasmid partitioning protein
yafY 23 18 putative transcriptional regulator LYSR-type
yogN 92 94 orf, hypothetical protein
yahB 12 18 putative transcriptional regulator LYSR-type
yahK 62 54 putative oxidoreductase
yahN 34 59 putative cytochrome subunit of dehydrogenase
yohO 17 27 orf, hypothetical protein
yeiT 6 4 putative oxidoreductase
ykfB 54 71 orf, hypothetical protein
ykgG 25 44 orf Unknown function
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5.3.4 Analysis of expressed gene lists using DAVID bioinformatics resources
To determ ine the bacterial metabolic pathways which were significantly affected by 
peptide exposure, the upregulated genes were subm itted to  the Database fo r 
Annotation, Visualisation and Integrated Discovery (DAVID) analysis too l. Functional 
annotation clustering (FAC) analysis o f 48 upregulated genes in response to  Smp24 
trea tm ent resulted in 9 enriched functional clusters under the medium stringency 
option.
Siderophore biosynthetic processing and di - tr i valent ion binding and transport were 
the most biologically im portant gene groups w ith  enrichm ent scores (ES) o f 5.45 and 
4.86 respectively (P < 0.05) fo r Smp24 (Figure 5.8A). FAC revealed fou r genes are 
included in siderophore biosynthesis processing and th irteen genes were counted in 
the second cluster o f cation binding and transport functions. The remaining FAC 
clusters o f upregulated genes were dom inated by genes o f amino-acid biosynthesis, 
magnesium ion binding, and nucleotide binding (chloride channels).
The m ajority (60%) o f enriched clusters identified fo r polymyxin B upregulated genes 
were similar to  those clustered fo r Smp24 upregulated genes, both treatm ents share 
clusters related to  cation binding, siderophore biosynthesis and nucleotide binding 
(Figure 5.8A). FAC analysis clustered the ten common upregulated genes in response 
to  Smp24 and Polymyxin B treatm ents in one enriched functional cluster including 
mainly cation binding and transport processes under the medium stringency option 
(ES= 3.82, p <0.05).
FAC analysis o f 72 down regulated genes o f Smp24 generated seven enriched clusters. 
The highest enriched gene group was cellular respiration (ES= 10.11), fo llow ed by
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cation (iron) binding and transport (ES= 5.1). Some other clusters with lower ES were 
mainly related to cellular respiration such as electron transport and formate 
dehydrogenase (NAD+) activity. All of these clusters are shown in figure 5.8B.
Smp43 down regulated genes were clustered into 14 enriched clusters, the highest two 
clusters were cellular respiration and cation (iron) binding, the same as identified for 
Smp24 and the down regulated gene clusters are cellular respiration arid cation (iron) 
binding and transport with very close ES, 4.69 and 4.31 respectively. The next highest 
Smp43 down regulated gene groups according to ES values were post-segregation 
antitoxin CcdA, stress response, electron transport chain, and some other metabolic 
pathways. Clusters such as post-segregation antitoxin CcdA (ES 3.84), Arginine and 
proline metabolism (ES 3.59), stress response (ES 3.21), cation binding (ES 1 .99), iron -  
sulfur cluster binding (ES 1.4) and electron transport chain (ES 1.1) were also identified 
for polymyxin B down regulated genes(Figure 5.8B).
Interestingly, the biological processes of cation binding, cellular respiration, and 
electron transport were the most affected processes in response to both Smp24 and 
Smp43 treatments.
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Figure 5.8 DAVID Functional Annotation Clustering (FAC) analysis of 
differentially expressed genes obtained by Microarray analysis of E. coli 
following exposures to subinhibitory concentrations of AMPs. A. Enriched 
functional gene clusters for the 58 and 28 up-regulated genes of Smp24 and 
Polymyxin B respectively. B. Enriched functional gene clusters for the 12, 81 and 
71 down regulated genes of Smp24, Smp43 and polymyxin B respectively. 
Significance is determined by corresponding enrichment scores.
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In conclusion, microarray analysis of the E. coli response to Smp peptides compared 
with the absence of peptides has revealed seventy two genes were down-regulated by 
Smp24 and eighty one genes were down-regulated by Smp43. Of these, thirteen 
genes were down-regulated in common and were associated with bacterial 
respiration. Forty eight genes were specifically up-regulated by Smp24; these genes 
were predominantly related to sideophores biosynthesis and transport as well as 
cation transport, especially iron.
These gene lists has been interpreted using DAVID, gene clusters mainly associated 
with siderophore biosynthesis, cation transport, electron transport chain, cellular 
respiration and oxidative stress responses were the most biologically important 
enriched gene groups.
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5.3.5 Screening the Kieo collection
The Keio collection is the most used genome-wide screens o f E. coli knockout strains. 
This library includes singe gene deletions fo r 3,985 genes representing more than 90% 
of the E. coli K-12 genome. This analysis method has successfully been used as a too l in 
the last decade by screening m utant cells against antim icrobial agents to  identify  and 
assess the most fundam ental genetic variant or tra it fo r antim icrobial mode o f action 
or bacterial resistance (Liu, Tran et ol. 2010, Audrain, Ferrieres et al. 2013, Stokes, 
Davis et ol. 2014).
To characterise the genes tha t effectively contribute to  the E. coli response to  Smp 
peptides, a tota l o f seventy nine strains from  the Keio collection were tested fo r 
Smp24 and Smp43 susceptibility, each o f which have a single deletion o f highly 
d ifferentia lly  expressed genes of E. coli identified by m icroarray analysis (Table 5.5). 
The BW25113 parent strain o f E. coli was assayed firs t against concentrations o f 
Smp24 and Smp43 (0-512 pg/m l) to  determ ine w ild-type MIC (32 pg/m l). The 
sensitivity profile o f Smp24 was determ ined against th irty-e ight single-gene knockouts. 
Only fifteen mutants showed d iffe rent MICs against Smp24 compared w ith  the w ild- 
type strain. Ten m utant strains were more resistant to  Smp24 and had an increased 
MIC (64 pg/m l) w ith  respect to  the parent strain. The m ajority (> 75%) o f these genes 
(fiu, entC, entA, entB, entH, fepA  and fhuA) are involved in the biosynthesis o f 
sideorphores and the transport o f ions. Also, the deletion o f the protein binding gene 
fim C  increased resistance to  Smp24. Moreover, the m utant cell o f tatE, a com ponent 
o f TatABCE protein export complex, exhibited resistance to  Smp24 (Table 5.6).
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Knocking out genes sodB,fdnG, ycgK, soxS and ccmB resulted in cellular sensitivity to  
Smp24 w ith a one fold decrease in the MIC compared w ith  the w ild type strain. Two of 
these genes sodB and soxS play an im portant role in bacterial protection from  
superoxide; however fdnG  and ccmB are involved in the n itrate reduction process 
during anaerobic respiration (Table 5.7).
Forty one strains from  the Keio knockouts were tested fo r Smp43 susceptibility. Only 
nine mutants displayed d iffe ren t MICs against Smp43. The single deletion m utants o f 
the genes nopC, garK, fdnG, dsmA, hypA and fdnH  which are involved in anaerobic 
respiration and oxidoreductase gene ubiH, implicated in response to  oxidative stress, 
exhibited increases in susceptibility to  Smp43 (16 pg/m l) (Table 5.7). Two strains 
showed increased resistance, one of these carried a deletion o f proB, a gene tha t has a 
function in magnesium ion binding and kinase activity. W hile the other resistant strain 
has a deletion of ykfB which is an uncharacterised 'hypothetical' gene (Table 5.6).
Eight genes (ihfB , uxuR, hcoT, cysG, ugpQ, idnT, yghB and pbpC) which were not 
d ifferentia lly  expressed were randomly selected to  assess single gene deletion effect 
on the susceptibility o f E. coli to  Smp peptides as experimental controls; all showed the 
same MIC fo r Smp peptides when compared w ith  the wild type strain.
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Table 5.5 MICs for Smp peptide aginst Keio strains compared with the wild type strain 
(Smp24 and Smp43 MIC= 32 pg/ml)
Smp24 (pg/ml) Smp43 (|ig/ml)
Strain MIC Strain MIC Strain MIC Strain MIC
AFiu 64 AyjjV 64 A betA 32 A nopC 16
A entC 64 AsodB 16 AbetB 32 AnarG 32
A ybdB 64 AhybA 32 A bet! 32 AnarH 32
AentA 64 AfdnH 32 AbetT 32 AnarJ 32
AentB 64 AfimC 64 Acfa 32 ApepD 32
heir A 32 Aatos 32 AcodA 32 AproB >32
Anrdl 32 AfdnG AdmsA 16 AprpB 32
AnrdE 32 Aintf 32 AfdnG 16 AprpC 32
AentF 32 AybiX 32 AfdnH 16 AprpD 32
AfepA 64 AykgL 32 AflgG 32 AubiH 16
AyncE 32 AycgK 16 AfrsA 32 AyafY 32
AfhuB 32 AccmB 16 AgarK 16 AyagN 32
AnrdF 32 AfldB 32 AgarR 32 AyagV 32
AfhuA 64 AdmsC 32 Agpt 32 AyahJ 32
AtatE 64 AhypC 32 AhypA 16 AyahK 32
Aflil 32 AhypO 32 AintF 32 AyahO 32
AfliH 32 Anfo 32 Alacl 32 AykfB >32
AbioD 32 AynfF 32 AlacY 32 AykfC 32
AsoxS 16 AyqeC 32 AmhpR 32 AykgF 32
AmmuM 32 AykgG 32
AnapB 32
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Table 5.6 Mutant strains with increased resistance to Smp24 and Smp43
Peptide Functional Group Gene Function
Gene
knockout
Putative outer membrane receptor 
for iron transport
flu
Outer membrane receptor for ferric 
enterobactin
fepA
Siderophores transport 
and biosynthesis
Outer membrane 
ferrichrometransport system
fhuA
Isochorismate synthase entC
IMQ.
E
Z,3-Dihydro-Z,3-dihydroxybenzoate
dehydrogenase
entA
in Z,3-dihydro-Z,3-dihydroxybenzoate 
synthase; Asochorismatase
entB
thioesterase required for efficient 
enterobactin production
ybdB (entH)
Protein transporter 
activity
Component of TatABCE protein 
export complex; Protein translocase
tatE
Nuclease activity Putative DNase (nuclease activity) yjjv
Protein binding Periplasmic chaperone fimC
m
Unknown Function Unknown Function ykfB
Q.
£in Magnesium ion binding
Glutamate 5-kinase, proline 
biosynthesis
proB
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Table 5.7 Mutant strains with increased susceptibility to Smp24 and Smp43
Peptide Functional Group Gene Function
Gene
knockout
Oxidative stress
Global transcription regulator for 
superoxide response
soxS
response Superoxide dismutase; response to 
oxidative stress
sodB
PMQ.
£
Formate dehydrogenase-N fdnG
m
Anaerobic respiration
Heme exporter 
subunit;cytochrome c biogenesis 
system
ccmB
Unknown Function Unknown Function ycgK
Oxidative stress 
response
2-octaprenyl-6-methoxyphenol
hydroxylase
ubiH
Dimethyl sulfoxide reductase dmsA
Formate dehydrogenase-N fdnH
m
*3"Q.
Metal ion binding hyp A
E
m Anaerobic respiration
Quinol dehydrogenase, electron 
source for NapAB; Cytochrome c- 
type protein (electron carrier)
napC
Formate dehydrogenase-N fdnG
Glycerate kinase garK
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5.3.6 Real Time PCR
Prior to  perform ing a RT-PCR analysis, the quality o f the extracted RNA was assessed 
using the NanoDrop spectrophotom eter. Only RNA samples w ith  A260/280 and 
A260/230 > 1.9 were used fo r DNA preparation and RT-PCR analysis. RT-PCR analysis 
was perform ed on fou r selected genes identified in the m icroarray analysis. The 
selected genes were d ifferentia lly  expressed fo llow ing E. coli responses to  e ither 
Smp24 or Smp43 as determ ined from  Keio collection screening. Two upregulated 
genes selected fo r RT-PCR were related to  siderophore transport functions; f lu  is an 
outer membrane siderophore receptor fo r iron transport and fepA  is an outer 
membrane receptor fo r siderophores. The tw o down regulated genes chosen fo r 
revalidation are proB, involved in magnesium ion binding in proline biosynthesis, and 
fdnG, which has metal (iron and selenium) binding functions and is involved in electron 
carrier activity in anaerobic respiration. Validation o f the m icroarray data by RT-PCR 
analysis showed tha t the expression o f most o f the assayed genes in cells treated by 
Smp24 were comparable w ith the m icroarray analysis (Figure 5.9 and Figure 5.10).
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Figure 5.9 RT-PCR analysis of the relative mRNA expression levels of selected 
upregulated genes in polymyxin B, Smp24 and Smp43 treated E. coli when 
compared with an untreated control. A: shows relative mRNA the expression of 
fepA among the different treatments, table inset shows the expression pattern of 
the gene by microarray. B: represents the relative expression of fiu among 
different treatments, table inset shows the expression pattern of the gene by 
microarray. Data are expressed as the meaniSE. Statistical analysis was performed 
by the Kruskal-Wallis test. *Significant P <0.05. **Significant P <0.01. 
***Significant P <0.001.
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Figure 5.10 RT-PCR analysis of the relative mRNA expression levels of 
selected down regulated genes in polymyxin B, Smp24 and Smp43 treated 
E. coli when compared with an untreated control. A: shows the relative 
mRNA expression of fdnG among the different treatments, table inset shows 
the expression pattern of the gene by microarray. B: represents the relative 
expression of proB among different treatments, table inset shows the 
expression pattern of the gene by microarray. Data are expressed as the 
mean±SE * P<0.05 vs. untreated control cells. Statistical analysis was 
performed by the Kruskal-Wallis test. *Significant P <0.05. **Significant P 
<0.01. ***Significant P <0.001.
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5.4 Discussion
Prior to  this study there was no data regarding the interaction o f Smp peptides and live 
bacterial membranes in living cells. The mechanism of action o f Smp peptides against 
synthetic prokaryotic membranes models have been investigated before using 
liposome leakage assays, AFM and QCM-D and revealed tha t Smp24 induced pore 
form ation in synthetic membrane models causing lipid segregation (Harrison, Heath et 
al. 2016).
In our study, transcriptom ic responses o f E. coli to  subinhibitory concentrations o f Smp 
peptides was analysed using DNA microarray. DNA microarray has been used to  
provide insights into the mode of action o f AMPs and AMP-resistance mechanisms to  
understand how bacteria respond to  AMPs. Antim icrobials at subinh ib itory 
concentrations may act as stress inducers or signalling molecules tha t induce the 
expression of specific genes tha t help in understanding the mechanism of action of 
many antim icrobial agents (Linares, Gustafsson et al. 2006, Bernier, Surette 2007, 
Fajardo, Martinez 2008, Xu 2016).
Overall, the results o f our m icroarray analysis correlated well w ith  RT-PCR results, 
indicating accurate detection o f the d iffe rentia lly  expressed genes by m icroarray from  
a to ta l o f twelve comparisons (four genes x three treatm ents). RT-PCR analysis showed 
tha t the selected down regulated genes in Smp43 treated cells showed a significant 
change in the ir expression as they exhibited lower expression than untreated cells. 
fepA  was overexpressed in Smp24 and polymyxin B treated cells as exhibited in the 
m icroarray analysis and RT-PCR analysis. Some differences between m icroarray and 
RT-PCR have been observed, however. For example, fepA  was significantly
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overexpressed in Smp43 treated cells compared w ith  control cells when analysed by 
RT-PCR, while the m icroarray analysis fo r this upregulated gene showed no significant 
expression in Smp43 treated cells (p>0.05). This type of variation is o ften seen 
between microarray and RT-PCR data. This disagreement may refer to  the differences 
between the tw o  methodological procedures such as the dyes or prim er sets. Also, the 
variability o f normalisation between both analyses has a great impact on this 
disagreement. Agilent One-Colour Microarray-based Gene Expression Analysis 
undergoes global normalisation which includes transform ing all m icroarray intensity 
values below 1 to  1 and then dividing by the median of all intensity values. This is in 
contrast to  RT-PCR which uses housekeeping genes as a reference point fo r 
normalisation which may contribute to  the lower correlations between m icroarray and 
RT-PCR results (Etienne, Meyer et al. 2004, Morey, Ryan et al. 2006).
The data in our study clearly dem onstrate tha t E. coli exhibits transcriptional 
differences in response to  sublethal concentrations o f Smp24 and Smp43. Most 
identified d ifferentia lly  expressed genes in our study responding to  Smp peptides 
stress were genes tha t have been reported w ith  increased expression during 
siderophore biosynthesis and cation binding and transport. Also, genes im plicated in 
antioxidant responses and anaerobic respiration were prom inent amongst the 
d ifferentiated genes responding to  Smp peptides.
In order to  increase iron uptake, bacteria synthesise siderophores to  chelate ferric  iron 
and make complexes (Vassiliadis, Peduzzi et al. 2007). In the present study, entC, entA, 
entB, entF and entH  were upregulated in response to  Smp24 stress. The ent gene 
cluster encode proteins related to  the biosynthesis o f enterobactin (Fischbach, Lin et
al. 2006, M iethke, Marahiel 2007, Salvail, Lanthier-Bourbonnais et al. 2010).
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Siderophore ferric complexes w ill cross Gram negative bacteria outer membrane 
through specific receptors and are translocated to  the cytoplasm by inner membrane 
transporter proteins to  deliver iron (Vassiliadis, Peduzzi et al. 2007, Stintzi, Barnes et 
al. 2000). The microarray analysis o f E. coli responses to  a sublethal dose o f Smp24 
revealed tha t four genes encoding these types o f receptors (fiu, fepA, cirA and fhuA) 
were found to  be significantly overexpressed compared w ith  untreated cells. Also, the 
siderophore transporter fepC  was upregulated.
Siderophore biosynthesis is regulated by the ferric uptake regulator (Fur) system, as 
Fur cluster genes repress the siderophore biosynthesis according to  the availability o f 
Iron (Crosa, Walsh 2002, Dale, Doherty-Kirby et al. 2004). Also Fur has roles in cellular 
oxidative stress defence such as activation o f superoxide dismutase sodB which is 
involved in oxidative stress response (Zhang, Ding et al. 2012, da Silva Neto, Braz et al. 
2009). Fur is regulated by the oxidative stress response regulon soxS (Pomposiello, 
Bennik et al. 2001). The microarray data revealed both soxS and sodB were 
significantly down regulated in response to  Smp24 treatm ent. The down regulation o f 
these oxidative stress response genes leads directly to  lower resistance to  oxidative 
stress. Additional evidence comes from  the susceptibility testing o f Keio m utants which 
support these findings by showing tha t the deletion o f genes sodB or soxS resulted in 
increased cellular sensitivity to  Smp24 compared w ith  the w ild type strain. The 
deletion o f oxidative response gene ubiH  generated higher susceptibility than seen in 
the parent stain. Accordingly, Smp peptides may induce oxidative stress causing cell 
death.
These results are in good agreement w ith  o ther recent studies which have shown the
production and upregulation o f siderophores in response to  oxidative stress (Chen,
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Yang et al. 2014, Ruiz, Bernar et al. 2015). Particularly, enterobactin plays an im portant 
role in the reduction o f the oxidative stress in E. coli. Enterobactin is hydrolysed to  
release iron which is essential fo r the activities o f antioxidants and the hydrolysed 
enterobactin can scavenge radicals d irectly (Eisendle, Schrettl et al. 2006, Chung 2012, 
Adler, Corbalan et al. 2014, Achard, Chen et al. 2013). However, both iron deficiency 
and excess free iron can induce oxidative stress (Fernaeus, Land 2005, Galaris, 
Pantopoulos 2008). Siderophores can act as a source o f hydrogen atoms and effic iently 
term inate radical chain reactions (Povie, Guillaume, et a l.2010). Our findings suggest 
tha t an imbalance in iron homeostasis and oxidative stress m ight be involved in E. coli 
response to  Smp peptide treatm ent. These suggestions are consistent w ith  o ther 
antim icrobial peptides in the lite ra ture which induce oxidative stress, such as microcin 
J25 which increase the production o f reactive oxygen species and is recognised by the 
siderophore outer membrane receptor FhuA (Destoumieux-Garzon, Duquesne et al. 
2005, Mathavan, Zirah et al. 2014). Interestingly, the m icroarray analysis o f the 
transcriptom ic response o f E. coli exposed to  Smp24 revealed the significant 
upregulation of fhuA. Polymyxin B can also produce reactive oxygen species (ROS) 
when it enters Gram negative bacterial membranes. The induced ROS by polymyxin B 
such as H2O2 affects iron homeostasis by oxidising Fe2+ to  Fe3+ through the Fenton 
reaction (Sampson, Liu et al. 2012, Yu, Qin et al. 2015).
A recent study (Dong et al., 2015) has reported tha t the trea tm en t o f E. coli w ith  
polymyxin B induce a 35-fold increase in soxS expression level compared w ith  the 
untreated strain (Dong, Dong et al. 2015). Similarly, our m icroarray data analysis 
revealed tha t soxS is down regulated when E. coli was stressed by subinh ib itory 
concentrations o f polymyxin B. Furthermore, polymyxin B induced the upregulation o f
164
genes tha t encode siderophore receptors (fepA, fhuA, and cirA), siderophores 
biosynthesis (entF, entB, and entE) and iron transporters proteins [feoB, feoA  and 
feoC ) , similar to  the E. coli response to  Smp24.These finding agree w ith  o ther studies 
which have shown tha t mutants o f some siderophore biosynthesis and receptor genes 
such as fiu , fepA, fhuE cirA, fhuA, entA, entB, entC, entD, entE, feoA, feoC  and feoB  
have a higher resistance to  polymyxin B than w ild type strains (Barrios 2013, Guo, Nair 
et al. 2 0 1 1 ).
Production of ROS leads to  inactivation o f Fe -S  clusters which are involved in many 
cellular functions such as respiration (Ayala-Castro, Saini et al. 2008). 4Fe-4S Fes 
protein is required fo r iron release from  the ferric siderophore complex, there fore  Fe-S 
inactivation leads to  a loss iron which results in ROS detoxication deficiencies (Li, Wang 
et al. 2016). Our Functional Annotation Clustering (FAC) analysis results showed tha t 
the Fe-S cluster was significantly down regulated in response to  both Smp peptides 
treatm ents. These findings also support the theory tha t the mechanism o f action o f 
Smp peptides may involve oxidative stress. In addition, the susceptibility assay o f the 
Keio collection against Smp peptides revealed tha t knockout m utants o f genes related 
to  oxidative stress response showed a marginally higher level o f sensitivity to  e ither 
Smp24 or Smp43 compared w ith  the parent strain.
The oxidative stress tha t causes inactivation o f Fe-S clusters which are im portan t
components o f many proteins involved in anaerobic respirations such as DmsA, FdnH,
FdnG and NapC (Jormakka, Tornroth et al. 2002, Tang, Rothery et al. 2011).These facts
are amongst likely explanations o f the highly significant down regulation o f anaerobic
related genes follow ing exposure to  sublethal doses of both Smp peptides. Also, the
screening o f some m utant strains from  the Keio collection such as dmsA, fdnH, fdnG
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and nope) against Smp peptides revealed tha t deletions o f genes related to  anaerobic 
respiration results in slightly decreased MIC fo r e ither Smp24 or Smp43 compared w ith  
the parent strain.
Gene clusters mainly related to  the electron transport chain and cellular respiration 
were found to  be highly significantly enriched as revealed by FAC analysis o f down 
regulated genes in response to  Smp24, Smp43 and polymyxin B treatm ents. 
Disruptions in the electron transport chain which have been reported before fo r 
polymyxin trea tm ent in £. coli enhance oxidative stress by producing ROS (Sampson, 
Liu et al. 2012). In addition, polymyxin B has the ability to  inh ib it some respiratory 
enzymes such as alternative NADH dehydrogenase, quinone oxidoreductase and type II 
NADH-quinone oxidoreductases (NDH-2) (Deris, Akter et al. 2014). Consistently, o ther 
reports have found increases in the transcriptional levels o f sim ilar genes involved in 
envelope and oxidative stress responses fo r polymyxin treated bacteria (Sikora, 
Beyhan et al. 2009a, Ramos, Custodio et al. 2016).
The role o f siderophores in enhancing the antibacterial activity o f some antib iotics has 
been recently investigated. Some antibiotics such as albomycin and salmycin are linked 
naturally to  siderophores to  facilita te  the ir delivery to  the cell through iron uptake 
pathways, known as the T ro jan Horse' strategy. These s iderophore-an tib io tic  
conjugates are called sideromycin which consists o f a siderophore, a peptide linker, 
and an antib iotic (Braun, Pramanik et al. 2009, Wencewicz, Long et al. 2013, Ferguson, 
Coulton et al. 2000).
Siderophore uptake pathway is one of the most exploitable biological pathways in 
bacteria to  help antibiotics reach the ir cytoplasmic target. This strategy has been
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applied to  increase susceptibility to  antib iotics by avoiding or lim iting the exposure of 
antibiotics to  resistance mechanisms providing an opportun ity  to  recycle old 
antibiotics rendered useless by resistance (Wencewicz, Long et al. 2013). The 
antibacterial activity o f [3-lactam antibiotics such as ampicillin and amoxicillin has been 
investigated when bound to  siderophores, the conjugates exhibited high antibacterial 
activity compared w ith  parent drugs (Ghosh, Ghosh et al. 1996, Kinzel, Tappe et al. 
1998, Ji, M ille r et al. 2012) (Ji, Cheng, 2012).
The potential uptake of Smp peptides by siderophores receptors has been supported 
by assaying the susceptibility o f Smp24 against single-gene knockout m utants o f E. coli 
(Keio collection). Knockout mutants o f genes from  the Ent gene cluster (AentB , AentH, 
AentC and AentA) and iron-regulated outer membrane receptors (AfepA , Afiu, and 
AfhuA) showed a marginally higher level o f resistance to  Smp24 compared w ith  the 
parent strain. Also, the antibacterial activity o f the modified form  o f m icrocin E492, a 
pore-form ing antim icrobial peptide, is mediated by enterobactin oute r membrane 
receptors such as FepA, Cir and Fiu. MccE492m is an 84 amino acid long firs t peptide 
isolated from  Klebsiella pneumonaie. It was post-translationally m odified by binding 
the C-terminal serine residue to  a siderophore molecule via an ester linkage to  form  
conjugates w ith enterobactin w ith  a broader spectrum o f antibacterial activity 
(Thomas, Destoumieux-Garzon et al. 2004, Destoumieux-Garzon, Peduzzi et al. 2006, 
Nolan, Fischbach et al. 2007, Raines, Moroz et al. 2016). Microcins are rich in serine 
and glycine residues w ith a conserved serine-rich C- term inus (Vassiliadis, 
Destoumieux-Garzon e ta l. 2010). Both Smp24 and Smp43 have serine residues in the ir 
C-terminal tail, and are rich in serine and glycine amino acids tha t may enhance its 
binding to  siderophores to  form  Smp24 -  siderophore conjugates, tha t fac ilita te  the ir
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delivery inside the bacterial cell leading to  cell death. Similarly, sideromycins such as 
albomycin binds to  siderophores through a serine residue (Zeng, Roy et al. 2009, Zeng, 
Kulkarni et al. 2012). Moreover, most siderphores have a backbone based on serine 
and glycine residues (Zheng, Bullock et al. 2012). Siderophore receptors are amongst 
bacterial membrane targets tha t have been suggested to  recognise AMPs (Thomas, 
Destoumieux-Garzon et al. 2004).
Despite the ir roles in iron transport, siderophores may act as a metallophores fo r a 
variety o f o ther metals and play a crucial role in the protection o f bacteria from  
oxidative stress. Some sideophores have the ability to  scavenge radicals through 
prevention o f the Fenton reaction by chelating iron (Johnstone, Nolan 2015, Peralta, 
Adler et al. 2016). AMPs prom ote the generation o f ROS and induce plasma membrane 
disruption which may contribute to  cell death (Oyinloye, Adenowo et al. 2015).
Some AMPs exert the ir effects through alternative modes o f action and may in fact act 
upon m ultip le targets, however, the activities o f AMPs are mainly dependent upon 
direct interaction w ith  the bacterial cell membrane (Jenssen, Hamill et al. 2006).
In conclusion, the microarray analysis o f Smp treated E. coli revealed some similar 
gene induction patterns w ith  polymyxin b but also some distinctly d iffe ren t ones. The 
upregulation o f siderophore biosynthesis, cation transport and oxidative stress 
response genes may increase sensitivity o f E. coli to  both Smp peptides, dem onstrated 
by deletion o f these upregulated genes, point to  the role o f oxidative stress in the 
inh ib itory effect o f Smp peptides against E. coli. This should be verified biochemically 
in fu tu re  studies.
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6 Influence of cations on antimicrobial activity of Smp24
against Escherichia coli.
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6.1 Introduction
Electrostatic binding is key to  AMP interaction w ith  the negatively charged molecules 
of bacterial cell membrane. Such interactions between AMPs and the phospholipid 
headgroups and other negatively charged molecules at numerous sites covering the 
surface of bacteria are the in itia l driving force fo r AMPs mode of action (Berglund, 
Piggot et al. 2015). A result o f the electrostatic interaction is positively charged AMPs 
destabilise bacterial membranes by interacting w ith  negatively charged structures, 
which displace or release divalent cations from  the bacterial membrane leading to  its 
d isruption (Hyldgaard, Mygind et al. 2014, Mojsoska, Jenssen 2015).
Cations are essential components o f the bacterial cell membrane, they are also 
necessary fo r a range of metabolic processes. Divalent ions such as M g2+ and Ca2+ 
electrostatically cross-link and stabilise the LPS and teichoic acids which are major 
anionic components o f Gram negative and Gram positive bacterial cell membranes 
(Baddiley, Hancock et al. 1973, Thomas III, Rice 2014, Arunmanee, Pathania et al. 
2016). These negatively charged molecules represent the firs t targets o f cationic 
AMPs leading to  the ir antibacterial effects (Sun, Shang 2015, Malanovic, Lohner 
2016). However, the attachm ent o f cations to  LPS and teichoic acids increases the 
rig id ity o f bacterial membranes and decreases or neutralises the ir negative charges 
reducing the ir a ffin ity  fo r the cationic AMPs (Hughes, Hancock et al. 1973, Sahalan, 
Aziz et al. 2013). Therefore, removal o f these ions or the ir displacement by cationic 
AMPs from  the ir relative binding sites facilitates the binding o f the peptide leading to  
perm eability o f the outer membrane, potentia lly leading to  cytoplasmic access to  the
170
AMP which is defined as the self-prom oted uptake model (Giuliani, Pirri et al. 2007, 
Laverty, Gorman et al. 2011).
A num ber o f studies have shown tha t polymyxin B is taken up by the self-prom oted 
uptake route by displacing divalent cations from  the ir binding sites in the LPS 
molecules in order to  release the LPS com ponent from  the bacterial surface leading 
to  membrane disruption and subsequent cell death (Sahalan, Aziz et al. 2013). The 
role o f divalent cations in the antibacterial action o f polymyxin B has been w idely 
studied against a wide range o f Gram negative bacteria. For instance, it was found 
tha t Ca2+ and Mg2+ at 20 mM protect the outer membrane of some Pseudomonas 
strains from  the inh ib itory damage caused by polymyxin B at 25m g/m l (Chen, 
Feingold 1972). Furthermore, polymyxin B-induced leakage o f the oute r and inner 
membrane enzymes ((3-lactamase and (3-galactosidase) from  E. coli was significantly 
reduced (2 to  3 folds) in the presence of Mg2+ and Ca2+ (Sahalan, Aziz et al. 2013).
Increasing the concentration o f divalent cations reduced or inhibited the activ ity o f 
several cationic peptides against Gram negative bacteria such as Human (3 defensin 2 
(Tomita, Hitom i et al. 2000), ostricacins ((3-defensins AMPs) (Sugiarto, Yu 2007) and 
thanatin (insect defence peptide) (Wu, Ding et al. 2008). It is thought tha t basic 
residues o f the peptides are likely to  compete w ith  the cations fo r the same binding 
sites in the lipid head group region (Kandasamy, Larson 2006). The effect o f cations 
on MICs against E. coli was studied by determ ining MICs at increased concentrations 
of monovalent and divalent cations. Treatm ent w ith  divalent cations (M g2+ and Ca2+) 
at lOm M  inhibited the bactericidal activities o f three cathelicidin peptides 
significantly against E. coli. All three o f the test peptides had MICs tha t were higher
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in presence o f m onovalent cations (Na+ and K+) than in the absence o f these cations. 
These findings indicate tha t these peptides appear to  be ineffective at high salt 
concentrations, tha t may lim it the binding a ffin ity  o f LPS to  these cationic peptides 
which negatively affected the ir bactericidal activities (Anderson, Yu 2005). 
Bacteriocin peptide enterocin (Kumar, Srivastava 2011) and F12W-magainin 2 
(Matsuzaki, Sugishita et al. 1999) induced no membrane permeabilisation in LPS- 
containing liposomes in presence o f some cations such as Mg2+ and Ca2+ when 
evaluated using the calcein leakage assay as the rig id ity o f the membrane was 
increased which is probably due to  cross-linking o f adjacent LPS molecules w ith  
these cations.
The sensitivity o f some AMPs to  high salt concentrations may lim it the ir application 
as pharmaceutical agents due to  salt induced -inactivation in vivo (Yu, Tu et al. 2011). 
Several strategies were developed to  increase the salt tolerance of AMPs such as the 
incorporation o f arginine residues at the C-terminal end o f synthetic defensins which 
overcame the salt-resistance effect by increasing peptide cationic net charge which 
improved electrostatic interaction between the peptide and the anionic bacterial 
membranes (Li, Saravanan et al. 2013). Further several short amphipathic helical 
peptides w ith potent antim icrobial activities and sa lt-to lerant properties have been 
designed more recently (Mohamed, Hammac et al. 2014, Mohanram, Bhattacharjya 
2016).
Divalent metal cations increase the activity o f anionic AMPs such as kappacin (an 
AMP derived from  bovine milk) (Dashper, O'Brien-Simpson et al. 2005) and DCD-1L 
(an AMP derived from  Human Sweat) (Paulmann, Arnold et al. 2012). Interestingly,
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daptomycin has potent antibacterial activity against Gram positive bacteria rather 
than the Gram negative bacteria as the outer membrane o f Gram negative bacteria 
act as a barrier to  daptomycin. The Gram positive cytoplasmic membrane has a 
higher an anionic phospholipid content than tha t found in Gram negative 
membranes (Streit, Jones et al. 2004, Randall, M ariner et al. 2013). The insertion o f 
daptomycin in to the cytoplasmic membrane o f Gram positive bacteria is mediated 
by calcium ions causing depolarisation and leakage o f some ions to  induce cell death 
(Steenbergen, Alder et al. 2005, Straus, Hancock 2006, Mascio, A lder et al. 
2007).NMR analysis o f daptomycin in the presence o f a 1:1 molar ratio o f Ca+2 
suggested tha t calcium binds T rp l and Kynl3 residues on daptomycin in order to  
enhance its oligomerization and am phipathicity leading to  insertion into the 
membrane and the form ation o f a m icellar structure (Ho, Jung et al. 2008). These 
findings were confirmed by CD spectra as the peptide showed significant 
conform ational change in the presence o f 5 mM CaCh and PC/PG liposomes, 
indicating tha t the binding o f daptomycin to  the negatively charged model 
membrane is Ca2+ dependent (Jung, Rozek et al. 2004).
X-ray photoelectron spectroscopy (XPS) is a surface sensitive analysis technique tha t 
characterises and quantifies the elemental composition o f surfaces o f solid 
materials. XPS has been used in the last decade to  provide insights about the 
variation of bacterial surface elemental composition at various conditions such as 
over a range of pH values (Leone, Loring et al. 2006) and follow ing Zn 2+ exposure 
(Ramstedt, Leone et al. 2014). XPS has been used to  characterise the chemical 
changes w ith in  ~10 nm o f the surface in d iffe ren t E. co li LPS mutants w ith  a range
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of surface compositions. The analysis is able to  detect proteins/peptidoglycan, lipids, 
and polysaccharides which reveal the changes o f LPS content between d iffe ren t 
mutants tha t may help in explaining changes in surface hydrophobicity which play a 
crucial role in protecting bacteria against antim icrobial agents (Ramstedt, Nakao et 
al. 2011). These studies provided im portant surface compositional biochemical 
in form ation tha t can help in exploring molecular level processes at the bacterial 
surfaces in response to  external stim uli which may affect metabolic activity o f the 
cells leading to  change of the composition of cell surface molecules. However, the 
bacterial surface characterisation o f elemental composition fo llow ing the exposure 
to  AMPs has been not examined using XPS before.
The objective o f this chapter is to  gather inform ation about increasing 
concentrations o f cations tha t may enhance or decrease the activity o f Smp24 which 
may explain the upregulation of cation binding genes in response to  Smp24 
treatm ent as revealed by m icroarray analysis. In addition, the influence o f Smp24 on 
the elemental composition o f E. coli surface was analysed using XPS in order to  get 
chemical inform ation on the outerm ost portion o f bacterial cells when treated by 
Smp24 to  provide o ther insights to  help elucidate the mechanism o f action of 
Smp24.
6.2 M ethod Summary
The effect o f salt concentration on the antim icrobial activity o f Smp24 was tested by 
determ ining the MICs against E. coli at various cation concentrations. The surface 
composition o f E. coli has m onitored using XPS a fte r 10 m inutes o f incubation w ith  
Smp24 at 0 and 12 pg/m l.
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6.3 Results
6.3.1 The antimicrobial activity of Smp24 against E. coli at different
concentrations of cations.
The bactericidal activity of Smp24 against E. coli was compared under various
concentrations of ions by determining the MIC in a variety of chloride salts. One
monovalent cation, Na+at concentrations of 0 to 24 mM and four divalent cations
Ca2+, Mg2+, Fe2+ and Mn2+which were added at 0 to 3 mM. This concentration range
indicates excess concentrations of cations and doesn't represent their physiological
concentrations. The MIC of Smp24 increased with increasing the ionic strength of
Ca2+ and Mg2+. Smp24 had an eight-fold increase in MIC at 3 mM of CaCb and MgC-fe
(p-values were less than 0.05) (Table 6.1). However, the activity of Smp24 was stable
at the highest concentration used of NaCI. Also, no significant differences in the MIC
of Smp24 were obtained when determined in the presence of divalent cations Fe2+
and Mn2+. An increase in Fe2+ and M n2+concentrations was shown to have no effect
on the growth rate or viability of E. coli.
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Table 6.1 The effect of increased cation concentration on the minimum inhibitory 
concentration (MIC) of Smp24 against E. coli.
Cations
Concentrations
(mM)
MIC (|ig/m l)
No additional ions 0 32
3 32
Na+ 6 32
12 32
24 32
0.375 32
Ca2+ 0.75 64
1.5 128
3 256
0.375 64
Mg2+ 0.75 64
1.5 128
3 256
0.375 32
Fe2+ 0.75 32
1.5 32
3 32
0.375 32
M n2+ 0.75 32
1.5 32
3 32
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6.3.2 XPS Analysis of Smp24- treated E. coli.
The ion content of Smp24- treated E. coli surface was characterised by XPS to 
determine the effect of the treatment on the chemical structure of the bacterial 
membrane. Survey scans were successfully collected from bacterial cells at a 
reduced temperature. However, these scans did not show a significant change to 
surface ion content as a result of treatment with the peptide in either washed 
and unwashed samples when compared with a peptide-free control (Figures 6.1 
and 6.2). Rich oxygen content was detected in both samples. There was little 
variation in the C: N ratio between treated and untreated cells. Both Na+ and Cl" 
ions were largely removed by washing with water (Table 6.2 and Table 6.3).
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Table 6.2 Surface composition of unwashed samples determined by quantifying survey 
scans (atomic%).
Name
Na1s
01s
Ti2p
N1s
C1s
Mo3d
CI2p
S2p
P2p
Si2p
Pos.
1070.00
531.00
442.00
400.00
285.00
212.00
198.00
163.00
FWHM Area 
3.47 10188.83
3.90 27117.28
2.84 1947.04
3.77 7433.88
4.44 29175.71
2.37 16363.60
3.72 5071.57
3.92 198.27
At%
4.68
20.93
0.54
8.60
56.74
3.25
4.13
0.22
Name Pos. FWHM Area At%
Nals 1068.00 3.84 7426.40 4.00
01s 531.00 4.06 24444.29 22.08
N1s 400.00 3.78 6872.23 9.31
C1s 285.00 4.19 26131.88 59.47
CI2p 199.00 4.85 4177.01 3.98
S2p 164.00 3.59 124.71 0.16
P2p 133.00 3.76 411.53 0.73
Si2p 102.00 3.04 113.54 0.29
-------------------- 1-------------------------1------------------------ 1-------------------------1-------------------------1------------------------ ]-------------------------1-------------------------1-------------------------1-------------------------t-------------------------r
900 600 300
Binding E n erg y  (eV )
Figure 6.2 XPS survey scan from Smp24-treated E. coli after 10 minutes of incubation.
w ide
900 600 300
B inding E nergy (eV )
Figure 6.1 XPS survey scan from untreated E.coli.
Sample Na F 0 Ti N C Mo Cl S P Si
Control 4 <0.1 22.1 <0.1 9.3 59.5 <0.1 4 0.2 0.7 0.3
Treated 4.7 <0.1 20.9 0.5 8.6 56.7 3.3 4.1 0.2 0.3 0.6
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wide
Name Pos. FWHM Area 
01s 530.00 5.45 28111.'
At%
N1s 
C1s
Mo3d 204.00 2.26 15508.20 
P2p 134.00 4.71 717.98
399.00 4.82 7938.00
285.00 5.37 34428.15 65.20 
3.00 
1.05
>.95
Z 25_
10:
900 600
Bindina E n era W e V I
300 0
Figure 6.3 XPS survey scan from washed untreated E.coli
wide
Name Pos. FWHM Area
01s 531.00 5.81 28468.82 22.1'
At%
N1s 400.00 4.21 5262.80 6.15
C1s 285.00 5.79 34115.82 66.93
Mo 3d 211.00 2.91 14623.16 2.93
P2p 134.00 5.87 835.63 1.27
10:
900 600 300 0
Bindina E n era v (eV )
Figure 6.4 XPS survey scan from washed Smp24-treated E. coli after 2 hours of incubation.
Table 6.3 Surface composition of washed samples determined by quantifying survey scans 
(atomic%).
Sample Na F 0 Ti N C Mo Cl S p Si
Control/ washed <0.1 <0.1 21.1 0.7 9.0 65.2 3.0 <0.1 <0.1 1.1 <0.1
Treated/ washed <0.1 <0.1 22.2 0.6 6.2 66.9 2.9 <0.1 <0.1 1.3 <0.1
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6.4 Discussion
The functional classification o f the upregulated genes o f E. coli in response to  Smp24 
trea tm ent revealed tha t the most abundant group o f genes was predom inantly 
related to  cation binding and transport. These findings indicated tha t cations may 
play a role in the mechanism o f action o f Smp24 against E. coli.
The current study showed tha t the monovalent cation sodium ions Na+ had no effect 
on the inh ib itory activity o f Smp24, while the activity o f the peptide was significantly 
decreased in the presence o f the divalent cations, Ca2+ and Mg2+ as the MIC of 
Smp24 was higher than in the absence o f theses cations. Similar results o f the effect 
o f these cations on AMPs have been reported by other investigators. The 
antibacterial activity o f short cationic peptide; Human Beta Defensin 2 (HBD-2) was 
reduced by the Ca2+ and Mg2+ ions. Whereas at higher concentration o f Na+, HBD-2 
still retained its antim icrobial activity (Tomita, Hitomi et al. 2000).
A sim ilar trend has also been reported w ith  three cathelicidin peptides (SMAP29, 
OaBac5mini and OaBac7.5mini) as Ca2+ and Mg2+ ions had a larger effect on the ir 
antibacterial activities than the monovalent cations. Particularly, SMAP29 was 
completely inactive against E. coli in presence o f Ca2+ and Mg2+ ions at lO m M  
(Anderson, Yu 2005). Moreover, lactoferricin B is salt sensitive, they decrease or 
inh ib it its antibacterial activity in presence of excess o f Na+, K+, M g2+ or Ca2+ 
ions(Bellamy, Takase et al. 1992).
The antagonistic effect o f Ca2+ and Mg2+on Smp24 and other cationic AMPs against 
E. coli may occur through competing interactions w ith  these antim icrobial agents.
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The cationicity o f AMPs is essential to  enhance the electrostatic binding to  the 
bacterial membrane, by com petitive displacement o f cations tha t are norm ally cross- 
linked to  the LPS in Gram negative bacteria leading to  membrane disruption (Grubor, 
Meyerholz et al. 2006, Ebenhan, Gheysens et al. 2014).
Polymyxin is an example o f a cationic AMP which disrupts the bacterial membrane 
through displacing divalent cations from  the LPS leading to  disorganisation o f the 
membrane (Sahalan, Aziz et al. 2013). Such displacement mechanisms have been 
proposed fo r cationic AMP such as bactenecin, it showed distinct ability to  displace 
dansyl-polymyxin tha t were bound to  LPS in the dansyl-polymyxin B displacement 
assay(Wu, Hancock 1999). However, bivalent ions compete w ith these cationic 
molecules fo r anionic binding sites on the cell surface (Tille 2013).
A similar mechanism was also identified fo r aminoglycoside antibiotics (Yeaman, 
Yount 2003). The bactericidal activity o f gentamicin, streptomycin and related 
aminoglycoside antibiotics vary significantly in the presence and in the absence o f 
divalent cations (Pimenta de Morais, Corrado et al. 1978, KUSSER, ZIMMER et al. 
1985). The binding o f labelled gentamicin to  Pseudomonas aeruginosa increases in 
absence of calcium and magnesium ions (Ramirez-Ronda, Holmes et al. 1975).
It has been reported tha t replacement o f arginine residues w ith lysine residues in
human a-defensin - 1  led to  a decrease of its antim icrobial activity and a higher
sensitivity to  increasing salt concentrations suggesting tha t lysine is more sensitive to
salt than arginine (Zou, de Leeuw et al. 2007, Li, Vorobyov et al. 2013). Many m arine-
derived AMPs are to lerant o f high salt concentrations. Thus may be because the ir
positive charge is based mainly on arginine rather than lysine (Falanga, Lombardi et
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al. 2016). However, the cationicity o f Smp24 is based mainly on lysine residues which 
may explain the salt sensitivity.
Similar concentrations o f o ther d ivalent cations, Fe2+ and M n2+, had no effect on the 
antim icrobial activity o f Smp24 against E. coli. In Gram negative bacteria, metals can 
diffuse across the oute r membrane and are transported into the cytosol by ABC 
transporters (Zhen, Jacobsen et al. 2009). The a ffin ity  to  these transporters fo r Fe2+ 
and M n2 exceeds tha t fo r Mg2+ and Ca2+. The tendency preference follows the 
universal order o f the Irving-W illiam s series (M g2+<Ca2+ < M n2+ < Fe2+) (W aldron, 
Robinson 2009). In addition, specialised chelators such as siderophores are also bind 
inorganic elements (notably iron) to  diffuse across the outer membrane. The iron 
tha t is transported in to cells by siderophores can act as a signalling agent plays an 
im portant regulatory role in iron homoeostasis (Muckenthaler, Galy et al. 2008).
In conclusion, calcium and magnesium reduce the activity o f Smp24 against E. coli 
which might be a challenge fo r the application o f Smp24 in vivo. Therefore, fu rthe r 
modifications are needed fo r Smp24 to  be salt-resistant peptide in order to  develop 
it as novel antim icrobial therapeutic.
The XPS analysis o f bacterial samples indicates tha t this technique is capable o f
probing the cell surface and collecting data regarding the ir ion content. However,
Smp24-treated samples exhibited quite sim ilar XPS spectra to  those o f untreated
cells, no considerable difference were obtained from  both survey scans. These
results may be a ttribu ted  to  the depth o f the XPS analysis as it was less than 10 nm,
where LPS can extend up to  40 nm from  the oute r membrane o f Gram negative cells
(Beveridge 1999). Therefore, the analysis was not able to  reach deeper to  the cell
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membrane. It is more challengeable in case of the Gram positive bacteria surface as 
it has a thick peptidoglycan layer (30-100 nm) containing teichoic acids, lipoteichoic 
acids, and proteins (Ramstedt, Leone etol. 2014).
Similar challenges of the analysis depth were obtained during the XPS analysis of E. 
coli LPS mutants with a varied composition of LPS (Ramstedt, Nakao et al. 2011) as 
the analysis was affected by the presence and size of surface structures and the 
outer membrane composition. In addition, our analysis revealed that both XPS 
spectra of control and treated bacterial surfaces were too rich in oxygen that may 
because the experiment was carried out between -70°C to -39°C, therefore any 
excess water present will also contribute to the oxygen content. High-resolution 
spectra (C Is  and O Is) would have given more information on alterations to 
functional groups on the bacterial surfaces components such as polysaccharides, 
peptides, and lipids (Dufrene, van derW al e ta /. 1997).
In addition, Smp24 may have no effect on the elemental composition of E. coli. 
Higher concentrations of Smp24 or extended incubation periods may affect the 
balance of ions of the surface of treated cells to be detected by XPS.
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7 Current perspective and hypothesised mechanism of action
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The progressive development o f resistance to  classical antim icrobial agents causes an 
increasing challenge to  public health. It has led to  an urgent need fo r novel 
antim icrobial agents w ith  novel mechanisms o f action. AMPs play an essential role in 
the innate immune system of the host as a firs t line defence in most living organisms 
against invaders. They are considered to  be useful templates fo r the design o f novel 
antibiotics (Li, Xiang et al. 2012, Seo, Won et al. 2012).
Snake and scorpion venoms are diverse sources o f biologically active components and 
various candidate therapeutics have been characterised including AMPs (Harrison, 
Abdel-Rahman et al. 2014). However, the m ajority o f venoms have not been fu lly  
exploited as antim icrobial molecules. Therefore, there has been considerable in terest 
in potentia l novel AMPs from  Egyptian snake and scorpion venoms as unexplored 
sources fo r such candidates.
Scorpion venom is composed mainly o f small peptides. A variety o f AMPs have been
identified from  scorpion venoms using proteom ic and genomic techniques. Smp24 and
Smp43, tw o  novel AMPs, have been identified from  a cDNA library from  the venom
gland of the Egyptian scorpion Scorpio maurus palmatus (Abdel-Rahman, Q uintero-
Hernandez et al. 2013). Both peptides have potent antim icrobial activities against a
wide range of Gram positive and Gram negative bacteria and fungi. Smp43 exhibits
negligible haemolytic properties, in comparison Smp24 caused significant erythrocyte
disruption in a concentration dependent manner. Both peptides induced kidney cell
line death in a concentration-dependent manner. However, keratinocytes were not
affected by Smp43 at 4x MIC and low cytotoxic activities were detected fo r both
peptides against both cell lines at concentrations higher than the MIC fo r Gram
positive strains. Proteins (> 10 KDa) are the major constituents o f snake venom and
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include enzymes, which are the main compounds exhibiting antim icrobial activity. Few 
interm ediate sized (3-7 KDa) non-enzymatic proteins w ith  antim icrobial activity have 
been reported from  snake venoms (Wang, Hong et al. 2008, Yamane, Bizerra et al. 
2013, Jin, Bai et al. 2016). In the current study fou r 3FTxs-like proteins have been 
isolated and partially characterised from  three Egyptian elapid venoms Naja haje, 
Walterinnesia aegyptia  and Naja nubiae. 3FTxs have been proposed to  destabilize the 
bilayer o f anionic phospholipid-containing model membranes which is sim ilar to  the 
action o f most cationic AMPs against bacterial m imic membranes (Dubovskii, Lesovoy 
et al. 2003, Dubovskii, Utkin 2014). The purified proteins exhibited inh ib ito ry activity 
mainly against Bacillus subtilis in comparison w ith  o ther bacteria. B. subtilis has an 
unusually enriched outer leaflet membrane in the anionic phospholipid PG (Clejan, 
Krulwich et al. 1986, M arquardt, Geier et al. 2015). Interestingly, B. subtilis is one of 
the most commonly isolated bacteria from  the oral cavity o f snakes which may point 
us in the direction o f co-evolution o f snakes and this soil bacterium (Fonseca, M oreira 
et al. 2009).
Improvem ent o f the disadvantages tha t impede the developm ent o f AMPs as 
therapeutic agents is crucial fo r clinical application o f AMPs (Hancock, Sahl 2006). Such 
lim itations include low therapeutic index, high cost o f production, salt resistance, 
gastrointestinal enzymatic degradation , short half-lives and rapid elim ination and a 
broad spectrum of activity which may disrupt the indigenous m icroflora tha t protect 
the host against pathogenic organisms (Bommarius, Jenssen et al. 2010, Aoki, Ueda 
2013, Mohanram, Bhattacharjya 2016)
High therapeutic indices o f AMPs are required to  avoid cytotoxic effects on host cells. 
Cationicity is undoubtedly crucial fo r the initia l electrostatic binding o f AMPs to
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negatively charged membranes of bacteria (Yeaman, Yount 2003, Aoki, Ueda 2013). 
However, the electrostatic binding of AMPs is less im portant fo r mammalian 
membranes due to  the ir zw itte rionic nature. Although truncation o f the last fou r C- 
term inal residues o f Smp24 resulted in a reduction in net positive charge, it increased 
the therapeutic index as it displayed less haemolytic effect than tha t o f the unm odified 
peptide (Harrison, Heath et al. 2016). Similar modifications increase the potency and 
specificity o f some scorpion AMPs fo r bacterial cells and thus improves the ir 
therapeutic indices (Rodriguez, Villegas et al. 2014, Luna-Ramirez, Tonk et al. 2017).
The understanding of the fundam ental mechanism o f AMP action is critical to  the 
development o f AMP-based antibiotics (Nguyen, Haney et al. 2011, Yang, Wang et al. 
2013). Synthetic bilayer model membranes created to  mimic the properties o f living 
cells membranes help researchers to  investigate AMP-membrane interactions based 
on the structure and hydrophilic ity/hydrophobic ity o f AMPs and the composition o f 
lipid model membranes. Such biophysical interactions provide insights about AMP 
transport, d istribution and efficacy improving our understanding o f AMP mechanisms 
of action (Peetla, Stine et al. 2009). However, not surprisingly, model membrane 
systems do not fu lly  explain the interaction w ith  m icrobial membranes or the response 
o f microbes to  the presence o f AMPs (Omardien, Brul et al. 2016). Previously, Smp 
peptides were found to  cause pore form ation in synthetic prototypical prokaryotic and 
eukaryotic membranes (Harrison, Heath et al. 2016). However, the mechanism of 
action of AMPs against the living cell membrane may include more complicated 
mechanistic interactions compared w ith  simple artific ial systems (Gee, Burton et al. 
2013).
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Microscopic imaging includes useful techniques tha t may be used to  explore the 
antim icrobial action o f AMPs against living cell membranes (Torrent, Sanchez-Chardi et 
al. 2010). Of interest are SEM and TEM which provide an overall picture o f damage of 
the bacterial cell envelope upon AMP exposure (Hartmann, Berditsch et al. 2010). EM 
micrographs o f E. coli and 5. aureus treated w ith  Smp24 and Smp43 revealed changes 
in cell morphology. Similar EM data have been reported fo r several AMPs against E. 
coli and 5. aureus such as cathelicidin-related AMPs (Chen et al., 2009), m oricin (Hu et 
al., 2013) and human lactoferrin peptide HLP2 (Chappie et al., 1998). These findings 
indicated the permeabilisation effect o f cationic AMPs against bacterial cells 
(Makobongo, Gancz et al. 2012, Verdon, Coutos-Thevenot et al. 2016)
However, even though SEM and TEM are complem entary techniques fo r observing 
alterations in bacterial membrane in tegrity o f cells treated w ith  AMPs, it cannot clarify 
the detailed mechanisms of cell death. Therefore, a combination o f d iffe ren t methods 
and techniques are needed as to  gain a bette r understanding o f the mode o f action o f 
AMPs or the response o f bacteria to  AMPs (Hartmann, Berditsch et al. 2010, 
Omardien, Brul et al. 2016).
DNA microarray has been used to  analyse the transcriptom ic responses o f E. coli
stressed by subinhibitory concentrations o f Smp24 and Smp43 w ith  polymyxin B as a
positive control. This analysis identified approximately 2% o f E. coli genes were
significantly d ifferentia lly  expressed in response to  each peptide treatm ent.
Siderophore biosynthesis, cellular respiration, oxidative stress response and di - tr i
valent ion binding and transport were the most biologically im portan t gene groups
fo llow ing exposure to  Smp peptides and were similar to  those clustered fo r polymyxin
B -induced d ifferentia lly  expressed genes. The deletion o f genes involved in the
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biosynthesis o f sideorphores and the transport o f ions increase resistance to  Smp24 
compared w ith the parent strain. In contrast, mutants w ith decreased resistance to  
Smp24 and Smp43 were associated w ith  oxidative stress responses and anaerobic 
respiration.
Beyond the known function of siderophores as an iron uptake-facilitator, several lines 
o f evidence indicate tha t siderophores play an alternative role in bacteria as an 
antioxidant cytoprotector (Achard, Maud ES, e t al 2013) (Johnstone, 2015). It was 
found tha t hydrolysed enterobactin in E. coli has exposed hydroxyl groups tha t can 
scavenge radicals and therefore reduce oxidative stress. Therefore, siderophore 
biosynthesis can be mediated by agents tha t affect oxidative stress (Adler, Corbalan et 
al. 2012, Adler, Corbalan et al. 2014)
Many genes o f the respiratory chain were found to  be downregulated fo llow ing 
exposure to  Smp peptides and polymyxin B. Downregulation of these components may 
contribute  significantly to  the change in membrane potential, and the  reduced 
respiration may lead to  a decline in energy consumption (Liu, Dong et al. 2013). The 
deletion o f these genes increased susceptibility to  Smp24 and Smp43.
Cell envelope perturbations fo llow ing exposure to  Smp peptides, as seen in EM 
micrographs, may induce common signalling pathways tha t u ltim ate ly lead to  internal 
oxidative stress and misregulation o f iron homoeostasis (Sikora, Beyhan et al. 2009b). 
AMPs disturb membrane structural in tegrity and function through disturbing proteins 
involved in energy generation and redox balancing (Hurdle, O'neill et al. 2011). 
Oxidative stress can be an im portant con tribu to r to  the lethal e ffect o f these 
nonspecific- target agents (Guilhelmelli, Vilela et al. 2014). Oxidative stress results in a
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more general cellular response leading to  bacterial self-destruction by internal 
production o f hydroxyl radicals (Feld, Louise,2012)
It has been proposed tha t positively charged AMPs similar to  the Smp peptides and 
affect redox status or electron transfer. Cationic cathelicidin peptide LL-37 was found 
to  influence the redox and ion status o f cells. It enhanced production o f reactive 
oxygen species causing lethal membrane depolarization (Liu, Dong et al. 2013). It has 
been reported tha t polymyxin can possibly induce oxidative stress by ROS through the 
accumulation o f hydroxyl radical (*OH) which readily damages DNA, lipids, and 
proteins and u ltim ately results in cell death (Yu, Zhiliang, et al. 2015) (Yu, Zhiliang, et 
al. 2017).
Cation deficiency or the displacement o f Mg2+ and Ca2+ may result in oxidative stress. It 
was found tha t an increase in the concentration o f ions like calcium may induce 
oxidative defences by signalling the bacteria to  upregulate antioxidant proteins (Rosch, 
Jason W., et a l.2008). These findings may support the oxidative stress induced effect 
by Smp24 which has been found to  be sensitive to  the presence o f Ca2+ and M g2+. 
Therefore, a quantita tive study o f ROS release in cells fo llow ing exposure to  Smp 
peptides is required to  assess the role o f oxidative stress in the antibacterial action of 
Smp peptides.
Data and observations obtained fo r the d iffe ren t methods in this study have resulted 
in a proposed transport mechanism for Smp24 across the cell envelope membranes of 
Gram negative bacteria (Figure 7.1). We propose tha t the integration o f cationic 
peptides like Smp24 in to the membrane may disturb metal cation homeostasis. The 
most d ifferentia lly  expressed genes fo llow ing Smp24 exposure were cation binding
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and transport. Smp24 also upregulates siderophore biosynthesis and transport genes. 
Siderophore receptors are m ultifunctional proteins tha t can transport the antibiotics 
such as albomycin and rifamycin across the outer membrane. The involvem ent o f a 
siderophore receptors in susceptibility to  Smp24 was supported by the observation 
tha t siderophore receptor-m utant E. coli strain was resistant to  Smp24. Disruption 
o f metal ions homeostasis is highly associated w ith  oxidative stress. Therefore, 
increasing concentrations of cations may protect bacteria from  oxidative stress 
induced by Smp24. Oxidative stress inactivates Fe-S dependent and leads to  the 
release o f ferrous irons (Fe2+) which is oxidized to  ferric iron (Fe3+), along w ith  the 
form ation  o f »OH, which is called the Fenton reaction and may also mediate 
siderophore biosynthesis fo r the chelation Fe3+ and prevent the fo rm ation  o f »OH. 
Oxidative stress can also result from  decreased protection against oxidants. 
Siderophore biosynthesis is regulated by the ferric uptake regulator (Fur) which is an 
iron protein tha t tends to  lose activity under oxidative stress, and could potentia lly  
lead to  depression o f the iron acquisition system and the stim ulation o f iron im port. 
The downregulation o f transcriptional (bacterial Fur) regulators and iron-sulfur clusters 
which mediate electron transfer to  the Fe-siderophore substrate results in the 
expression of a broad array o f genes involved mainly in iron acquisition or reactive 
oxygen species (ROS) protection. The deletion o f oxidative stress-response genes have 
increases the sensitivity o f E. coli to  Smp24. High levels o f ROS can induce lipid 
peroxidation leading to  disruption the membrane lipid bilayer and the in tegrity  o f cell 
membranes as seen even at low concentration of Smp24 against E. coli.
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Results obtained in this study support the idea tha t venoms are a viable source of 
AMPs and tha t microscopy, biochemical and transcriptom ic approaches can be used in 
drug discovery to  successfully develop new AMPs. These results indicate tha t the 
identified AMPs from  both scorpion and snake venoms were found to  exhibit 
promising antibacterial activities w ith  favorable cytotoxic effects. Progress has been 
made in understanding the mode o f action o f AMPs and the response o f bacteria to  
these peptides. These properties can be used as a starting point to  develop AMPs as a 
promising tem plate fo r the design o f novel classes of antibacterial agents to  help 
overcome the crisis o f antim icrobial resistance.
Salt-sensitivity may lim it the clinical use o f Smp peptides as novel antim icrobial 
therapeutics. D ifferent strategies have been employed to  overcome salt resistance to  
some AMPs. Increasing helix stability o f salt-sensitive AMPs by the in troduction  o f 
helix-capping motifs at the helix term in i resulted in structurally stable peptides w ith  
potent antim icrobial activities in high salt concentrations (Park, Cho et al. 2004). 
Nature produces a number o f salt-resistant AMPs such as marine-derived AMPs which 
have evolved to  adapt to  the high salt concentration in sea water. Salt tolerance of 
marine-derived AMPs may be a ttribu ted  to  the ir cationicity being mainly based on 
arginine rather than lysine residues. Understanding the chemical tolerance 
mechanisms o f marine AMPs may represent a valuable approach fo r the design o f 
novel salt-resistant AMPs (Fedders, Michalek et al. 2008, Falanga, Lombardi et al. 
2016). Like scorpions and snakes, marine organisms are another a ttractive source to  
isolate and characterise novel AMPs.
Although the purified snake proteins discussed in this thesis have lim ited cytotoxic and
no haemolytic properties, much more work is required in order to  evaluate the ir
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potential as antim icrobial templates. In general, 3FTxs have lim ited promise in this 
regard due to  the ir neurotoxic and cardiotoxic effects as well as synthesis d ifficulties 
due to  the ir size and the presence of disulfide bonds. (Fruchart-Gaillard, M ourie r et al. 
2012, Chandrudu, Simerska et al. 2013). Nevertheless, investigating the structure- 
function relationships o f these molecules using an alanine scanning m ethod to  
determ ine the key functional residues tha t bind phospholipids and disturb the 
membrane surface may help in the synthesis o f shorter peptides mimicking 3FTxs w ith  
increased antibacterial activity and bette r therapeutic characteristics (lannucci, 
Gonzalez et al. 2011, Cantisani, Finamore et al. 2014). It was found tha t a lteration of 
the positive charges of Lysine residues to  neutral or negative charges resulted in the 
loss o f the lytic activity o f CTX-1 from  Naja nigricollis crawshawii venom (Kini, Evans 
1989).
High production cost o f AMPs presents a real obstacle to  the pharmaceutical industry. 
Peptide synthesis costs five to  tw enty  times as much as the synthesis o f small organic 
molecule classical antibiotics. Expression and purification of AMPs in E. coli is an 
obvious alternative method fo r the production o f synthetic AMPs but it is lim ited by 
the antim icrobial activity o f AMPs against the host and peptide susceptib ility to  
proteolytic degradation by the host cell (Giuliani, Pirri et al. 2007). The production o f a 
fusion protein between an AMP and Small Ubiquitin-like M odifie r (SUMO) prote in 
protects the peptide from  the host degradation enzymes and bacteria from  the toxic ity 
o f AMP and can be scaled up fo r industrial-scale production fo r therapeutic  use 
(Bommarius, Jenssen et al. 2010).
Poor stability o f AMPs in serum has also lim ited the ir use as novel therapeutics.
However, disulfide-bridged peptides are more resistant to  protease degradation than
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linear peptides, therefore jo in ing the term inal ends of peptides by disulfide-bridges 
(cyclisation) constrains the peptide structure and thereby enhances antim icrobial 
activity (Brewer, Lajoie 2002, Rozek, Powers et al. 2003, Nan, Shin 2011)
The delivery o f AMPs is another crucial factor lim iting the ir clinical application. 
Systemic and pre-systemic enzymatic degradation and rapid hepatic and renal removal 
from  the circulation are challenging fo r oral and systemic adm inistration routes. 
Therefore, the most common adm inistration route o f AMPs is localised topical 
application (Mahlapuu, Hakansson et al. 2016). Several types o f nanotools have been 
used successfully to  deliver AMPs providing specificity to  particular cell types or 
locations (Brandelli 2012, Urban, Jose Valle-Delgado et al. 2012). Recently Silva, 
Gongalves et al. (2016) have succeeded in reducing proteolytic degradation o f LL-37 by 
encapsulating the peptide w ith  nanogels. This nanocarrier stabilises the peptide and 
delivers it towards the main infected sites leading to  the reduction o f its cytotoxic 
activities w ith  increased efficacy against Mycobacterium tuberculosis in vivo (Silva, 
Gonsalves et al. 2016). Interestingly, some nanomaterials have antim icrobial activities 
independent o f AMPs which can enhance the inh ib ito ry activity o f peptides and reduce 
any potential bacterial resistance (Malmsten 2011).
The synergistic effect o f antibiotics combined w ith  AMPs is a valuable approach to  
overcome the increasing recurrence and rising o f antib io tic resistance rates. Such 
combinations enhance the potency o f antibiotics making them effective against more 
than one target in the cell and maximises the concentration of antim icrobial agents at 
the site o f infection. Membrane perturbation or pore form ation on the bacterial 
surface may facilita te the uptake and access o f antibiotics in to the bacterial cell 
(Giuliani, Pirri et al. 2007, Nuding, Frasch et al. 2014). Some successful com binations o f
195
antibiotics with AMPs has led to an increase in antibacterial activity of conventional 
antibiotics such as erythromycin and rifampicin (Ulvatne, Karoliussen et al. 2001).
Further research is needed for to better understanding of the mechanisms of action of 
Smp peptide to develop their potency and stability.
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Appendix 1 List of other scorpion and snake venoms have been purified with no antibacterial 
activity against E. coli, S. aureus and B. subtilis
Venom Chromatography
Androctonus australis Reverse Phase Liquid Chromatography
co
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Androctonus amoreuxi Reverse Phase Liquid Chromatography
V)
Size exclusion Chromatography
JX. Cerastes cerastesnj
c
<S)
SP Sepharose cation exchange Chromatography
1
Ap
pe
nd
ix
 
2 
Di
ffe
re
nt
ia
lly
 
ex
pr
es
se
d 
ge
ne
s 
of 
E. 
co
li 
fo
llo
wi
ng
 
ex
po
su
re
 
to 
su
bi
nh
ib
ito
ry
 
co
nc
en
tra
tio
n 
of 
Sm
p2
4 D
es
cr
ip
tio
n
su
pe
ro
xid
e 
di
sm
ut
as
e,
 i
ron
 
[b
l6
56
]
pr
ob
ab
ly 
he
xo
se
 
tra
ns
fe
ra
se
; 
lip
op
ol
ys
ac
ch
ar
id
e 
co
re 
bi
os
yn
th
es
is
 
[b
36
23
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[Z
42
16
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
31
13
]
or
f; 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
08
02
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
28
77
]
cy
to
ch
ro
m
e 
c-
typ
e 
pr
ot
ei
n 
[b
22
02
]
pu
ta
tiv
e 
ox
id
or
ed
uc
ta
se
, 
Fe
-S 
su
bu
ni
t 
[b
l5
89
]
hy
po
th
et
ic
al
 p
ro
te
in
 
[E
Cs
06
36
]
ga
m
m
a-
gl
ut
am
yl
ph
os
ph
at
e 
re
du
ct
as
e 
[b
02
43
]
pu
ta
tiv
e 
sy
nt
ha
se
s 
[b
28
75
]
pr
ob
ab
le
 
pr
oc
es
sin
g 
el
em
en
t 
fo
r 
hy
dr
og
en
as
e-
2 
[b
29
93
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
28
76
]
fla
ge
llu
m
-s
pe
ci
fic
 
AT
P 
sy
nt
ha
se
 
[Z
30
31
]
fo
rm
at
e 
de
hy
dr
og
en
as
e-
N
, 
ni
tra
te
-in
du
ci
bl
e,
 c
yt
oc
hr
om
e 
B5
56
 
[b
l4
76
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
06
27
]
pu
ta
tiv
e 
DM
S0
 
re
du
ct
as
e 
an
ch
or
 s
ub
un
it 
[b
l5
90
]
Le
tA 
pr
ot
ei
n 
[]
ac
et
oh
yd
ro
xy
 
ac
id 
sy
nt
ha
se
 
II 
[Z
52
79
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
l0
60
]
re
pr
es
so
r 
of 
ma
lX 
an
d 
Y 
ge
ne
s 
[b
l6
20
]
G
en
eS
ym
bo
l
so
dB
w
oa
U
'S?cn td
cF
yb
iJ "5cnX na
pC
1X EC
s0
63
6
pr
oA
yq
eB
hy
bD ocnX fd
nl
ta
tE 1X ilv
G
bs
sS
m
ol
l
co’■£
J2 c c c c c C c c c c c c c c. c
ao <: £ <: £ 5 $ $ <: <: <:<u o o o o o o o o CL CL o o o Q_ o CL o Q . CL o occ 13 ~o ~o 13 13 -a 13 13 D D 13 13 13 35 13 D 13 35 D T3 13
Os 'Lf ro 00 ' t ' t t-H rsl ro o j LD LO Os LD LD'wT LD LO LD rsi rsi 00 O LD 't" LD Os ro ' t Os cn LD rsi rsi rsi T—1-Q cn cn tH cn rsl LO 00 ro Os 00 tH ro 00 LO ro LO LD ro
ro LD t—1 ro ' t rsi LD t-H rsi O LO O o LD LO LD LO O cn cn00 LD o ro Os cn o rsl LD Os O Os cn T—1 tH ro LO LO rsi LOu LO ro o> 00 ' t Os rsl o 00 LO LO cn ro ' t rsj LD st" rsi 't" LD
LL. q 00 cn ro q q q tH o rsj o j 00 tH rH q T—1 ro 00 rsi 0s ro
(N rsi no rsl ro ' t ' t ro rsi ro ro rsi LD rsi 00 rsi rsi rsi rsi ’si" rsj
■t" LD •t" LO LO ' t ' t - ' t ' t ’t" LO St" ' t ' f 't" 't - 't"
O O o O O O O O O O O O O o O o o O o o O
Q . LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU
LD rsi o rsi ro o> T—1 r—1 rsi Os LD LD ' t ' t rsj LO ro Os LO cnq Os o o o o. o rsi CO o j q q cn rH O q Os q q q
o-i Os' LO rsi 00 LO rsj (N ro rsi tH ' t LO rsi rH LD r*H rsi o i LD LO
dj CM o~ T—1 ro rsi cn LD Os O o j o Os T—1 LO ro rsi LO T—1 LO
r* 't" LO ro cn LD LO cn Os o ro ■t" o cn Os O 00 T—1 O ro
C ro o LD rsi ' t ro o> LO rsj cn ro tH ro LD st" Os LO T—1 rsj LO Osre 00 o~ LO O ' t LD o o " t O ' LD rsi LD cn cn O cn o j T—1 Oz T—1 tH o O o o rsi LO o O tH O ' t o o rsi LO LO o rsi<u o o o o O o o o O o O o O o o o O o O o O
S i CL I CL I CL1Q_1CL 1 CL 1 CL I CL■CL i CL | CL 1 CL ■CL 1 CL 1 CL1 CL1CL 1 CL1CL 1CL 1 CL1ov_ 1r-s 0* rs iO'. 1r^ Os 1O ' Os Os Os Os Os 1Os 0s 0s 1Os
CL o i o i o 1o i o i o i o i o i o I o i o 1o 1o 1 o 1 o 1 o 1 o 1 o 1o 1 o 1o 1i
< <
1
<
i
<
i
<
i
<
i
<
i
< < < < <
1
< <
1
< <
1
< < < < <
rsl
c n
rs i
LDno
_Q
o>
j =
4->
c
X
LO
o
l a
CL)
o
CJ
CL)
~ o
U
Uro
LO
>
O
Q .
O
Q .
rsl
T—I
00 
T—I
n o
i
o
rsi
O
O
x
o
c n
o
Os 
T—I
o
Cl
I
O '
o
LD
c n
o j
o
_Q
_C
‘cu
+-»
oL_
CL
"to
U  
■4—•
CD
_ C
-t->
o
CL
X
s z
CD
00
CD
COu
’+->
CD
+-»
o
CL
X
0 0
•R
c
5
o
~ a
cn
-iC
x
1 3
X
CL
D
CD 
r—I
r o
LO
rsl
c n
q
n o
• t -
O
LO
c n
O '
CD
T—I 
00 
o  
o
Cl
I
Os
o
CD
' t "
^ t
Os
c n
t-H
x
"t"
o
o
o
oo
" t -
00
tH
o
CL
I
Os
o
LO
r o
O
_Q
CD
LO
ro
c
CD
CUO
O
" D
X
SZ
CD
1 3
CD
1 3
X
S I
CD
q
<o
+->
CD
u
CO
u .
C l
- c
£
CL
D
0 s
LOT—I
X
0  
00 
O s
0 1
' t -
o
CD
O
CD
"t"
00
O
O
CL
I
X
o
o j
r o
-Q
CD
LO
co
-M
coi_
1 3
X
s z
CD
1 3
CD
C
’l _
CD
D
CL
C
£
o
1 3
X
O
T—I
o
q
' t
LO
oi
LU
00
O
cn
x
o
o
o
Cl
I
X
O
X
CD
O
't "
- O
c
q
D
OjO
CD
L
CD
LO
c
o
CL
LO
CD
L_
CD
~ 0
X
ol_
CD
CL
D
LO
O
L0
c
£
o
1 3
X
O
CD
O
T—I 
X
o
LO
o
x
q
LO
LO
cn
o o
o
o
Cl
I
X
o
X
o
X
1 3
X
c
$
o
1 3
LO
X
r o
00
00
r o
X
rsi
o
X  
00 
LO 
00 
T—I
o
Cl
I
X
o
r o
cn
LO
o
SZ
to
L0
CD
s z
■*->
c
X
LO
o
Id
q
"a)
s z
u
oi_
CD
+->
c
CD
x "
CD
C
'CD
+->
o1—
CL
"ro
u
*4—1
CD
SZ
+->
o
Q .
X
s z
D
E
x
X
oi_
1 3
X
SZ
CD
+->ro
E
to
O
SZ
<_>
o
LO
O+-i
c
CD
X
X
CD
tH
o
CL
I
X
o
’t ’
oo
CD
O
CD
1 3
S Z i
X
q
'CD
CD
O
CL
X
CL
D
X
r o
X
X
LO
q
rsi
r o
<t-
o
cn
q
x
r o
r o
T—I
r o
O
CL
I
X
O
CD
-Q
M—
CD
Uro
CD
c
CD
00
<
00to
u
CL
XL_
u
L|—
o
t—
o
+->_ro
33
00
CD
"ro
c
o
c  ^  ro O 
s_ S Z
CQ
1 3
■Q
X
00
X
oo
X
c n
x
r o
x
' t
o
x
o
CL
33
LO
LO
r o
c n
CD
x
q
r o
O
' t '
q
X
X
r-H
cn
X
o
o
CL
I
x
o
CD
cro
s z
E
CD
E
_ r o
CL
O
+->
X
u
cd'
ro
4->
CL
33
C
o
c
CD
1 3
C  ,—  
CD r o  
CL LO 
CD t H  
1 3  O  
1 S Z  CD Z Z L
E CD 
ro c  
>< o  
2  g-
1 3  E 
X  o
SZ u
0 0
Q_
ZZ
ro
E
1 3
E
LO
_ r o
CL
CD
c
o
+->
o
c
D
L*—
>
- D
E
CD
LO
LOro
c n
c n
tH
X
- Q
U
c
‘ CD
+-»
ov_
CL
v_
CD
O
CL
X
CD
0 )
E
CD
CD
q
' c l
CL
LO
o
s z
C L
>
oro
CD CDtoro
c
CD
00
o
1 3
X
s z
CD
1 3
CD
+->ro
E
00
LO
CD
s z
Q J
q
0  
D  
1 3  
q
1
CD
+->ro
CD
LOro
c
CD
00
o  ^
" O  *-n  
X  X  
s z
0J
1 3  q  
CD 4- .
r o  c
E 13 E -Q
o  3
>4- LO
3 :
c
£ ,
o
1 3
X
X
LO
00
LD
0 0
LD
' f
o
' t -
' t -
LD —^I
r o
- Q
CDro
L
X !
E
CD
CL
X
1 3
CD
' 5
c r
CD
i—
Q J
c
oi_
CD
CLro
sz
u
u
E
LO
J U
Q .
'l
CD
CL
X
00
q
‘ CD
+->
oL_
CL
"ro
u
’+ -»
CD
X
+->
o
CL
X
c
$
o
1 3
LO
LO
LO
X
c n
LO
T—I
rsi
o
c n
q
LO
LO
X
' t -
r o
o
CL
I
X
o
o
cn
00
o
X
o
00
LO
q
rsi
r o
,t -
O
I
LU
X
q
rsi
CD
cn
r o
r o
O
CL
I
X
o
r o
LO
00
O
SZ
sz
X
CL
CD
O
CD
c
CD
1 3
C
CD
CL
CD
1 3
i
CD
C
o
+-»
_CD
SZro
s z
O
CUD
CDi_
C
o
4-J
U
33
1 3
LO
Cro
D
CL
- Q
X
o
1 3
LD
,t ’
LD
LO
O0
LD
X
rsi
o
I
LU
X
q
rsi
o o
T—I
X
' t -
o
o
Q -
I
X
o
r o
~Q
X
pu
ta
tiv
e 
tra
ns
al
do
la
se
 
[b
39
46
]
pu
ta
tiv
e 
ca
rb
ox
yla
se
 
[b
07
11
]
fla
ge
lla
r 
bi
os
yn
th
es
is
; 
ex
po
rt 
of 
fla
ge
lla
r 
pr
ot
ei
ns
? 
[b
l9
40
]
Pu
ta
tiv
e 
de
ox
yr
ib
on
uc
le
as
e 
yjjV
 
[c
_5
46
1]
cy
to
to
xi
c 
pr
ot
ei
n 
Le
tB 
[]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
43
80
]
ou
te
r 
m
em
br
an
e 
re
ce
pt
or
 f
or
 i
ro
n-
re
gu
la
te
d 
co
lic
in 
1 r
ec
ep
to
r; 
po
rin
; 
re
qu
ire
s 
to
nB
 
ge
ne
 
pr
od
uc
t 
[b
21
55
]
pr
ob
ab
le
 
se
ns
or
 p
ro
te
in
 
[b
39
11
]
pu
ta
tiv
e 
en
zy
m
e 
[b
02
61
]
ni
tra
te
 
re
du
ct
as
e 
1, 
alp
ha
 
su
bu
ni
t 
[b
l2
24
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
l6
85
]
fla
vo
do
xi
n 
2 
[b
28
95
]
2,
3-
di
hy
dr
o-
2,
3-
di
hy
dr
ox
yb
en
zo
at
e 
sy
nt
he
ta
se
, 
is
oc
hr
oi
sm
at
as
e 
[b
05
95
]
cy
to
pl
as
m
ic
 
fe
rri
tin
 
[b
l9
05
]
ou
te
r 
m
em
br
an
e 
re
ce
pt
or
 f
or
 f
er
ric
 
en
te
ro
ba
ct
in
 
[b
05
84
]
hy
po
th
et
ic
al
 p
ro
te
in
 
[E
C
s2
92
9]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
30
70
]
fu
m
ar
as
e 
B 
[E
C
s5
10
4]
gl
uc
os
ep
ho
sp
ha
te
 
iso
m
er
as
e 
[b
40
25
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
26
35
]
an
ae
ro
bi
c 
di
m
et
hy
l 
su
lfo
xi
de
 
re
du
ct
as
e 
su
bu
ni
t 
C 
[Z
12
42
]
D
et
hi
ob
io
tin
 
sy
nt
he
ta
se
 
[c
_0
85
8]
2,
3-
di
hy
dr
o-
2,
3-
di
hy
dr
ox
yb
en
zo
at
e 
de
hy
dr
og
en
as
e,
 e
nt
er
oc
he
lin
 
bi
os
yn
th
es
is
 
[b
05
96
]
pu
ta
tiv
e 
L-
se
rin
e 
de
hy
dr
at
as
e 
[b
31
11
]
fs
aB C3)-QX fli
H
:g ci
rA
cp
xA
m
m
uM
no
rG
yd
iH
fld
B
en
tB C
<
£ a:S5X EC
s5
10
4
5)Q_ s dm
sC
bi
oD
en
tA
c c c c c c c c c. c c
£ $ <: 5 £ <? <: <: $ 5o Q_ CL Q. CL o cl CL CL o o o Q. o Q_ o Q. o o Q_ o CL CL 0~a D D D D XS D D D ~o ~o ~o D T3 D T3 D ~o ~o D T3 D Z3 ~o
rs rsi ro rH 00 LD ro rsi ro rsi LD 00 LD ro ISm rH1 rH LO O ro CD LO rH rs. rsi 00 rH ro LO LD o o rs ro O LOLO cn rH ro LD LD rs o LO LD cn rsi ro rsi ro ro o LD 'vl- 00rH rsi LD 00 rs 00 cn ro 00 LD o rH ro o LD LO o LO 00IX) rsj is O O rs rsi ro o cn rH LO 00 O ro rs 00 LD 00 00 rHrs rH rsi O o 00 q O cn q o q is 00 ro q LD cn rs 00 LO rs qq o q q ro q LO rsj q o rs cn rH LO rsj ro 00 q o rs q 00 LOrsj rsj rsj ro LO LO ro ro rsj rsi rH cn ro rsj rH rsi rsj rsj rH ro
LO •vf LO LO >3- ''t '3- LO 'Zf 'sf LOo O O O O O o O O O o O o o o O O o o O 0 O O 0
llj LU LLJ LU LU LU LU LU LU LU LU LU LU LU LU LU LLJ LU LU LU LU LU LLJ LULD is rs rsi cn 00 cn cn rsi o LO LD LO rs ro LO cn LO rsi LD cn 0 ro ISq q 00 rH q 00 q rH CO q q rsj rH rs is q rH 00 o 00 °9 q q 0
T—1 is LO ro ro ro LD rsj oj LD rsj LD rsj ro LO ro rH LO rsi ro ro
00 LO LO rH 00 LO o <3- LD ro LD rsi rH ro o cn rs IS 00 ro LD is ojo |S LD LO rH 00 m O is rs. ro cn 00 cn rs LD LD ro ro LD ro 00IX) o o ro rH LO LO ro O O "nT rs rH LD rs o LO rs LO O sj- rs rsi
cn o LO is O) rs ro cn 00 rs. 00 LD LD LD LD LO o rH 00 O rsi ro LD OrH rH rH ro LO rH O rH o o rH o rH rH rH LO o LD o rH LO ro rH OO O o O O O O o o o o o O O o o o O o O O O O OQ_1 CL1 CL1 CL1 CL1 CL1 CLi CL1 CL1 CL1 CLi CL1 CL■ CLI CL1 CL1 CL1 CL1 CL CL CL c l CL CLI
is rs is 1is rs is rs r-s r^ rs rs rs IS 1IS IS rs IS 1rs 1IS 1IS 1rs 1rs rso i o i o i o i o i o i o i o i o i o 1 o i o i o i O i O 1 O 1 o | O 1 o 1 O 1 0 1 0 1 0 1 0 1i< i< i< i< i< i< i< i< < 1< i< < < 1< < < < < < •1< < 1< 1< <
ri
bo
nu
cl
eo
si
de
-d
ip
ho
sp
ha
te
 
re
du
ct
as
e 
2, 
be
ta
 
ch
ai
n,
 f
ra
g 
[b
26
76
]
he
m
e 
ex
po
rt
er
 
pr
ot
ei
n 
B, 
cy
to
ch
ro
m
e 
c-
ty
pe
 
bi
og
en
es
is
 
pr
ot
ei
n 
[b
22
00
]
en
do
nu
cl
ea
se
 
IV 
[b
21
59
]
Su
pe
ro
xi
de
 
di
sm
ut
as
e 
[c
_2
05
0]
H
yp
ot
he
tic
al
 p
ro
te
in
 
yjjW
 
[c
_5
46
2]
C
oA
:a
po
- 
[E
C
s3
42
9]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
22
95
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
l3
3
3]
pu
ta
tiv
e 
tr
an
sp
or
t 
pr
ot
ei
n 
[b
36
85
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
08
50
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
66
]
pl
as
m
id
 
pa
rt
iti
on
in
g 
pr
ot
ei
n 
[L
70
68
]
or
f 
U
nk
no
w
n 
fu
nc
tio
n 
[Z
07
26
]
pu
ta
tiv
e 
tr
an
sp
os
as
e 
[b
02
57
]
ou
te
r 
m
em
br
an
e 
pr
ot
ei
n 
re
ce
pt
or
 f
or
 
fe
rr
ic
hr
om
e,
 c
ol
ic
in
 
M
, 
an
d 
ph
ag
es
 
T
l, 
T5
, 
an
d 
ph
i8
0 
[b
01
50
]
A
TP
-b
in
di
ng
 
co
m
po
ne
nt
 
of 
fe
rr
ic
 
en
te
ro
ba
ct
in
 
tr
an
sp
or
t 
[b
05
88
]
am
in
oa
cy
l-h
is
tid
in
e 
di
pe
pt
id
as
e 
[b
02
37
]
hy
po
th
et
ic
al
 p
ro
te
in
 
[E
C
s5
28
9]
ne
ga
tiv
e 
re
gu
la
to
r 
of 
ex
u 
re
gu
lo
n,
 e
xu
T,
 u
xa
A
C,
 a
nd
 
ux
uB
 
[b
30
94
]
an
ae
ro
bi
c 
di
m
et
hy
l 
su
lfo
xi
de
 
re
du
ct
as
e 
su
bu
ni
t 
C 
[E
C
s0
98
1]
am
in
op
ep
tid
as
e 
A
/I 
[b
42
60
]
an
ae
ro
bi
c 
di
m
et
hy
l 
su
lfo
xi
de
 
re
du
ct
as
e 
su
bu
ni
t 
C 
[b
08
96
]
m
aj
or
 t
yp
e 
1 
su
bu
ni
t 
fim
br
in
 
[E
C
s5
27
3]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[Z
07
39
]
Pu
ta
tiv
e 
di
m
et
hy
l 
su
lfo
xi
de
 
re
du
ct
as
e 
ch
ai
n 
yn
fE
 
pr
ec
ur
so
r 
[c
_1
97
7]
nr
dF
cc
m
B
nf
o
so
dB
ac
pS
us
pE
yi
dE
q
c^Tis
CQcnoX so
pA
Z0
72
6
fh
uA
oCL
pe
pD
EC
s5
28
9
ex
uR
EC
s0
98
1
pe
pA
dm
sC
EC
s5
27
3
yb
dB
X
c c c c c c c C c c c c c c
$ $ <: $ £ £ <: § £
CL o o o o Cl o o o o Q. CL CL Q. CL Q. CL o o o CL o o Q_ oD ~o ~o T3 T3 D ~a ~a ~a -a D D D D D D D T3 T3 T3 D ~a “D D T3
LO rs ro ro 'L}- rsj rsi LO LO rH LD 00 rs ro ro rsj LDrs 00 rsi ro rsi rH LO 00 cn rsi ro LD ro LO rH O' cn LO LO rs cnLO LD 00 O no LD LD 00 LO ro LD LD Os O ro rH Os cn rH ro 00'sf rH rs rs 00 ro O 00 00 00 LD LD 00 rH rsj ro rH 00 o- cn LD orsi no 00 ro rsl o> rs LD rsj rs 00 o LD LD o 00 00 LO ro rsi rH cn 00 o rHq ro LO rs o rs cn rsi rH rH rH ro q O LD q rH LO ro rH rH LO 00 LO
t—i rs ro o LO rs cm LO no LO rH rq LO rH q rH q rH q o q q o LD rHrH rsj rsj ro rsj rsi rsj ro rsj rsj rsi oi T—1 rsi rH rsi rsi oi LO rsi o>i oj 'sf
LO "sf "sf *3-O o o O O O O o O O O O o o o O O o O o o o o o O
LU LLJ LLJ LU LU LU LU LU LLJ LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU LULD rsj rH o rsi rs 00 T—1 rH o rH LO o O rH LD rH rH ro LO 00 ro cnrsl cn q q q rsj rH rsi o q rq q rH rH rH q q q q rH q q q q q
LD i< rsi rsi rH is-* rsi LO rH ro r^ ro r^ no rH LO oi ,sj- rH rH LD ro
rH rs LD ro LD LO LO LO LD T—1 ro ro rH rsj rsj 00 LD rH cn ro 00 LD Os Os rHLD 00 LO ro LO 00 LD 'sT LO o ro LD cn rH cn cn LD cn LO rsi O o00 Os LO no ro rs LD ro rs O cn cn cn rs LD 00 rs rH O 00 cn Os O rorH o ro rsi o* ro ro rs 00 00 rH rs rsi LD Os rH O ro ro <sj- rH rsiO o o ro LO rH rH rH o O LO o o rH o LD O LD o O LDO o o O O O o O O o O o O o o O o O O o o o O o OCL1 CLi CL1 CL1 Cl i Cl i CLi CL1 CLI CL1 CL1 c l i CL1 CL1 Cl 1 CL1 CL1 CL1 CL1 Cl 1 Cl 1 CL1 CL CL1 CL|1o> ii'-'. 1rs rs Io* I1^ 1hs rs rs 1rs 1 rs 1rs 1rs 1 Os rs rs Os Os 1rs 1Os Os Oso i o 1 Oi o i o i O i o 1 o i o i o i o i o i o i o I o i o i o 1 o 1 o I o 1 o 1 o 1 o 1 o 1 o 1i< 1< i< i< < i< 1< < < < < < < < < < 1< < < < 1< < 1< < 1<
rib
on
uc
le
os
id
e-
di
ph
os
ph
at
e 
re
du
ct
as
e 
2, 
alp
ha
 
su
bu
ni
t 
[b
26
75
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
05
97
]
pr
ob
ab
ly 
tra
ns
cr
ip
tio
na
l 
re
pr
es
so
r 
of 
be
t 
ge
ne
s 
[b
03
13
]
H
yp
ot
he
tic
al
 p
ro
te
in
 
yh
aV
 
[c
_3
88
5]
hy
po
th
et
ic
al
 p
ro
te
in
 
[E
C
sl
l7
3]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
ll7
8
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
26
74
]
pr
ot
ea
se
 
sp
ec
ific
 
fo
r 
ph
ag
e 
lam
bd
a 
ell
 r
ep
re
ss
or
 [
b4
17
4]
pu
ta
tiv
e 
DE
OR
-ty
pe
 
tra
ns
cr
ip
tio
na
l 
re
gu
la
to
r 
[b
43
00
]
AT
P-
bi
nd
in
g 
co
m
po
ne
nt
 o
f 
hy
dr
ox
ym
at
e-
de
pe
nd
en
t 
iro
n 
tra
ns
po
rt 
[b
01
51
]
pu
ta
tiv
e 
ox
id
or
ed
uc
ta
se
, 
Fe
-S 
su
bu
ni
t 
[b
l6
71
]
So
pB
 
pr
ot
ei
n 
[]
pu
ta
tiv
e 
ou
te
r 
m
em
br
an
e 
re
ce
pt
or
 f
or
 i
ron
 
tra
ns
po
rt 
[b
08
05
]
En
te
ro
ba
ct
in
 
sy
nt
he
ta
se
 
co
m
po
ne
nt
 
F 
[c
_0
67
3]
Hy
dr
og
en
as
e-
2 
op
er
on
 
pr
ot
ei
n 
hy
bA
 
pr
ec
ur
so
r 
[c
_3
73
3]
cu
rli
 p
ro
du
ct
io
n 
as
se
m
bl
y/
tra
ns
po
rt 
co
m
po
ne
nt
, 
2n
d 
cu
rli
 o
pe
ro
n 
[b
l0
39
]
pu
ta
tiv
e 
AT
P-
bi
nd
in
g 
co
m
po
ne
nt
 o
f 
a 
tra
ns
po
rt 
sy
ste
m 
[b
l6
82
]
pu
ta
tiv
e 
re
ce
pt
or
 [
bl
45
2]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
51
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
42
53
]
Kp
LE
2 
ph
ag
e-
lik
e 
el
em
en
t; 
pr
ed
ict
ed
 
pr
ot
ei
n,
 C
-te
r 
fra
gm
en
t 
(p
se
ud
og
en
e)
[b
45
60
]
H
yp
ot
he
tic
al
 p
ro
te
in
 
[c
_1
02
0]
re
so
lva
se
 
[]
pu
ta
tiv
e 
re
gu
la
to
r 
[b
02
72
]
noK
UjT3
CQ +3 C3
*-H
*~H
f t cn QCu o3 ll+~i ~Q UjC3l UjLJ —i nr* cnv. -Q CU -c u s. cn .c c is LO c: c? >LJ) C3C is -Q is Uj is C -c; L0 is cu -C O L 0 is is is
c C C c c c c c c c
£ £ <: 5 5
CL Q. CL o o o CL CL o CL o CL CL CL o o Q. CL CL o o o CL Q.
3 3 3 T3 ~o -a 3 3 ~o 3 T3 3 3 3 “O *o 3 3 3 X5 T5 T3 3 3
LD ro IS LO LO is LO 00 LD 00 00 LD LO rs (SJ
st Sj" rs 00 00 LO rH LD cn LD IS ro LO 00 LD rH ro is LO cn oo LD
LD cn IS 00 ^r rH LO cn cn ro cn IS fs rsi ro LO rH LO LO LD rH cn 00
LO cn cn cn LD ^r LO cn o cn cn LD rsl cn rsi rsi '3- ro rs LD LO 00 rH
00 LD rH LD LO LD rH •3- 00 rH LO <3- ro rsi LD LO 's T rsj LO rsi o 00
LO (SJ T—1 cn cn q LD rH rH ( N rq (S J (SJ rs rH rs is 00 rsi CSI O
LO ro q rH q o 00 rH LO (S J 00 (S J cn |S 00 q o q o q o q q qT—1 rH ro <sj ro rsi rH rsi rsi ro rsi rsi no T—1 "sf (sj LD cn rsi no no LO LO ro
'3' ^r ^r LO sj- LO LO <3- LO LO J^-
O o O o o o o O o o O O o o O o O o o O O O o O
LLJ LLJ LLJ LU UJ LU LU LU LU LU LU LU LU LLJ LU LU LU LU LLJ LU LU LU LU LU
LD LD (SJ LO ro cn (S J rH LD 00 IS ro ro cn rsj LD 00 ro no o 00 IS o
O'; LD LO ro q q rsj q q rq IS. o q o q rH (S J q (S J q q CO q q
ro T—1 t—i LO ro ro LO LD LO on LD ro 00 rH rH rsi rH 00 rH rsi (sj
LD 00 rH rH ro rH 00 00 cn LD rH LD ro ro cn LO rsi rH rH LO LO
LO rs cn 00 (S J rH O ro IS rH rsi o LD LO LD rH LD O rsi LD
00 rs CM IS cn 00 00 LO o rs rH ro rs ''t ro cn 00 LD 00 rH o
tH LD 00 rH rH LD rH rH (S J 00 cn rH LD rH 00 cn IS no O no cn 00o T—1 o LD O O rH o o rH LO O ro ro o rH O O O rH no LO oo o o o O O O O o o O o o o O o o o O O o o o o
CL1CL1 CL1 CLI CLI CL1 CLI CL1 CL1 Cl i CL1 CLI CL1 Cl ■ CLi Q_■ CL1 CL1 Q_I CL 1 CL1 CL1 CL 1 CL 1Irs 1rs 1IS 1IS 1rs 1IS 1rs IS rs rs IS rs 1 is IS 1is rs 1rs rs rs iso i o i o 1 O i o i o 1 o i O i o i o i O i o i o i O ■ O i O i o ■ o i o i o I o 1 o 1 o 1 O 1i
<
i
<
1
<
I
< < < < < < < <
i
< < < < < < < < <
1
<
1
< < <
pr
ob
ab
le
 
pr
oc
es
si
ng
 
el
em
en
t 
fo
r 
hy
dr
og
en
as
e-
2 
[Z
43
47
]
5-
am
in
ol
ev
ul
in
at
e 
de
hy
dr
at
as
e 
= 
po
rp
ho
bi
lin
og
en
 
sy
nt
ha
se
 
[b
03
69
]
H
yp
ot
he
tic
al
 p
ro
te
in
 
[c
_0
12
0]
Pu
ta
tiv
e 
tra
ns
po
rt 
pr
ot
ei
n 
[c
_3
23
4]
pl
ei
ot
ro
ph
ic
 
ef
fe
ct
s 
on 
3 
hy
dr
og
en
as
e 
is
oz
ym
es
 
[b
27
28
]
th
io
kd
is
ul
fid
e 
in
te
rc
ha
ng
e 
pr
ot
ei
n 
[b
06
04
]
pu
ta
tiv
e 
ox
id
or
ed
uc
ta
se
, 
m
aj
or
 s
ub
un
it 
[b
l5
88
]
se
ns
or
 p
ro
te
in
 
At
oS
 
fo
r 
re
sp
on
se
 
re
gu
la
to
r 
At
oG
 
[b
22
19
]
pu
ta
tiv
e 
en
zy
m
e 
[b
08
04
]
pu
ta
tiv
e 
hy
dr
og
en
as
e 
su
bu
ni
t 
[b
29
97
]
as
pa
rto
ki
na
se
 
1, 
ho
m
os
er
in
e 
de
hy
dr
og
en
as
e 
1 [
b0
00
2]
Fe
rr
ie
nt
er
ob
ac
tin
 
re
ce
pt
or
 p
re
cu
rs
or
 
[c
_0
66
9]
hy
bD
he
m
B
a-c ds
bG 1 ato
S
yb
iX
hy
bO
th
rA s .
■ C. c c c c c c c
£ £ $ £ <:o o o o o Q. o o C L o C L Q."O 73 73 73 73 3 73 73 3 73 3 3
cn LD on LD LO LD00 cn LO m LO cn rsi LD LO 00 cnrH o CM o rH LD cn O LO cno LO LD 'vf 'vf 00 LD rsirH m LO LO rH o 00 LO LO 00 cncn CM cn on LD on rsj q 00 on rHcn o LO O rsj rH rH LO o(N Osj rsi cn on ovi rsi rH on rsj
■vf Ssf LOo O O o o O O O O o o O
LLJ LLJ llj UJ LLJ UJ LLJ LU LLJ LLJ LLJ LLJcn 00 cn cn on on LO rsj rH cn OLO (N cn o q O'. on q q o on
CN LD on LO rsj o4 LD LD LO
on LD LO CM o cn LO on LO LD 'sT orH LD LD LO cn h- 00 rH o rH00 cn LD o LO 00 rH onto O LO rH CM LD o o rsi o rHCM m o rH rsi o o rH rH ono O o O o o o o o O O OCL1CLi Q.i CL.1CLi Q_■CL1CL| CL1CL1Gl1CL■1 1Cv i 10- i 1h* 1 1 1 1 1 1h*o i o 1o i o 1o i O i o t o I o i o i o I o 1
< < < < < < < < < < < <
Ap
pe
nd
ix
 
3 
Di
ffe
re
nt
ia
lly
 
ex
pr
es
se
d 
ge
ne
s 
of 
E. 
co
li 
fo
llo
wi
ng
 
ex
po
su
re
 
to 
su
bi
nh
ib
ito
ry
 
co
nc
en
tra
tio
n 
of 
Sm
p4
3
D
es
cr
ip
tio
n
ga
m
m
a-
gl
ut
am
at
e 
kin
as
e 
[b
02
42
]
Pu
ta
tiv
e 
ox
id
or
ed
uc
ta
se
 
[c
_0
40
9]
hi
gh
-a
ffi
ni
ty
 
ch
ol
in
e 
tra
ns
po
rt 
[Z
04
01
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
03
29
]
pu
ta
tiv
e 
tra
ns
po
rt
er
 [
EC
s0
34
6]
cy
to
ch
ro
m
e 
c-
ty
pe
 
pr
ot
ei
n 
[b
22
02
]
hy
po
th
et
ic
al
 p
ro
te
in
 
[L
70
89
]
pr
ob
ab
le
 
pr
oc
es
si
ng
 
el
em
en
t 
fo
r 
hy
dr
og
en
as
e-
fo
rm
at
e 
de
hy
dr
og
en
as
e-
N
, 
ni
tr
at
e-
in
du
ci
bl
e,
Le
tA 
pr
ot
ei
n 
[]
pu
ta
tiv
e 
ph
os
ph
at
as
e 
[b
l7
27
]
La
cl 
pr
ot
ei
n 
[c
_0
46
0]
pu
ta
tiv
e 
ph
ag
e 
in
te
gr
as
e 
[b
02
81
]
cy
to
ch
ro
m
e 
c-
ty
pe
 
pr
ot
ei
n 
[b
22
03
]
pu
ta
tiv
e 
tr
an
sc
rip
tio
na
l 
re
gu
la
to
r 
LY
SR
-ty
pe
pu
ta
tiv
e 
tr
an
sp
or
te
r 
[E
Cs
03
46
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
89
]
Xa
nt
hi
ne
-g
ua
ni
ne
 
ph
os
ph
or
ib
os
yl
tr
an
sf
er
as
e
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
58
]
gl
ut
ar
ed
ox
in
 
2 
[b
l0
64
]
pl
as
m
id
 
m
ai
nt
en
an
ce
 
pr
ot
ei
n 
[L
70
63
]
o-Q
E
£
<o7J- CO
<D CQ h~ O CQO u> U> Q C^J CQ OQ CQO Cj CQ CQ
at os +oCL) -co CJ Q.<3 £ ~ois c73 c
u. Clo -cC3 U) CnO
+oQ_ & 73uo Cl -Q is Uj c: -c < X ,c c Uj is Cn is CD CJ
cn T—1 LD rs rH CD rs LO CD CD cn LO CD 00 00 00rs LD 00 00 CD rs rH 00 ro rH rs ro ro <D CD rH LO 00 ro
o rs ro ro rs LO CD rs ro CD 00 rH LO 00 O CD ro 00 LOu. LD CT) rs LO rs LO 00 rsl CD 'Lj- 00 rH rsj CD ro rs LO 00 CD cn
WJ 00 LD LO o 00 00 "Cf q is. q q 00 q O q q rH q q q qo—J 1 rsi1 i i i rHi CD1 r—i I rsii roi r—1i 00i i rsii roi i I LOi rsii rH1 LOi
rs cn 00 cn ro rsj rH CD rs 00 CD rs rH 00 '3- CD 00 ■vf CD 00
to rs LO <3- rsi O rH rs LD O ro CD CD ro LO rH CD CD ISCD CD rH o cn O O rH ro rH cn cn O T—1 O rH ro 00 CD rHcn LD 00 LO 00 IS 00 rsj O q rsi ’ O is rH LO rH ro rsi 07 00
FC
00 ro CD 00 q rs rsj CD LO q nnIS o o rsi o 00 o q q rHrsi LDi rsii rHi rsii roi ooi roi CDi rHl rsii 1 roi '=7i rHI roi rHi LO1 CDi rsii LOi
LD rs CD CD ro rsi rsi ro rsi CD LO ro rs rsj
rsl 00 00 O') rsi rH rH CD rs 00 CD rs O 00 ro CD 00 ro CD 00o (X) rs LO *3- rsi O rH rs LD r^ o ro CD CD ro LO rH cn cn IS■U cn cn rH O CD O O rH ro r—1 q CD O rH O rH ro 00 CD rHIV# cn LD 00 LO 00 rs 00 rsi O q rsj r>r\ o rs rH LO rH ro rsi ro °9u 00 ro CD 00 q rs rsi q LO q
r) 
rs d o rsj o 00 o '3' q T—1
LL rs LD rsi rH rs ro 00 ro CD rH rsi ro rH ro rH LO CD rsi LO
co
+3
c C c C c c c c c C c c c c C c C c c c c
CuO £ £ £ <i £ $ £ $ £ <: <: £ $ $ $0) o o o o o o o o o o o o o o o o o o o o oo: 73 73 73 73 73 73 73 73 73 73 73 73 73 73 73 73 73 73 73 73 73
LD LD LO 'St LO LO CD LO LO
O O O o O O o O O O O O o O O O o o O o O
LLJ UJ LLI LLJ UJ LU LLJ LLJ LLJ LU LLJ LU LLJ LLJ LLI LLI LLI LU LU LU LULD cn ro rsi O LO rsi 'Lj- rs LO LO LO rs LO CD IS CD no00 rsj o rH q rs. q rsj rsj q q q q q 00 IS T—1 o
Q. LO ro rsj rH CD rsi ro rH rH ro 00 rH CD rH IS ro rsj rsi rH LO
'3' rH CD rs LO CD O O LD LO LO rsj O Osl rH 00 IS rs rH ro
rsi rH O ro ro CD LO O rs rH 00 ro O O IS "sf ro CD cn rsl ro
<u cn cd CD ro CD IS O rH rH CD O rH 00 rsi IS rH cn LO CDc rs o rH 00 rsi O CD CN CD CD 00 rH 00 o 00 rsi 00 rH IS rH 00c o ro LD O CD O "nJ- rH O LO rH ro o o O CD O o OCO o O O O O O o o O O O O o o O O O o o O oz Q.1 CL1 CL1 Q.i CL1 Q.1 Cl i CL1 CLi Cl i CLi CL1 Ol1 CL1 CL1 CL1 CL1 CL1 CLI CL1 CL10)
.Q rs
1rs rs rs. rs IS rs rs IS rs IS
1rs IS rs 1r^ rs
o o i o i o i o i o i O I o i o i O i o i O i o i o 1 o 1 o 1 o I o i o i o i o i o |La
CL
i< i< < < < I< i< < < < < < < < < < < < < < <
pu
ta
tiv
e 
ox
id
or
ed
uc
ta
se
 
[b
21
46
]
ni
tra
te
 
re
du
ct
as
e 
1
, d
elt
a 
su
bu
ni
t, 
as
se
m
bl
y
hi
gh
-a
ffi
ni
ty
 
ch
ol
in
e 
tra
ns
po
rt 
[E
C
s0
36
0]
cy
cl
op
ro
pa
ne
 
fa
tty
 
ac
yl 
ph
os
ph
ol
ip
id
 
sy
nt
ha
se
fo
rm
at
e 
de
hy
dr
og
en
as
e-
N
, 
ni
tra
te
-in
du
ci
bl
e,
fo
rm
at
e 
de
hy
dr
og
en
as
e-
N
, 
ni
tra
te
-in
du
ci
bl
e,
hy
po
th
et
ic
al
 p
ro
te
in
 
[E
C
s2
15
4]
ga
la
ct
os
id
e 
pe
rm
ea
se
 
[b
03
43
]
an
ae
ro
bi
c 
di
m
et
hy
l 
su
lfo
xid
e 
re
du
ct
as
e
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
03
34
]
pu
ta
tiv
e 
ta
il 
fib
er
 c
om
po
ne
nt
 
L 
of 
pr
op
ha
ge
pu
ta
tiv
e 
ou
te
r 
m
em
br
an
e 
pr
ot
ei
n 
[b
l2
56
]
cy
to
to
xi
c 
pr
ot
ei
n 
Le
tB 
[]
pu
ta
tiv
e 
en
zy
m
e 
[b
02
61
]
Pr
ob
ab
le
 
tR
NA
 
m
od
ifi
ca
tio
n 
GT
Pa
se
 
trm
E
ni
tra
te
 
re
du
ct
as
e 
1, 
alp
ha
 
su
bu
ni
t 
[b
l2
24
]
pu
ta
tiv
e 
cit
ra
te
 
sy
nt
ha
se
; 
pr
op
io
na
te
ch
ol
in
e 
de
hy
dr
og
en
as
e,
 a 
fla
vo
pr
ot
ei
n 
[Z
03
98
]
tra
ns
cr
ip
tio
na
l 
re
pr
es
so
r 
of 
the
 
lac
 
op
er
on
be
ta
-D
-g
al
ac
to
si
da
se
 
[b
03
44
]
pu
ta
tiv
e 
de
am
in
as
e 
[b
03
24
]
pu
ta
tiv
e 
ex
cis
io
na
se
 
[E
C
sl
50
2]
hy
po
th
et
ic
al
 p
ro
te
in
 
[L
70
85
]
he
m
ag
gl
ut
in
in
-a
ss
oc
ia
te
d 
pr
ot
ei
n 
[]
ye
/7
"
na
rJ
EC
s0
36
0
cf
o
fd
nG
fd
nH
EC
S2
15
4
la
cY
dm
sA
pr
pD
Z3
08
2
c l
5o m
m
uM
na
rG
S -
CL be
tA
la
d
la
cZ
ya
hJ
E
C
sl
50
2
L7
08
5
CD r o rsi r o rsi LO rH rH rH c n c n c n c o rH CD O' 0 0 O' S t s t 0 0rsl c n rH LO rH LO 0 0 O O' c n LO rsj rsj c n CO rsi CD cn LO rsi O' o 0 0rsi c o rH rsi 0 0 rsi rsj LO rsi rH rsj O' LO rsi r o s t o c n LO LO s t rH o
s t 0 0 c n rH o CO o 0 0 o st r o O' rsi rH 0 0 O rH o 0 0 S t St S t s t rHq r q 0 0 c o q r q q q q rsi o C O st q 0 0 q s t q 0 0 q St St 0 0 q
rsji s ti s t1 rHI rsji rsji rHi sti rsji sti rsji rHi c di i Oi LOi S t1 s ti c ni LO1 r oi rHi o ji rsii
COo 0 0rH c nr o 0 00 0 rsis t s to o LOr o rsis t rHLO rH 0 0CD c n rH r oc n c no O 'CO rsi r os t 0 0S t rsirH r orsl rsj LOr o
rHrsi
r o rsi o- O ' CD o O ' 0 0 LD r o c n rH CO O s t c n rsi O q LO c n rsi LO O 'st c n CO LO O st s t q q 0 0 CO o q s t s t q o 0 0
s t
q 0 0 rsi c o s t
rNj o d o LO rH o LO q 0 0 q q c d s t °9 c n r—1 c d r o O q rH LO
c d
1
rsli rs ji r oi l<1 LOi r oi rsii LO1 rHi sti r oi 0 0i rsii rHi r oi rsii rsii c ni LO1 rHI rsii O^i c di
LO
o *
c o
O '
c o
0 0
s t
0 0
c orH St LO rsi r orH O 'r o rsi0 0 r oO O 'c n r or o CO0 0 S tO ' 0 0c n r or o 0 0 r orsi r or o O 'c n LO StrHo rH r o 0 0 s t 0 0 r o s t LO rH c o c n o c n o CO rH s t s t rH rsi rH r o rsi
r o rsi O' c o o O ' 0 0 CO r o c n rH CD o St c n rsj O q LO cn rsi LO O '
s t cn c o LD o s t st q O ' q 0 0 CO o q s t s t q O 0 0
s t
q 0 0 rsi c o Strsi o c n o uq rH o LO q 0 0 o q c d st C O c n rH c d r o d q rH LO
c d rsj rs j r o LO r o rsi LO rH s t r o 0 0 c n rH r o rsi rsi c n LO rH o j O^ c d
c c c c c C c c c C c c c c C c c c c c C c C c
£ < i £ £ 5 $ <: <: $ £ § <: 5 5 B: £o o o o o o o o o o o o o o o o o o o o o o o o
~ o "O T3 ~ o ~a ■D "O -a T3 T3 ~ o T3 -a -Q T3 T3 T3 ~ o ~o ~ o T3 ~ o T3 -O
s t LO LO LD LO s t st LD s t St s t st CO st s t LO LO LO CO LO s t s t " t - s to o O O o O o O O O o O o O o O O o o o O o O o
UJ LLJ LLJ LU LLI LLJ LLJ LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU LU
c n c n r o st rsi o CO c n r o r o c n CD 0 0 LO r o O LO r o s t rH o r o LO
r o LO st rsi q cq rsj c n 0 0 0 0 q q s t q q q q q q q q q q q
T—1 fs j s t 0 0 LO r—i r o o^ rsj r o r—1 r o rH rH rH c d r o rH rsj oi r o rH rH r o
rH r o CO 0 0 rH 0 0 O' CO rsi CD c o 0 0 CO rH r o CO CO c n rsj c n O ' O ' s t
c n 0 0 r o CO CD CO o rH c o St rH rH O O LO O ' rH rH T—1 0 0 rsj LOst O c n r o St r o s t cn r o rsj rH O c n o r o c o s t s t r o LO o rH
r o rsi 0 0 c n c n s t 0 0 st 0 0 c n 0 0 rH O' 0 0 r o 0 0 0 0 0 0 O c n c nO o c o rH o o LO o o O st o LD o s t o o s t O O O c o St LOO o O o o o O o o O o o O o O o o O O O O o o o
CL 1 CL1 Cli Cl i CL1 CLi CL■ CLi CL1 CL 1 CLi Q-1 CL ■ CL 1 CL 1 CLi CL1 CL 1 CL1 CL 1 CL I CL 1 Q.1 CL 1
O'. O' O' O' o~ O' O ' O' 1 r^ O ' O ' o* O ' O ' O'o i o 1 o i o i o i o i o i o i o i o i o i o 1 O i o I o ■ o i o 1 o 1 o 1 o I o 1 o 1 o 1 o 1
< 1< i< < < < < < < < < < < < < < < < < < < < < <
H
ig
h-
af
fin
ity
 
ch
ol
in
e 
tr
an
sp
or
t 
p
ro
te
in
pu
ta
tiv
e 
ph
os
ph
on
om
ut
as
e 
2 
[b
03
31
]
pl
as
m
id
 
pa
rt
iti
on
in
g 
pr
ot
ei
n 
[L
70
68
]
pu
ta
tiv
e 
tra
ns
po
sa
se
 
[b
02
57
]
am
in
oa
cy
l-h
is
tid
in
e 
di
pe
pt
id
as
e 
[b
02
37
]
an
ae
ro
bi
c 
di
m
et
hy
l 
su
lfo
xi
de
 
re
du
ct
as
e
or
f 
U
nk
no
w
n 
fu
nc
tio
n 
[Z
03
86
]
pr
ob
ab
ly
 
tr
an
sc
rip
tio
na
l 
re
pr
es
so
r 
of 
be
t 
ge
ne
s
H
yp
ot
he
tic
al
 p
ro
te
in
 
yh
aV
 
[c
_3
88
5]
re
co
m
bi
na
se
 
[]
pl
as
m
id
 
m
ai
nt
en
an
ce
 
pr
ot
ei
n 
[L
70
62
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
03
07
]
Re
pF
IB
 
[]
So
pB
 
pr
ot
ei
n 
[]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
31
24
]
pu
ta
tiv
e 
ox
id
or
ed
uc
ta
se
 
[b
03
25
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
39
]
ga
m
m
a-
gl
ut
am
at
e 
kin
as
e 
[Z
03
03
]
H
yd
ro
ge
na
se
-2
 
op
er
on
 
pr
ot
ei
n 
hy
bA
 
pr
ec
ur
so
r
hy
po
th
et
ic
al
 p
ro
te
in
 
[E
C
s4
84
7]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
51
]
re
so
lv
as
e 
[]
pu
ta
tiv
e 
tr
an
sc
rip
tio
na
l 
re
gu
la
to
r 
LY
S
R
-ty
pe
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
80
]
CQ Q Cjto tD u. CQ
K
7t
00'St cl <:+-> cl Cl cn +3 c a cn v_ -c o -Q On OnOi lT o Qj u; 0) -c C_) O O £ L. X o cT O O-O CL io CL 73 X -o X CJ X cn X Q. -c Uj X X X
cn OsJ rH rH 00 un rsl om ■st rH un rsi on on LD rH un 00 rsi on00 cn O LO CD un cn ^t cn CD 00 00 'St 00 CD rsj st un LD CD o un oncn on rH on 00 ^t un on O CD cn r^ r-» O [■"s r"> on on on r-v on un rsiCD CD ^t cn on ■St un ■st on un O CD rH rH o un on rH 00 ■t 'St on rsi rsiLO 00 CD CD un CD CD ' t * t q q rH rH r—1 q q q rsi q cn q rsi q q'St1 oni CDi oni 00i rHI ■sti CDi r—iI 'sti oni CDi * tI CDi oni uni CDi uni rHI rHI ^ ti oni oni CDi
cn on CD on rsi ■Tt 00 un rH ' t on rH cn CD CD CD CD on rsiun cn O on on CD ■st o rsi 00 CD rH rsi CD rH rsi O rsi 00 LO unm LO on 00 co o CD un rsi rsj on CD cn rsi * t rsj O rsl 00 00 rsi rH rsiiq un CO cn ^__j rsi rsj o on rsj O 00 on q O rH __l rH rH ■St on ■3- q q
ro 'st cn rsi rH un r-i q un un r—i cri q rsi
n
tH l< rsj q on 00 rH rHrsii rHi cni r—1 i on■ onI rsji 00i rsii rsii rHI r-»i rHI CDi oni CD1 tHI oni oni rsii rsii on■ rHi oni
CD cn 00 rH on on rH un 1"- on cn un rsl CD cn rsi LO 00 CD on un CD un rsj00 ON LO on rsj O r-v ■st rH on cn on O 00 CD <£> CD un un rsi CD CD rsi
LD cn o on on CD 's t o rsl r^ 00 un rH rsi CD h* T—\ rsi O rsi 00 un unon LO on 00 CD o CD un rsi rsi cn CD cn rsi ' t (N O rsi 00 00 rsi rH rsi0-- LO 00 cn rsi rsj o cn rsi o 00 on o O rH t _ { rH rH ■st q * t q q
on cn rsi r^ . rH un q un un rH K cri q rsi rH rsi q on 00 rH rHrsi rH cn rH on on om 00 rsj rsi rH rH CD cri CD tH on on rsj rsj on rH on
c C c c c c c c c c C c C c c c C c c c c c C c
£ 5 £ <: £ <i $ <: £ 5o o o o o o o o o o o o o o o o o o o o o o o o73 73 -a ~o ~o 73 ~o 73 ~o 73 73 73 73 73 73 73 73 73 73 73 73 73 73 73
LD LO un ln CD ■st ■st un * t ■vf un un CD ■st st LO LO ■st un CD 'St 'St ^rO O o o O o o o o O O o o O o o O O O o O O O o
LLJ LU LU LLI LU LU LU LU LU LU LU LU LLJ LU LU LU LU LU LU LU LU LU LU LU
LD rH rH CD rsi un o on cn on rsi 00 cn rH ■ t O O o O on 00 CDq cn 'St cn rH un q rH rsj rH rH q 00 q q * t q on rsj q q q O00 r—1 LO ■st rH rH r - i rsj on Osj rH CD on rH on rsi 00 on on CD rsj rsj rH
CD 00 on rsi CD CD un 00 rH un O CD rH rH on o f"- r^ on CD rsi 'St rH rsj00 ^ t cn cn rsi O un 00 on rsi cn on "St rsi O on om CD rsi O onCD on cn cn 00 cn cn rsi O cn rsi o rH on on on 00 00 on rH r—1 OO 00 00 ■st rH 00 rH cn 00 00 on on o 00 rH CD on 00 00on o ^t o O o un O ^t un 'st O un un o O o un on un O un o o
o o o o o o O O O o o O o O o O o O O o O o o o
CL
1
Cl
i
CL
1
CL
i
CL
i
Cl
i
CL
1
CL
i
CL
I
CL i a_i CL 1 Cl 1 CL | CL 1 CL I CL1 CL 1 CL I o_I Cl 1 CL 1 CL 1 CL 1
r>. r-- h- n- I"- r^ 1 r .^ 1 r'-
o
i
o
i
o
i
o
i
o 1 o i o i o 1 o i o i o i o 1 o i o i o 1 o I o I o i o I o I o | o | o I o Ii
<
i
<
i
<
i
<
1
<
i
< <
1
<
i
<
i
<
i
< < < < < < < < < < < < < <
gu
an
in
e-
hy
po
xa
nt
hi
ne
pu
ta
tiv
e 
de
hy
dr
og
en
as
e 
[b
31
25
]
ni
tra
te
 
re
du
ct
as
e 
1, 
be
ta 
su
bu
ni
t 
[b
l2
25
]
tra
ns
cr
ip
tio
na
l 
re
gu
la
to
r 
fo
r 
mh
p 
op
er
on
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[Z
54
67
]
pl
ei
ot
ro
ph
ic
 
ef
fe
ct
s 
on 
3 
hy
dr
og
en
as
e
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
50
]
2-
oc
ta
pr
en
yl
-6
-m
et
ho
xy
ph
en
ol
 h
yd
ro
xy
la
se
H
yp
ot
he
tic
al
 p
ro
te
in
 
[c
_5
44
7]
pu
ta
tiv
e 
de
hy
dr
og
en
as
e 
su
bu
ni
t 
[b
03
06
]
ph
os
ph
og
ly
co
la
te
 
ph
os
ph
at
as
e 
[b
33
85
]
fla
ge
lla
r 
bi
os
yn
th
es
is
, 
ce
ll-
di
st
al
 p
or
tio
n 
of
cy
to
si
ne
 
de
am
in
as
e 
[b
03
37
]
pu
ta
tiv
e 
cy
to
ch
ro
m
e 
su
bu
ni
t 
of
NA
D
+d
ep
en
de
nt
 
be
ta
in
e 
al
de
hy
de
■UiQ.C31 ga
rR
na
rH
m
hp
R
yi
iS a■c
5°-S' ub
iH u j
f
-c
clcn
CDCn co
d 
A
ya
hN
be
tB
-6
.7
70
08
-3
.9
47
36
-5
.4
05
97
-4
.3
53
98
-1
.4
30
9
-1
.7
74
69
-5
.7
49
74
0.
95
21
24
2.
41
15
62
-3
.7
71
26
-1
.0
15
48
1.
65
88
85
-4
.2
44
85
-5
.0
68
95
-7
.2
40
64
-1
09
.1
44
-1
5.
42
67
-4
2.
39
92
-2
0.
44
94
-2
.6
96
16
-3
.4
21
65
-5
3.
80
76
1.
93
47
19
5.
32
05
01
-1
3.
65
41
-2
.0
21
58
3.
15
77
24
-1
8.
95
95
-3
3.
56
64
-1
51
.2
34
10
9.
14
37
15
.4
26
73
42
.3
99
25
20
.4
49
36
2.
69
61
56
3.
42
16
51
53
.8
07
59
1.
93
47
19
5.
32
05
01
13
.6
54
07
2.
02
15
8
3.
15
77
24
18
.9
59
54
33
.5
66
4
15
1.
23
37
do
w
n
do
w
n
do
w
n
do
w
n
do
w
n
do
w
n
do
w
n
dn dn do
w
n
do
w
n
dn do
w
n
do
w
n
do
w
n
1.
30
E-
05 o■LUCMLD
ro 1.
07
E-
05
2.
17
E-
04
7.0
3 
E-
07
2.
49
E-
04
8.
81
E-
06
6.
40
E-
05
3.
79
E-
04
2.
94
E-
05
1.
45
E-
04
8.
95
E-
05 o1LU
r Ho
ro
oiUJ00
r H 7.
15
E-
05
A
_0
7_
P
00
79
03
A
_0
7_
P
00
03
46
A
_0
7_
P
00
70
77 rorsi
00ooQ.
1
o
<■' A
_0
7_
P
04
71
06
A
_0
7_
P
00
20
90
A
_0
7_
P
00
79
58
A
_0
7_
P
03
28
95
A
_0
7_
P
03
73
25
A
_0
7_
P
00
82
25
A
_0
7_
P
01
79
54
A
_0
7_
P
00
15
93
00r^ro00ooCL
1
o
< ’ A
_0
7_
P
00
83
32
A
_0
7_
P
00
82
51
Ap
pe
nd
ix
 
4 
Di
ffe
re
nt
ia
lly
 
ex
pr
es
se
d 
ge
ne
s 
of 
E. 
co
li 
fo
llo
wi
ng
 
ex
po
su
re
 
to 
su
bi
nh
ib
ito
ry
 
co
nc
en
tra
tio
n 
of 
po
ly
m
yx
in
 
B D
es
cr
ip
tio
n
ga
m
m
a-
gl
ut
am
at
e 
kin
as
e 
[b
02
42
]
pu
ta
tiv
e 
ac
yl
tra
ns
fe
ra
se
 
[E
C
s3
22
5]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
76
]
hi
gh
-a
ffi
ni
ty
 
ch
ol
in
e 
tra
ns
po
rt 
[Z
04
01
]
Py
ru
va
te
 
de
hy
dr
og
en
as
e 
[c
_1
00
4]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
03
29
]
pu
ta
tiv
e 
tra
ns
po
rte
r 
[E
C
s0
34
6]
hy
po
th
et
ic
al
 p
ro
te
in
 
[L
70
89
]
pu
ta
tiv
e 
ox
id
or
ed
uc
ta
se
, 
Fe
-S 
su
bu
ni
t 
[b
l5
89
]
ga
m
m
a-
gl
ut
am
yl
ph
os
ph
at
e 
re
du
ct
as
e 
[b
02
43
]
pu
ta
tiv
e 
AR
AC
-ty
pe
 
re
gu
la
to
ry
 
pr
ot
ei
n 
[b
03
00
]
pr
ed
ic
te
d 
pr
ot
ei
n 
[b
45
32
]
pu
ta
tiv
e 
DM
SO
 
re
du
ct
as
e 
an
ch
or
 s
ub
un
it 
[b
l5
90
]
Le
tA 
pr
ot
ei
n 
[]
La
cl 
pr
ot
ei
n 
[c
_0
46
0]
pu
ta
tiv
e 
ph
ag
e 
in
te
gr
as
e 
[b
02
81
]
si
ng
le
-s
tra
nd
 
bi
nd
in
g 
pr
ot
ei
n 
[]
or
f 
Un
kn
ow
n 
fu
nc
tio
n 
[Z
03
86
]
H
yp
ot
he
tic
al
 p
ro
te
in
 
ya
fA 
[c
_0
38
6]
Be
ta
-g
al
ac
to
si
da
se
 
[c
_0
45
9]
hi
gh
-a
ffi
ni
ty
 
ch
ol
in
e 
tra
ns
po
rt 
[b
03
14
]
Ge
ne
 
Sy
m
bo
l
pr
oB
fa
d! QlOX be
tT
gxod ya
hO
EC
s0
34
6
flm
C
1X pr
oA
yk
gA
yn
cN
1 in
tF Qi-i; la
cZ
be
tT
CO
*+->_ro
3
too c c C c c c c c c c c c c: c c c c c c c c
QJ <; £ £ $ 5 5cc o o o o o o o o o o o o o o o o o o o o o
T3 ~o T3 T3 T3 ~o T3 T3 ■a ~o -o T3 ~o -D T3 T3 ■a ~o -a T3 T3
rH
cn
00rH rsl rso T—1St strsi stO rHst
rsCD st rsjrH 00LO CDrH LOst
rs
o CDO rsjro rHst stCD rsistro 00 rH 00 cn cn st ro ro 00 o CD st rsj 00 rsi st rH rH rH rH oo rsi 00 o LO ro CD cn rH rH CD rsi ro st CD CD rs rH rs 00 oo CD 00 st rsj rsi rsj o CD ro 00 00 rsj O rH • q cn q "=t rou. rsi CD CD cri o is CD IS q oi rsi o q O oLO rH i< st rsi CD rsoro rsi rsi no rsi rsi rsi cn rsi LO st rsj rsj ro r—1 St rH st rs LO rH
to st st CD *t LO LO LO st CD sf st LO LO LO CD st LO CD LO CD
Q. o1 o o o O O o o o o o O O o O O o o O o OLU LLJ LLJ LLI LLJ UJ LLJ LU LLI LLJ LU LLI LU LLI LLJ LLJ LU LLJ LU LLJ LLIrsj 00 rH IS rs rsi rH 00 o CD ro 00 LO st cn St o 00 LO o strH LO CD IS. rH rsj LO rsi q CD 'si; rs rsj rH St o st 00 rs q q
LO St st 00 rH rs rH ro ro CD r—i ro st 00 r^ ro ro rsi rH rsj CD
ro st o rH CD rH LO O CD O st cn rsj LO rsi O O CD LO rs ' t -
E fM rs |S o 00 ro ro LO is ro cn rsi 00 T—1 no o rH rs rs rsj CDcn rsi O cn rs ro cn O LO cn rH st LO rH o rH rsi CD st O rsi(T3 rs no 00 rH ro 00 rsi cn O rs 00 o O cn rH 00 cn rH rH rH 00z o LD O LO ro O CD st rsi o o rH rsj LO ro O LO LO st ro oa; o O O O O O O o O o o O O o o o O O o o oJQn CL1 Qli CL1 CLI Q_i CL1 CL1 CL1 CL1 CL| CL1 CL1 CLI CL1 CL1 CLI CL1 CL1 CL1 CL1 CL1vJi- 1rs iis 1rs 1rs rs is rs rs rs 1 rs 1 rs 1rs 1rs rs 1rs rs rs 1rsQ. o i o i o i o i o o i O I o i o i o i o i o i o I o i o 1 o 1 o 1 o 1 o 1 o 1 o 1i< i< i< i< i< i< I< < < i< < < < < < 1< < 1< < < 1<
rsl
pu
ta
tiv
e 
tra
ns
cr
ip
tio
na
l 
re
gu
la
to
r 
LY
SR
-ty
pe
 
[b
03
16
]
pu
ta
tiv
e 
tra
ns
po
rte
r 
[E
C
s0
34
6]
py
ru
va
te
 
ox
ida
se
 
[b
08
71
]
St
ab
le 
pl
as
m
id
 
in
he
rit
an
ce
 
pr
ot
ei
n 
(F 
le
ad
in
g 
m
ai
nt
en
an
ce
Xa
nt
hi
ne
-g
ua
ni
ne
 
ph
os
ph
or
ib
os
yl
tra
ns
fe
ra
se
 
[c
_0
38
4]
or
ni
th
in
e 
ca
rb
am
oy
ltr
an
sf
er
as
e 
2, 
ch
ain
 
F 
[b
02
73
]
tra
ns
cr
ip
tio
na
l 
re
gu
la
to
r 
of 
cr
yp
tic
 
csg
A 
ge
ne
 
fo
r 
cu
rli
 s
ur
fa
ce
pu
ta
tiv
e 
m
em
br
an
e 
pr
ot
ei
n 
[Z
44
03
]
pl
as
m
id
 
m
ai
nt
en
an
ce
 
pr
ot
ei
n 
[L
70
63
]
pu
ta
tiv
e 
ox
id
or
ed
uc
ta
se
 
[b
21
46
]
hi
gh
-a
ffi
ni
ty
 
ch
ol
in
e 
tra
ns
po
rt 
[E
C
s0
36
0]
ga
la
ct
os
id
e 
pe
rm
ea
se
 
[b
03
43
]
py
ru
va
te
 
ox
ida
se
 
[E
C
s0
95
7]
pu
ta
tiv
e 
tra
ns
al
do
la
se
 
[b
39
46
]
cy
to
to
xi
c 
pr
ot
ei
n 
Le
tB 
[]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
03
02
]
pu
ta
tiv
e 
en
zy
m
e 
[b
02
61
]
ni
tra
te
 
re
du
ct
as
e 
1, 
alp
ha
 
su
bu
ni
t 
[b
l2
24
]
ch
ol
in
e 
de
hy
dr
og
en
as
e,
 a 
fla
vo
pr
ot
ei
n 
[Z
03
98
]
tra
ns
cr
ip
tio
na
l 
re
pr
es
so
r 
of 
the
 
lac
 
op
er
on
 
[b
03
45
]
glu
co
se
 
de
hy
dr
og
en
as
e 
[b
01
24
]
be
ta
-D
-g
al
ac
to
si
da
se
 
[b
03
44
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
52
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
84
]
ya
hB
EC
s0
34
6
gxod ClCD ar
gF
cr
i
Z4
40
3
cc
dB
ye
iT
EC
s0
36
0
la
cY
EC
S0
95
7
fs
oB
m
m
uM
no
rG
be
tA
lo
ci
gc
d
lo
cZ
ya
fZ CCCDC5>s
c c. c c c c c c c c c c c c c c c c c c c c C c
£ £ <: $ 5 £ £ <: <: £ <: £ <: $ $ 5o o o o o o o o o o o o o o o o o o o o o o o o~o T3 T3 T3 T3 T3 ~a "D ~o ~a -a T3 -a ~o ~o T3 "O T3 T3 T3 T3 -a T3 -a
LD LO rH LD LD LD ro 00 ro cn LO cn rH ro cn LD rs rs 00 rsrH LD (N LD LD O LD O rsl rsi r- o rsi rs LO cn 00 ^r ro 00 LD rHrsl LO cn LO 00 o rH cn cn LO CD rH ro rH o rs o rs LD LO 00 roLD LO r—1 O O CD rsj 00 o rsi CD 00 cn LD LO rs ^r 00 q LO rH 00rH ro LD o ro q CDo
rH q rs CD rs o ro rs q q rsj Lfi
rs
CD q q rsj
00 rs LD r—i rsj q ro rsj o LD rs rH cri q rri q LD Lri LDrH rs CD LO rH r—1 rs 'Lf rs ro rsj LD ro 00 rs rsj LD rs rH
LO LD LO r»* LO LD LO LD LD LO LO LO LD LO LO rs LOO O O O O o o o O O O O O O O O o o O O o o O O
UJ LU LLI LU LU LU LU LU LU LU LU LU LU LU LU LLI LU LU LU LU LU LLI LU LUo cn rs O rsi rH o ro ro ro ro 00 o rH CD LD ro
q q o rH rH q o q rs q q q q 00 ro q q CO o q 00 o q
ro rH oi r—i 00 rH r—i 00 LD rH cri ro l< r—i rH rri LD rsi LO LO rsj
rsl rH LD O LD rsi rH ro r—1 LD rH 00 00 LO LD ro LD cn LO rs rs LO
O ro LD LD rH LD ro CD ro o rH O rH o o rs rs r—1 00 rH LD rHrS r'- 00 rsi O CD 00 CD cn 'Lf O LO rH rs o o LD ^r LO <=t CD rH
00 rs CD rH 00 h- LD 00 ro rs 00 cn CD 00 00 r-» ro 00 rs 00 rs 00o LD o LD O O J^- O LD o LO rH LO O o o o O O o oo O o O O O o o O O O o o o O O o o O o O O o oQ_1 CL1 CL1 CL1 0 l 1 CL1 CL1 CLI CL1 Cl i CL1 CL1 CL1 CL■ CL1 CL| CL1 CL1 CL1 CL1 CL1 CL1 CL1 CL11 r^ . 1r^ rs 1^ rs r^ 1 rs rs rso i o i o i o i o i o i o i o i o i o i o i o I o 1 o i o I o i o i o I o 1 o 1 o i o i o 1 o ii< i< < < < < < < < < < < < < < < < < < < < < 1< <
ro
Hi
gh
-a
ffi
ni
ty
 
ch
ol
in
e 
tr
an
sp
or
t 
pr
ot
ei
n 
[c
_0
43
4]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
66
]
pl
as
m
id
 
pa
rt
iti
on
in
g 
pr
ot
ei
n 
[L
70
68
]
am
in
oa
cy
l-h
is
tid
in
e 
di
pe
pt
id
as
e 
[b
02
37
]
re
co
m
bi
na
se
 
[]
pl
as
m
id
 
m
ai
nt
en
an
ce
 
pr
ot
ei
n 
[L
70
62
]
So
pB
 
pr
ot
ei
n 
[]
pu
ta
tiv
e 
ox
id
or
ed
uc
ta
se
 
[b
03
25
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
39
]
ga
m
m
a-
gl
ut
am
at
e 
kin
as
e 
[Z
03
03
]
ch
ol
in
e 
de
hy
dr
og
en
as
e,
 a 
fla
vo
pr
ot
ei
n 
[b
03
11
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
51
]
re
pl
ic
at
io
n 
pr
ot
ei
n 
[L
70
54
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
80
]
ch
ol
in
e 
de
hy
dr
og
en
as
e 
[E
C
s0
35
7]
gu
an
in
e-
hy
po
xa
nt
hi
ne
 
ph
os
ph
or
ib
os
yl
tr
an
sf
er
as
e 
[b
02
38
]
pu
ta
tiv
e 
de
hy
dr
og
en
as
e 
[b
31
25
]
In
itr
at
e 
re
du
ct
as
e 
1, 
be
ta
 
su
bu
ni
t 
[b
l2
25
]
tr
an
sc
rip
tio
na
l 
re
gu
la
to
r 
fo
r 
mh
p 
op
er
on
 
[b
03
46
]
th
io
ga
la
ct
os
id
e 
ac
et
yl
tr
an
sf
er
as
e 
[E
C
s0
39
5]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
02
50
]
pl
as
m
id
 
pa
rti
tio
ni
ng
 
pr
ot
ei
n 
[L
70
69
]
cy
to
si
ne
 
de
am
in
as
e 
[b
03
37
]
pu
ta
tiv
e 
cy
to
ch
ro
m
e 
su
bu
ni
t 
of 
de
hy
dr
og
en
as
e 
[b
03
28
]
be
tT
yo
gB
so
pA
Q
CL
CD
CL cc
dA
yo
hK
frs
A
pr
oB
be
tA
ya
fY
L7
05
4
2 :
CnO EC
s0
35
7
4-J
CLcn ga
rR
no
rH
m
hp
R
lo
cA
yk
fB
gdos co
dA
yo
hN
c c c C c c c c c c c C c c: c c c c c c C c c c
$ £ $ £ $ £ <; 5 <: £ £ <; $o o o o o o o o o o o o o o o o o o o o o o o oT3 ~o T3 *c •a -O ~o ~a ~o T3 T3 T3 ~o ~o "D ~o ~o -a T3 ~o T3 ~o ~o ~o
cn cn CD O' 00 rsl LO cn CD rsj CD O' CD rsi ro CD rsi cn 00
00 rH CD ro cn LO LO LO CD 00 00 rsj ro CD LO LO rH CD ro LO O' CDO o I'' cn rsi rH CD o LO rsl sr *=3- 00 CD rsj o rsi cn rH rH ro CD
ro 00 00 ro rH cn (N rH 00 rH rsi O' LO CD rq rsi rsi cn rH cn CDIs*. rH CD rsi CD o rsj 00 q o ro 00 00 r'i O- iq rH rsj rH q rsi qcri o cri o CD o rri ro cri rH o oi rri 00 rH rH rH O rH oi o oi
rsi LO 00 cn ro CN rH LO rH LO ro rsi rsi cn ro rH rH rH rsi ro O' O' cri LO
CD LO LO LO CD sr CD CD LO CD LO CD "3- CD LO LO CD LO CD CD LO
O o o o o o O O O o O O O O O O O O O o O O o o
LLJ LLJ LLJ Llj LU LU LU LU LU LU LU LU LU Llj LU LU LU uj LU LU LU LU LU LU
rsi ro CD rs cn CM 00 O' LO LO rsl LO o O cn cn cn rsl rH rH cn 0000 rH o O'. CN rH rq 00 rH q q rH rH q CD rsi rH iq q rH
rri rsi r-'i rsi (N rH 00 rH oi rH rH rsi rH oi rH rri oi ro rri LO '=t oi rH
CD ro ro CD LO O rH O O'. O' O' rsl O rsi rH ro CD O' ro ''J- 00 CD 00 OJ
00 ro cn 00 ro ro rsl o cn CD cn cn O' O rsl LO O' rocn O cn 00 O cn rH ro cn 00 rsj cn 00 O 00 cn ro o cn cn cn ro ro
o 00 00 O' cn 00 cn 00 o* T—1 00 o* 00 00 ro O O' 00 ro O' 00 00 00
ro O o LO LO O o LO o o O LO o O o O LO o o OO O o o O o o O o o o o o o O o O o O O o o O OCLi Q_1 CL1 CL1 CLi CL1 Cl i Cli CL1 cli CL1 CL1 CL| CLI CL1 CL1 CL1 CL1 Cl1 CL1 CL CL1 CL CL1i 1O' 1O' 1O' I1". O' O' O' O' O' O' O' r^ 1O' O' O' O' 1O' O' 1O' O'
o i o 1 o i o 1 o 1 o i o 1 o i o i o 1 o i o I o i o i o I o i o i o 1 o 1 o 1 o 1 o 1 o 1 o 1i< 1< i< 1< 1< i< 1< i< < 1< < 1< < < < < i< < < < 1< < < <
N
A
D
+-
de
pe
nd
en
t 
be
ta
in
e 
al
de
hy
de
 
de
hy
dr
og
en
as
e 
[b
03
12
]
fe
rti
lit
y 
in
hi
bi
tio
n 
pr
ot
ei
n 
[]
hy
po
th
et
ic
al
 p
ro
te
in
 
[E
Cs
06
36
]
AT
P-
bi
nd
in
g 
co
m
po
ne
nt
 o
f 
ci
tr
at
e-
de
pe
nd
en
t 
iro
n 
[b
42
87
]
Hy
po
th
et
ic
al
 p
ro
te
in
 
yb
dB
 
[c
_0
68
4]
fe
rro
us
 
iro
n 
tra
ns
po
rt 
pr
ot
ei
n 
A 
[b
34
08
]
Pr
ot
ea
se
 
VI
I 
pr
ec
ur
so
r 
[c
_0
65
2]
pe
pt
id
as
e 
E, 
a 
di
pe
pt
id
as
e 
wh
er
e 
am
in
o-
te
rm
in
al
 r
es
id
ue
 
is
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
23
25
]
ou
te
r 
m
em
br
an
e 
re
ce
pt
or
 f
or
 i
ro
n-
re
gu
la
te
d 
co
lic
in 
1 r
ec
ep
to
r;
pu
ta
tiv
e 
re
gu
la
to
r 
[E
Cs
32
99
]
2,
3-
di
hy
dr
o-
2,
3-
di
hy
dr
ox
yb
en
zo
at
e 
sy
nt
he
ta
se
, 
is
oc
hr
oi
sm
at
as
e
AT
P-
de
pe
nd
en
t 
se
rin
e 
ac
tiv
at
in
g 
en
zy
m
e 
[b
05
86
]
ou
te
r 
m
em
br
an
e 
re
ce
pt
or
 f
or
 f
er
ric
 
en
te
ro
ba
ct
in
 
[b
05
84
]
2,
3-
di
hy
dr
ox
yb
en
zo
at
e-
A
M
P 
lig
as
e 
[b
05
94
]
Pu
ta
tiv
e 
ra
dC
-li
ke
 
pr
ot
ei
n 
ye
eS
 
[c
_2
52
9]
fe
rro
us
 
iro
n 
tra
ns
po
rt 
pr
ot
ei
n 
B 
[b
34
09
]
fla
ge
lla
r 
bi
os
yn
th
es
is
, 
ce
ll-
pr
ox
im
al
 p
or
tio
n 
of 
ba
sa
l-b
od
y 
ro
d
ou
te
r 
m
em
br
an
e 
pr
ot
ei
n 
re
ce
pt
or
 f
or
 f
er
ric
hr
om
e,
 c
oli
cin
 
M
, 
an
d
fla
ge
lla
r 
bi
os
yn
th
es
is
, 
co
m
po
ne
nt
 
of 
m
ot
or
 s
wi
tc
h 
an
d 
en
er
gi
zi
ng
,
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[Z
07
39
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
05
97
]
or
f, 
hy
po
th
et
ic
al
 p
ro
te
in
 
[b
34
10
]
m
et
hy
l-g
al
ac
to
si
de
 
tra
ns
po
rt 
an
d 
ga
la
ct
os
e 
ta
xis
 
[b
21
48
]
be
tB
EC
s0
63
6
fe
cE
yb
dB
fe
oA
om
pT UjQ.«L>CL
—i 
§ ci
rA
m
ur
Q
en
tB
en
tF CL
en
tE
fe
oB CQcn
sq fh
uA
fU
N
yb
dB
yb
dB
fe
oC
m
gI
C
c
o
c
5o CL CL CL CL CL Q. CL CL CL CL CL CL CL Q. CL CL CL CL Cl Cl CL CL■O T3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
rsjrsi ro rHro 00 00 O'. CDLO rorH ro00 LOLO h-LO 00LD LOo rHno cnLO ro o-LO '3-O rsl LDro '3'00 O'-rsi 00 r—1 00LD "3- 00 LD LO LO LO o ■'3- ro cn rsi LD o cn 00 LO o LD LD oro 00 rsl LD rsl n- ro ro LD rH LO LD r^ ,3- O 00 ro rsj r-- rsl LD rHO'. fNj rH ro o LD o ro q q 00 cn o h- LD n- LD ro
<N rH 00 rq Ov q o cri q rsj rri rsj o °9 q o rH q LD q 00 rsj
rH rH rri rH cri no ro rsj ro rsj rH rH rsi rH rri LO rri LO rri rH cri ,3:
LD LD LO LD LO '3- LD LO LO LO LOO o O o O o O o O o O o o o o o O o O o O o o O
LU LU LU LU LU LU LU LU LU LU LU LU LLJ LU LU LU LU LU LU LU LU LU LU LUO LD cn r^ rH O'. cn LO rH o o LO 00 n- LO rH rH o ro cnLD rH rH iq q o (N q q rH 00 q q q rH q rH CM q q q oj m q
rH rH r—i 00 LD rsi r - i rsj ro rri r—i rsj rsj rri rH cri rri 00 r j rri rsi
rH 00 rsi O ro 00 ro o rH rH O o cn rH ro 00 rsi rsiLD r^ O LD ro r- 00 rH o ro cn 00 rsj LO LD rH cn O Orsj CM rsl cn ro o rs cn LO LD LD cn o LO o o r^ o LO00 CD ro r—1 00 rH 00 ro no ro LD LD LD LD rH 00 rH rsj LO LD 00 roO LO LO o ro rH ro o rH O LO r—1 rH rH rH ro rH O O rH 'sj- rH rH OO O o O O o O o o O o o o O O O O O o O o O O OQ_
1
Q_
1
c l i Q_I CL 1 CL 1 CL 1 CL 1 Cl i CL 1 CL i CL 1 Q_i CL i CL 1 CL ■ CL 1 CL 1 Q_1 CL 1 CL 1 CL 1 CL 1 CL I1 1 ih- 11^ 1O'. n- h- 1r-v rv r>. 1^ h- r^ 1r>- r^ r-»O i o i o i o 1 o 1 o o i o 1 o i o i o i o o i o i o i o 1 o i o 1 o 1 o 1 o 1 o 1 o o 1i< i< i< 1< 1< i< i< 1< i< < < i< < < i< 1< < < < 1< 1< 1< < <
En
te
ro
ba
ct
in
 
sy
nt
he
ta
se
 
co
m
po
ne
nt
 
F 
[c
_0
67
3]
pu
ta
tiv
e 
re
ce
pt
or
 [
bl
45
2]
pu
ta
tiv
e 
re
gu
la
to
r 
[Z
36
93
]
fla
ge
lla
r 
bi
os
yn
th
es
is
, 
ho
ok
 
pr
ot
ei
n 
[b
l0
76
]
se
rin
e 
ac
et
yl
tra
ns
fe
ra
se
 
[b
36
07
]
py
rid
ox
al
 k
in
as
e 
2 
/ 
py
rid
ox
in
e 
kin
as
e 
[b
l6
36
]
en
tF
yn
cE
m
ur
Q UjCn cy
sE
pd
xY
CL Q. CL Q. Q. CL
3 3 .3 3 3 3
LD ro rH HCM LD O ro ro Orsl ro 00 00 cn LO
00 00 '3- O 00Ch H in LD LO
ro in in rsj ro fN
rH cri IN ro (N <N
in LOo o o O O o
LLJ UJ LLJ LLJ LLJ LLJ
00 rsi in LD in
LD ro 00 rH cn
rH rsj
ro LD ro cn t-H
rH in rH 00 rHro ro 00 in cn 00H cn rsi H LD O
ro O 'vf O rH CMO o o o O OQ.i Q_1 Q_■ Q.■ Q.■ CL1I 1r^ 1 1rv 1 1h*o i o I o i o ■ o i o 1
< < < < i< <
